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ABSTRACT 
Cytogenetic analysis of the malignant clone is clinically important in haematological 
malignancy. Analysis by metaphase cytogenetics is restricted to the small proportion of 
malignant cells which are actively dividing. This thesis explores the dynamics of 
malignant clones using the technique of fluorescence in situ hybridization (FISH) to 
visualize chromosomal abnormalities in interphase (non-dividing) cells. Hyperdiploid 
(>46 chromosomes) clones have been investigated by interphase FISH in acute 
lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML) and myelodysplastic 
syndrome (MDS) using appropriate chromosome-specific probes. A hyperdiploid clone 
was detected in interphase cells in 9/65 patients with ALL in whom metaphase 
cytogenetics had failed or was normal. A single hyperdiploid cell was identified as 
clonal in one patient with MDS but not in six others with AML, MDS or ALL. The 
involvement of different cell lineages in the malignant clone was investigated by 
simultaneous FISH and identification of the cell type by morphology or monoclonal 
antibodies. In ALL, hyperdiploid clones were restricted to the lymphoid blasts in 9/9 
cases, while Philadelphia (Ph) positive clones, (identified by probes to the genes m- 
BCR or M-BCR and ABL which fuse as a result of the translocation) were found either 
in lymphoid blasts alone (1/3 cases) or in both lymphoid and myeloid cells (2/3 cases). 
In AML trisomy 8 (using a chromosome 8-specific probe) and an 11 q23 abnormality 
(which split YAC 13HH4) were both found only in the myeloid blasts, in 3/3 and 2/2 
cases respectively. A sensitive method for the detection of hyperdiploid ? 50 clones in 
ALL was developed for minimal residual disease detection. Simultaneous probing of 
three chromosomes enabled detection of one hyperdiploid cell in 10,000. 
Heterogeneity in the speed with which the clone was eliminated in remission was seen 
in 16 patients and early relapse was detected in one patient. 
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ABBREVIATIONS 
ALL Acute Lymphoblastic Leukaemia 
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HD High Density fraction 
HGF Haematopoietic Growth Factors 
HM Haemopoietic Microenviroment 
Ig Immunoglobulin 
IL Interleukin 
MAC Morphology, Antibody, Chromosome 
Mb Megabase 
MDS Myelodysplastic Syndrome 
MGG May Grunwald Giemsa staining 
MNC Mononuclear Cells 
MPD Myeloproliferative Disorder 
MRD Minimal Residual Disease 
Ph The Philadelphia Chromosome 
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PI Propidium Iodide 
PCR Polymerase Chain Reaction 
PBS Phosphate Buffered Saline 
PV Polycythemia Vera 
RA Refractory Anaemia 
RAEB Refractory Anaemia with Excess of Blasts 
RAEBT Refractory Anaemia with Excess of Blasts in Transformation 
RAS Refractory Anemia with Sideroblasts 
RFLP Restriction Fragment Length Polymorphism 
RCLB Red Cell Lysis Buffer 
RT-PCR Reverse Transcryptase Polymerase Chain Reaction 
SSC Standard Saline Citrate 
TBS Tris Buffered Saline 
TCR T-Cell Receptor 
WCP Whole Chromosome Probe 
WBC White Blood Cell count 
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1.1 CYTOGENETICS AND FLUORESCENT IN SITU 
HYBRIDIZATION IN THE STUDY OF HAEMATOLOGICAL 
MALIGNANCY 
Cytogenetics has established itself as an important tool in haematological practice. A 
number of chromosomal abnormalities have been recognized that are very closely 
associated with subtypes of leukaemia and lymphoma. The detection of one of these 
recurring abnormalities can be quite helpful in establishing the correct diagnosis and 
can add information of prognostic importance. 
The application of fluorescence in situ hybridization (FISH) in the study of 
haematological malignancy has expanded rapidly since its invention in 1969 and the 
technique is now widely used in haematology as the means of supplementing 
cytogenetics both for diagnostic purposes and in research. 
1.1.1 Cytogenetics 
The clinical importance of chromosomal abnormalities has been demonstrated in 
acute lymphoblastic leukaemia (ALL), in acute myeloblastic leukaemia (AML) and 
in myelodysplastic syndrome (MDS). In the following section, the important features 
of each of the above diseases is mentioned briefly and the clinical importance of the 
major non-random chromosomal abnormalities is discussed. 
1.1.1.1 Acute Lymphoblastic Leukaemia (ALL) 
Acute lymphoblastic leukaemia is characterized by the accumulation of malignant, 
immature lymphoid cells in the bone marrow and often in peripheral blood. The 
disease is much more common in children than in adults. The incidence in childhood 
is 3 per 100 000. Males are more often affected than females. 
1.1.1.1.1 FAB classification 
The classification of ALL by the morphology of the blasts was devised by a French, 
American and British consortium and is known as the FAB classification (Bennett et 
al., 1976; Bennett et al., 1982; Bennett et al., 1985). This has been used as a means 
of distinguishing three subtypes of ALL. Ll describes ALL with blasts which are 
mainly small and relatively uniform in appearance with nuclei of regular shape and 
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indistinct nucleoi. L2 describes ALL with blasts that are larger than LI and more 
heterogeneous. The nuclear shape is more irregular and one or more nucleoi may be 
present. L3 describes ALL with blasts which are large and homogeneous. Prominent 
vacuolation of the basophilic cytoplasm is often present (Bain, 1998b). 
1.1.1.1.2 Immunological classification 
The use of monoclonal antibodies for the identification of cell surface antigens has 
helped us to understand the stages of differentiation of leukaemia and has provided 
means to further subdivide ALL. Thus, ALL is divided into two major categories; B 
and T-lineage ALL. There are further subdivisions within each category according 
to the expression of antigens known as clusters of differentiation (CD) which is 
related to the degree of the maturation of blast cell. 
B-lineage 
B lineage ALL is defined by the expression of at least two of the following three 
early B cell markers: CD19, CD79 or CD22. The major immunological classes are as 
follows: pro-B-ALL (B-I) with no expression of other differentiation B-cell antigens, 
common-ALL (B-II) which is CD 10 +ve, pre-B-ALL (B-III) which shows 
intracytoplasmic µ chains and mature B-ALL (B-IV) which shows cytoplasmic or 
surface kappa or lambda chains (European Group for the Immunological 
Characterization of Leukemias (EGIL) et al., 1995). 
T-lineage 
T-lineage ALL is defined by the cytoplasmic or membrane expression of CD3. Four 
subgroups of T-ALL are defined as follows: pro-T-ALL (T-I) which is CD7 +ve, 
pre-T-ALL (T-II) which is CD2 +ve and/or CD5 +ve and/or CD8 +ve, cortical-T- 
ALL (T-III) which is CD 1a +ve and mature-T-ALL (T-IV) which is membrane CD3 
+ve and CD 1a -ve (European Group for the Immunological 
Characterization of 
Leukemias (EGIL) et al., 1995). 
1.1.1.1.3 Chromosomal abnormalities 
An abnormal karyotype can now be demonstrated in between 44% and 90% of cases 
(IWCL3,1981a; Williams et al., 1985; Fenaux et al., 1989; Secker-Walker et al., 
1989; Crist et al., 1990; Jackson et al., 1990; Pui et al., 1990; Secker-Walker, 1990; 
Walters et al., 1990; Secker-Walker et al., 1991; Dastugue et al., 1992; Van der Plas 
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et al., 1992a; GFCH, 1993). ALL can be classified by numerical or structural 
cytogenetic features. 
Structural change 
t(1; 19) (g23; p13) and der(19)t(1; 19) 
This translocation is found in between 2% and 9% of ALL (GFCH, 1993; Harbott et 
al., 1993; Pui et al., 1994). It is strongly associated with a pre-B immunophenotype. 
The translocation can occur as a balanced t(1; 19)(g23; p 13) or an unbalanced variant 
der(l ; 19)t(l ; 19). At the molecular level the translocation results in the juxtaposition 
of the genes E2A (chromosome 19) and PBX] (chromosome 1). The prognostic 
significance of this abnormality is unclear. The association with poor risk features 
was shown in some reports (Lai et al., 1989). Other researchers failed to show any 
such correlation (Carroll et al., 1984; Michael et al., 1984). The intensification of 
treatment regimens appear to improve prognosis. Also the unbalanced variant of the 
translocation was shown to be associated with better prognosis than its balanced 
counterpart (Secker-Walker et al., 1992a). 
t(4; 11)(q21; q23) 
The incidence of this translocation has been reported as 2% in children (Mirro et al., 
1986; Seeker-Walker, 1990) and 5% in adults (IWCL3,1981a). However, it is now 
clear that most patients with t(4; 11) are infants (<1 years old). The incidence in this 
group of patients has been shown to be between 30% and 70% (Lampert et al., 1992; 
Ferster et al., 1994; Heerema et al., 1994). The t(4; 11) is associated with a null-cell 
immunophenotype (CD 19+, CD 10-) (Pui, 1992) and high (> 100x 109/1) WBC. The 
t(4; 11) has been associated with myeloid characteristics, which indicates possible 
pluripotent stem cell involvement (IWCL3,1981a; Morse et al., 1982; 
Parkin et al., 
1982; Nagasaka et al., 1983; Levin et al., 1984; Stong et al., 1985). It has been 
shown that at the molecular level the abnormalities 
involving 11 q23 often lead to 
rearrangement of the MLL (ALL], HRX, HTRXJ) gene 
(Cimino et al., 1991; Ziemin- 
van der Poel et al., 1991; Das et al., 1992; Djabali et al., 
1992; Tkachuk et al., 1992; 
Thirman et al., 1993) and that the t(4; 11) results in a fusion between the MLL 
(chromosome 11) and the AF4 (FEL, LTG4, MLLT2) gene on chromosome 4 (Gu et 
al., 1992; Chen et al., 1993; Corral et al., 1993; 
Domer et al., 1993; Morrissey et al., 
1993). Patients with this translocation have a poorer prognosis than that of any other 
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chromosomal subgroup. The average survival is probably no more than 6 months 
(IWCL3,1981a; Seeker-Walker, 1990), but longer survival have been amongst 2-10 
year olds (Johansson et al., 1998). 
t(9; 22)(g34; q11) 
The Philadelphia chromosome which is one of the products of the t(9; 22), was first 
described by Nowell and Hungerford in 1960 (Nowell, Hungerford, 1960). It occurs 
in more than 90% of CMLs and identifies a prognostically important subgroup of 
patients with ALL. The incidence of t(9; 22) in childhood is between 2.3% and 5% 
(Secker-Walker et al., 1976; Crist et al., 1990; Seeker-Walker, 1990; Fletcher et al., 
1992). In adult ALL the Philadelphia chromosome occurs in 11 % to 17% of cases 
(IWCL3,1981b; Seeker-Walker et al., 1997). 
The Ph translocation has been associated with a high (>30x109/1) white blood cell 
count (WBC). The difference between WBC in Ph+ ALL and Ph- ALL is 
particularly pronounced in childhood ALL (Crist et al., 1990). Blast cell 
immunophenotype has been shown to be mostly c-ALL (74%), followed by pre-B 
(16%) and T-ALL (10%) (Ribeiro et al., 1987; Crist et al., 1990). 
The Philadelphia translocation results in the fusion of part of the ABL gene, located on 
chromosome 9 and the BCR gene, located on chromosome 22. There are two different 
breakpoint cluster regions within the BCR gene: the 5.8 kb major breakpoint cluster 
(M-BCR) region and the 35 kb minor cluster region (m-BCR). Fusion between M-BCR 
and ABL gives rise to p210 protein while fusion between m-BCR and ABL gives rise to 
p 190 protein. M-BCR is the breakpoint in 99% of Ph positive CML cases and in 50% 
of Ph positive ALL cases. The remaining 50% of Ph+ ALL have a m-BCR breakpoint. 
Prognosis for patients with ALL and this translocation is poor. In childhood, the 
remission rate of Ph+ ALL is 78% to 80% as compared with 90%-99% in other ALL 
cases (Crist et al., 1990; Fletcher et al., 1992) and median event-free survival is only 
12-18 months. The event free survival in childhood ALL by five years is no more 
than 15% (Ribeiro et al., 1987; GFCH, 1993; Harbott et al., 1993). Similarly in adult 
ALL, patients with this translocation do worse than those without (Bloomfield et al., 
1989; Secker-Walker et al., 1991; Gotz et al., 1992a). The median event free survival 
in adult Ph+ ALL at three years is less than 14% (Gotz et al., 1992b; Secker-Walker 
et al., 1997). 
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The Ph translocation is accompanied by additional abnormalities at diagnosis in up 
to 60% of children and 90% of adults with ALL (IWCL3,1981b; Gotz et al., 1992b). 
In general this appears to be unimportant in terms of prognosis but Ph+ ALL with 
monosomy 7 has a particularly poor prognosis (Russo et al., 1991). 
t(8; 14)(g24; q32), t(2,8)(p12; q24) and t(8,22)(g24; q11) 
The three translocations are found in mature B-cell ALL which is associated with 
FAB L3-Burkitt-type morphology. At least one of the above translocations is found 
in over 80% percent of Burkitt Lymphoma (BL) or ALL L3 cases (Kornblau et al., 
1991). At the molecular level these three translocation share a common breakpoint 
at 8q24, the site of the oncogene MYC. The second breakpoint is at the site of an 
immunoglobulin chain gene, either the IGK light chain kappa at the 2p 12, the IGL 
lambda at 22g11 or the heavy chain IGH at 14q32. Prognosis for this group using 
standard ALL therapy used to be extremely poor with median survival of lees than 
one year (IWCL3,1981a). More recently the availability of special protocols, has 
improved survival of these cases. 
t(1; 14)(q32; qll) and t(8; 14)(q24; qll) 
These translocations are found in T-cell ALL. The t(1; 14) is found in between 3% 
and 6% of T-ALL cases (Carroll et al., 1990; Chan et al., 1992). At the molecular 
level the translocations share a common breakpoint at 14g11, at the site of the T-cell 
receptor genes TCRA. In the t(1; 14) the other gene involved is TAL-1, while in the 
t(8,14) the gene involved is the oncogene MYC. Prognosis for the patients with these 
translocation is poor and in the case of t(1; 14) the median event-free survival is 4 
months (Lange et al., 1992). 
del 6q 
Deletion of 6q is found in T and early B-lineage ALL and is found in 8% to 13% of 
childhood cases (IWCL3,1981 a; Crist et al., 1990; Dastugue et al., 1992) and 4% of 
adults (Secker-Walker et al., 1997). It involves breakpoints between 6g13-6g21 and 
6g21-6g23 . 
del 9p 
Deletion of 9q is found in T and early B-lineage ALL The incidence of del 9p occurs 
in between 5% and 10% of cases with T-ALL (Raimondi et al., 1988; Berger et al., 
1990; Seeker-Walker et al., 1992b; Van der Plas et al., 1992b; GFCH, 1993). At the 
molecular level the deletion is associated with the loss of the interferon genes 
INFA, 
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INFB and the multiple tumor suppresser gene MTSI and MTS2. This abnormality has 
been associated with `lymphomatous disease': lymphadenopathy, splenomegaly, 
CNS involvement and high leukocyte count (Kowalczyk et al., 1985). 
del 12p 
The abnormalities of 12p include deletions and balanced and unbalanced 
translocations. The incidence of an 12p abnormality in children, by cytogenetics 
using banding techniques, has been shown to be 10% (Raimondi et al., 1986). The 
12p translocations have proved to be very difficult to detect by G-banding due to 
pale staining of this region. It is now becoming clear that a proportion of the 12p 
deletions may now be reclassified as translocations. In 1994 Romana et al. 
investigated 8 patients with del(12p) using FISH with chromosome paints and 
showed that three of them had in fact t(12; 21) a translocation that had not been 
previously described (Romana et al., 1994). At the molecular level the t(12; 21) 
translocation results in the fusion of the AML1 gene located at 21q22 and the TEL 
gene located at 12p13. Fusion of TEL-AMLI has been seen by RT-PCR in up to 30% 
of children with ALL and it is associated with a very good prognosis. The projected 
event-free survival has been shown to be 74% at 3 years (Romana et al., 1995). 
Numerical change 
Hypodiploidy 
Hypodiploidy is defined as a clonal loss of at least one chromosome. In ALL it 
occurs in between 5% and 8% of childhood patients (Minden et al., 1978; Secker- 
Walker et al., 1985; Pui et al., 1987; Prigogina et al., 1988; Crist et al., 1990; Jackson 
et al., 1990; Pui et al., 1990; Secker-Walker, 1990; Van der Plas et al., 1992a; 
GFCH, 1993) and in 9% of adult patients (Secker-Walker et al., 1990). There is no 
consensus with regard to the prognosis for those cases. In some surveys hypodiploid 
cases have shown a better prognosis than average (Secker-Walker et al., 1982a; Van 
der Plas et al., 1992a) in others they have had a worse prognosis (Bloomfield et al., 
1989). 
Near haploidy 
Near haploidy is defined as a chromosomal gain from the haploid number of 23 
chromosomes. The chromosomes frequently gained are 10,14,18,21. Both sex 
chromosomes are frequently present. The incidence of near haploidy is in between 
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0.7% to 2.4% (Pui et al., 1987; Gibbons et al., 1991). The prognosis for cases with 
near haploidy is poor. 
Pseudodiploidy 
Pseudodiploidy is defined as the presence of 46 chromosomes and a structural 
change or loss of 1 or more chromosomes complemented by gain of the same 
number of other chromosomes. Pseudodiploidy accounts for 40% of cases with ALL 
(Crist et al., 1990; Jackson et al., 1990; Pui et al., 1990; Secker-Walker, 1990; 
Dastugue et al., 1992; GFCH, 1993). If hierarchical classification, in which structural 
change takes precedence over ploidy, is applied 10% of cases with this abnormality 
is found (Seeker-Walker et al., 1997). 
Low hyperdiploidy 
Low hyperdiploidy is defined as the presence of 47-50 chromosomes. The 
chromosomes most frequently gained are 21, X, 8 and 10. The incidence of low 
hyperdiploidy in childhood ALL ranges from 11% to 15% (Jackson et al., 1990; Pui 
et al., 1990; Secker-Walker, 1990; Raimondi et al., 1992; GFCH, 1993). In adults 
low hyperdiploidy accounts for between 8% and 11 % (Seeker-Walker et al., 1990; 
Walters et al., 1990). There is little consistency in the prognosis for the patients with 
this abnormality. Both better (Bloomfield et al., 1989) and worse (IWCL3,1981a) 
than average prognoses have been reported. 
High hyperdiploidy 
High hyperdiploidy is defined as the presence of 51-65 chromosomes. The 
chromosomes most frequently gained are X, 4,6,10,14,17,18 and 21. The 
incidence of high hyperdiploidy in childhood ALL ranges from 16% to 27% (Pui et 
al., 1990; Secker-Walker, 1990; Dastugue et al., 1992; Van der Plas et al., 1992a; 
GFCH, 1993). In adults the incidence of high hyperdiploidy is remarkably lower and 
accounts for between 4% and 5% of the diagnostic cases (Pui et al., 1989; Secker- 
Walker et al., 1990; Walters et al., 1990). This group is associated with good risk 
factors: age 2-9 years, leukocyte counts less than 10x109/1, female sex, C-ALL 
immunophenotype, FAB type L1. Patients with high hyperdiploidy enjoy the best 
prognosis. An average event-free survival of 5 years is achieved in 72% of children 
(Pui et al., 1989; Jackson et al., 1990; Van der Plas et al., 1992b). 
An initial report that the presence of a structural change in addition to high 
hyperdiploidy has an adverse impact on prognosis (Pui et al., 1989) has not been 
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confirmed in a more recent report from the same group (Raimondi et al., 1996). The 
gain of a particular chromosome has been related to prognosis. Jackson et al. showed 
that trisomy 6 was associated with a good prognosis in patients with hyperdiploidy 
(Jackson et al., 1990). Harris et al. showed that combined trisomy of chromosomes 4 
and 10 improves prognosis in patients with high hyperdiploidy (Harris et al., 1992). 
Hyperdiploid clones having a DNA index of more than 1.16 have been associated 
with a good prognosis (Look et al., 1985). Attempts have been made to uncover the 
mechanisms underlying the better prognosis of patients with high hyperdiploidy. The 
potential role of methotrexate, a basic component of treatment regimes in ALL, has 
been implicated in one report. High hyperdiploid cells have been shown to 
accumulate high levels of methothrexate and its metabolite, methothrexate 
polyglutamate, in vitro (Whitehead et al., 1992). The role of inferior survival 
capabilities of high hyperdiploid blasts in culture was shown in one report. Manabe 
et al. described a serum -free assay to compare survival requirements of leukaemic B- 
cell progenitors. In this assay the only two cases not giving rise to viable cells in 
culture were patients with a high hyperdiploid clone (Manabe et al., 1992). 
Triploidy/Tetraploidy 
Triploidy/Tetraploidy is defined as the presence of more than 65 chromosomes. It 
accounts for 7% of adults (Secker-Walker, 1990; Secker-Walker et al., 1990) but 
only 2.1 % of children (Secker-Walker, 1998). The prognosis in adults is good and in 
children is unclear. 
1.1.1.2 Acute Myeloid Leukaemia (AML) 
Acute myeloid leukaemia describes malignancies of adults and children affecting 
non-lymphoid cells. In contrast to ALL it affects mostly adults and occurs mainly 
between the ages 22-60 years. The total incidence of AML is 2.5 cases per 100 000. 
The cell involved is an immature blast cell and disease is classified according to the 
features of this cell. 
1.1.1.2.1 FAB classification 
The FAB system classification is based on blast cell morphology. It includes 8 
categories MO to M7. Thus, MO describes myeloblastic AML with minimal evidence 
of differentiation, MI is myeloblastic without maturation, M2 is myeloblastic with 
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maturation, M3 promyelocytic, M4 myelomonocytic, M5 monoblastic, M6 
erythroblastic and M7 megakaryoblastic (Bain, 1998b). 
1.1.1.2.2 Chromosomal abnormalities 
An abnormal karyotype can now be demonstrated in 69% to 84% of patients 
(Misawa et al., 1986; Schiffer et al., 1989; Rowley, 1990). The abnormal karyotype 
in AML involves numerical and/or structural changes. 
Numerical change 
Trisomy 8 
This abnormality is the most frequent abnormality in AML and is seen in 13% of 
cases (IWCL4,1984). This abnormality appears to be relatively specific to myeloid 
disorders. Trisomy 8 is not restricted to any particular FAB type but it is particularly 
frequent in M2, M4 and M5. 
Monosomy 7 
This is the second most frequent numerical abnormality in AML and is observed in 
9% of cases (IWCL4,1984) 
Structural change 
t(8; 21)(q22; q22) 
This translocation was first described by Rowley et al. in 1973 (Rowley, 1973). It is 
the most frequent structural abnormality in AML and it occurs in 15% of cases 
(Mitelman, Heim, 1992). It is also the most frequent abnormality seen in children 
with AML (Raimondi et al., 1989; Petkovic et al., 1992). This abnormality is 
strongly associated with the M2 variant of AML. Patients with this abnormality have 
a relatively favorable prognosis. 
t( 15; 17) (q22; q 11-21) 
This abnormality was first described by Rowley et al (Rowley et al., 1977). This 
abnormality is highly specific to M3 variant of AML and has not been recognized in 
any other type of leukaemia. Patients with AML M3 are younger than other patients 
with AML (Larson et al., 1983; IWCL4,1984; Larson et al., 1984). At the molecular 
level the translocation follows a break within the second intron of the retinoic acid 
receptor alpha gene (RARA) which is a part of the steroid/thyroid hormone receptor 
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superfamily. The truncated gene is then moved to chromosome 15 where it is fused 
to a gene called PML to give rise to a new PML/RARA hybrid gene. The reciprocal 
product of PML/RARA is found on chromosome 17. 
inv(16)(p13; q22) 
This rearrangement of chromosome 16 is detected in approximately 2% of the cases 
with AML. It has been strongly associated with AML M4 with eosinophilia (Arthur, 
Bloomfield, 1983). At the molecular level the inversion interrupts a myosin or 
smooth muscle heavy gene, MYH 11 in 16p 13 and in 16q22, the gene CBFB which 
normally encodes a subunit of a heterodimeric transcription factor. The subsequent 
inversion results in fusion of MYH 11 and CBFB to create a chimeric gene 
Rearrangements of 11q23 
A breakpoint at 11 q23 occurs in a number of translocations. The other chromosome 
involved most frequently is chromosome 9 as t(9; 11)(p21; g23) (Hagemeijer et al., 
1982), also seen is 6 as t(6; 11)(g27; q23) (Martineau et al., 1998), 10 as t(10; 11)(p 11- 
p15; g23) (Berger et al., 1982; Kaneko et al., 1986), 17 as t(11; 17)(g23; q25) (Berger 
et al., 1982; Dewald et al., 1983) and 19 as t(11; 19)(g23; p13) (Berger et al., 1982; 
Vermaelen et at., 1983; Kaneko et al., 1986). The 11g23 breakpoint has been 
strongly associated with AML M5. In this subtype of AML the 11 q23 abnormalities 
were found in 35% of patients (Berger et al., 1982). The association between l 1g23 
abnormalities and M5 is particularly strong in children (Rowley, 1983). The 11 q23 
rearrangements have been associated with lymphoid markers expression in AML 
(Cuneo et al., 1993; Drexler et al., 1993). 
1.1.1.3 Myelodysplastic Syndrome (MDS) 
Myelodysplastic syndrome constitutes a group of diseases of progressive bone 
marrow failure of normal maturation which leads to peripheral cytopenias. 
Usually 
more than one lineage is involved, very often three. It affects mostly elderly patients 
and the incidence is estimated as 1 per 100 000. Approximately 
20% to 40% patients 
with MDS eventually develop AML. 
1.1.1.3.1 FAB classification 
This classification subdivides MDS on the basis of the percentage blasts and some 
morphological features. Thus, refractory anaemia (RA) 
describes MDS with less than 
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5% blasts and less than 15% ringed sideroblasts in nucleated red cells, refractory 
anemia with sideroblasts (RAS) describes an MDS variant with less than 5% blasts 
but more than 15% ringed sideroblasts in nucleated red cells, refractory anaemia with 
excess of blasts (RAEB) describes MDS with 5%-20% of blasts and finally 
refractory anaemia with excess of blasts in transformation (RAEBT) describes MDS 
with 21% to 29% of blasts (Bain, 1998a). 
1.1.1.3.2 Chromosomal abnormalities 
An abnormal karyotype can be demonstrated in 35% to 75% of patients with a 
primary myelodysplastic syndrome (Knapp et al., 1985; Jacobs et al., 1986; Kerkhofs 
et al., 1987; Billstrom et al., 1988; Horiike et al., 1988; Musilova, Michalova, 1988; 
Yunis et al., 1988; Pierre et al., 1989; Geddes et al., 1990; Jotterand-Bellomo et al., 
1990; Suciu et al., 1990; Vila et al., 1990; Ohyashiki et al., 1991). In a review of 
3000 cases with primary MDS, the most frequent chromosomal change was 5q- 
which accounted for 27% of all cases with chromosomal abnormalities (Mufti, 
1992). This was followed by trisomy 8 (19%), monosomy 7 (15%), 11 q- (7%), 
trisomy 7(5%), 12q- (5%), 20q- (5%), i(17q) (5%), 7q- (4%), t(1; 7) (2%) and 13q- 
(2%). Rare abnormalities, accounting for 1% of cases, were as follows t(1; 3), inv 
(3)(q21; q26) and t(3; 3)(q21; q26). 
5q- chromosome 
The deletion of the long arm of chromosome 5, (5q-) constitutes 27% of all abnormal 
karyotypes in primary myelodysplastic syndrome (Mufti, 1992). When 5q- is 
associated with a combination symptoms, the presence of microcytic anaemia, 
elevated or normal platelet counts, hypolobulation of megakaryocytes, and a low risk 
of leukaemic transformation, it identifies the 5q- syndrome (Van den Berghe et al., 
1974). This occurs mainly in elderly women. 
Monosomy 7/7q- 
Monosomy 7 or 7q- accounts for 19% of all abnormal karyotypes in primary 
myelodysplastic syndrome (Mufti, 1992). Monosomy 7 has been associated with 
Down's syndrome (Bunin et al., 1991), Fanconi anaemia (Stivrins et al., 1984) and 
familial monosomy 7 (Paul et al., 1987; Gilchrist et al., 1990). The presence of 
monosomy 7 has been associated with poor prognosis (Nowell, 1992). 
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Trisomy 8 
Trisomy 8 is the most frequent trisomy in human neoplasia and has been shown to 
account for 194/349 of all cases with a single chromosomal gain as the only change 
(Heim, Mitelman, 1986). Trisomy 8 is also the most frequent numerical change in 
MDS and is found in 19% of all cases (Mufti, 1992). The presence of trisomy 8 has 
been associated with poor prognosis (Yunis et al., 1988; Nowell, 1992). 
1.1.1.3.3 Prognostic significance 
Patients with MDS and an abnormal karyotype have a shorter median survival and a 
higher rate of leukaemic transformation than patients with a normal karyotype 
(Kerkhofs et al., 1987; Pierre et al., 1989; Geddes et al., 1990; Suciu et al., 1990). 
The presence of complex karyotypic abnormalities is generally associated with a 
shorter survival rate and a higher leukaemic transformation rate (Pierre et al., 1989; 
Suciu et al., 1990). 
1.1.2 Fluorescence in situ hybridization 
1.1.2.1 Advances in in situ technology 
The technique of in situ hybridization (ISH) was first described in 1969 (Gall, 
Pardue, 1969; Pardue, Gall, 1969; Buongiorno-Nardelli, Amaldi, 1970). It allows the 
detection of specific nucleic acid sequences in biological specimens. It is based on 
the base pairing of a DNA or RNA probe to complementary sequences in cells of the 
tissue under investigation. DNA or RNA sequences are first labeled with reporter 
molecules. The probe and the target DNA are denatured. Complementary sequences 
are then allowed to reanneal. The probes are then detected either directly or 
indirectly following hybridization. The earliest methods used radioactively-labeled 
probes which were then detected by autoradiography. These methods, however. 
suffered from poor resolution and high background. To overcome these limitations 
Rudkin and Sollar described in 1977 the modification of ISH using fluorescent 
detection of chemically modified DNA named fluorescence in situ hybridization 
(FISH) (Rudkin, Stollar, 1977). In the early 1980s a method for direct labeling of 
fluorochromes to DNA probes was developed. 
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1.1.2.2 Probes 
A variety of cloned probes are now available for fluorescence in situ hybridization. 
Chromosome-specific repetitive sequence probes, whole chromosome specific 
probes and unique-sequence probes are now used for metaphase and interphase 
FISH. 
Chromosome-specific repetitive probes 
Repetitive elements of DNA have been cloned for all human chromosomes. 
Repetitive sequences form satellite DNA which occur at or near the centromeres of 
human chromosomes. When hybridized, chromosome-specific, repetitive probes, 
produce compact hybridization signals near the centromere or in heterochromatic 
regions of specific chromosomes. Using these probes it is possible to detect the 
presence and number of human chromosomes on metaphase spreads and in 
interphase nuclei. 
Whole chromosome probes. 
DNA sequences derived from a single human chromosome can be used to detect that 
chromosome in metaphase spreads and interphase nuclei. Such probes are derived 
either from somatic cell hybrids containing a single human chromosome or from 
suspensions of chromosomes purified by flow sorting. When hybridized, whole 
chromosome probes produce signals that cover nearly the entire length of the 
chromosome. 
Unique-sequence probes 
Depending on their size, unique-sequence probes have been cloned using different 
vectors. Thus plasmid vectors are used for cloning inserts of 1-10 kb, cosmid vectors 
contain inserts of 35-45 kb and yeast artificial chromosomes (YACs) contain 
inserts 
of 200 to 1000 kb. The efficiency of site detection decreases with 
decreasing probe 
size. 
1.1.3 The advantages and limitations of cytogenetics and 
FISH 
1.1.3.1 Detection of a clone by cytogenetic analysis 
The detection of clonal chromosomal abnormalities in patients with haematological 
disorders enables the distinction to be made between diseases of neoplastic and those 
of non-neoplastic origin. It constitutes, therefore, a useful 
diagnostic tool and has 
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important therapeutic implications. Cytogenetics is the only technique which is 
routinely used for the detection of clonality in patients with haematological disorders. 
The criteria used to define 'chromosomally abnormal' or 'cytogenetically clonal' 
neoplasm were established by ISCN 1985 and they are met when at least three cells 
with the same chromosomal loss or two sharing the same chromosomal gain or 
structural abnormality are detected (ISCN(1985), 1985). Applying these criteria 
cytogenetic analysis is now capable of detecting a chromosomally abnormal clonal 
population at diagnosis in up to 90% of cases of acute lymphoblastic leukaemia (ALL) 
(Pui et al., 1990; Seeker-Walker, 1990; Dastugue et al., 1992; Van der Plas et al., 
1992b; GFCH, 1993), 35%-75% of cases of myelodysplastic syndrome (MDS) (Knapp 
et al., 1985; Jacobs et al., 1986; Geddes et al., 1990) and 69%-84% of cases of acute 
myeloid leukaemia (AML) (Misawa et al., 1986; Schiffer et al., 1989; Rowley, 1990). 
Cases in which a clone is not detected in the bone marrow are either described as 
chromosomally normal, or as `fails' depending on the number of metaphases available 
for analysis. If less than 20 cells are available the case is described as failed. 
1.1.3.2 Clonality and chromosomal classification of `Normal' 
It is unclear whether chromosomally normal cases truly lack an abnormal clone, or 
whether such cases result from the limitations of the cytogenetic technique. 
Cytogenetic analysis is limited by time constraints to no more than 20 cells. This puts 
serious limits on the sensitivity of the technique. It has been shown that analysis of 20 
metaphases will exclude the presence of an actively dividing >I I% clone with 90% 
confidence (Hook, 1977). It follows that clones involving less than 11% of the 
metaphase population are likely to be missed on routine cytogenetic examination and 
such cases will be classified as chromosomally normal. This is of particular 
importance in cases where malignant cells are dividing less efficiently in culture than 
their normal counterparts. As a result a malignant clone which is underrepresented 
within the dividing population may escape cytogenetic detection. The existence of 
malignant clones with low survival properties has been shown in one report. Manabe at 
al. described a serum -free assay to compare survival requirements of leukaemic B-cell 
progenitors. In this assay, two cases not giving rise to viable cells in culture were 
patients with high hyperdiploid clones (Manabe et al., 1992). 
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1.1.3.3 Clonality and random abnormal cells 
Chromosomally normal cases are of two kinds: those in which no abnormal cell is 
detected and those with random changes i. e. having a single cell showing structural 
change or chromosomal gain, or no more than two cells with the same chromosomal 
loss. The presence of a single abnormal cell among 20 cells analyzed raises doubts 
about its clonal nature. It has been reported that a single abnormal may precede the 
emergence of a malignant clone. Seeker-Walker et al. described a patient in remission 
from ALL in whom a single cell with monosomy 7 was found in a bone marrow 
sample. Six months later a clone with monosomy 7 was detected on cytogenetic 
analysis. This was followed by the emergence of AML (Seeker-Walker, Sandler, 
1978). McConnel et al described a patient with AML in whom a random trisomy 8 cell 
was seen several months before full emergence of a clone with trisomy 8 (McConnell 
et al., 1991). 
1.1.3.4 Clonality of cryptic chromosomal abnormalities. 
Another aspect of cytogenetic examination which may lead to a diagnostic 
misinterpretation is the size of the chromosomal lesion. With improved banding 
techniques it is now possible to detect chromosomal defects as small as 5 Mb. Even 
though, the gap between cytogenetic sensitivity and the scale of a molecular event 
remains enormous. The likelihood that there are cases where a chromosomal change 
is not large enough to produce a visible distortion in a chromosomal banding pattern 
remains high. 
1.1.3.5 Clonality and a chromosomal classification of `fail'. 
Cases in which a clone is not detected and the number of available metaphases is lower 
than required (usually 20) are classified as `failed'. The reported failure rate in ALL 
is 
as high as 23% to 33% (Jackson et al., 1990; Secker-Walker, 1990; Harris et al., 
1992). 
This leaves a considerable margin of cases in which the cytogenetic diagnosis is not 
possible due to a lack of dividing cells. It has been shown in one report that the chance 
to obtain an adequate number of metaphases depends greatly on the quality of sample. 
Hawkins et al. showed that the likelihood of obtaining 10 or more cells for analysis in 
adult ALL was as low as 10% for suboptimal samples 
(Hawkins, Seeker-Walker, 
1991). 
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1.1.3.6 Clonality and FISH 
Fluorescence in situ hybridization (FISH) is a technique which can be used to detect 
the presence of chromosome abnormalities to which probes are available in both 
mitotically active and resting cells. In contrast to cytogenetics it is possible to include 
large numbers of cells in the analysis, making for more sensitive clone detection. In 
addition the use of unique sequence DNA probes makes it possible to delineate 
cytogenetically invisible genetic changes. Interphase FISH with chromosome-specific 
centromeric probes has been used to look for trisomy and monosomy and to determine 
the presence of clonal chromosome abnormalities in various haematological 
malignancies. Anastasi et al (Anastasi et al., 1992) used a chromosome 12 specific 
centromeric probe in cases with chronic lymphocytic leukaemia. FISH confirmed the 
presence of trisomy 12 in the diagnostic bone marrow samples in 7/7 patients in whom 
the above abnormality had been previously found by cytogenetics. In addition trisomy 
12 was detected in 5 cases: in one case thought to have a normal karyototype, in two 
cases that had been inadequate for routine cytogenetic analysis, and in two cases that 
had been found to have an abnormal karyotype without trisomy 12. FISH using 
chromosome 7 and chromosome 8 specific probes has been applied to detect 
monosomy 7 and trisomy 8 in patients with myeloid neoplasia (Kibbelaar et al., 
1993). In that report most samples with nonclonal metaphase aberrations, including 
those with only a few metaphases, had increased numbers of aberrant interphase cells: 
20% to 80% for -7 and 3% to 43% for +8. In report by Jenkins et al (Jenkins et al., 
1992), a chromosome 8 specific probe has been used to detect trisomy 8 in patients 
with myeloproliferative disorders (MPD), myelodysplastic syndromes (MDS) and 
acute myeloblastic leukaemia (AML). In 4/13 patients in whom the initial diagnostic 
cytogenetic analysis revealed a single abnormal metaphase, FISH analysis found 
significant levels of cells with trisomy 8. Brizard et al (Brizard et al., 1994) reported 
that FISH using chromosome-specific centromeric probes revealed monosomy 7 which 
was undetectable by karyotypic study in 5%-22% cells from 15 patients with MDS. In 
a report by Chen et al (Chen et al., 1993b), in 10/10 patients with a single trisomic cell 
on metaphase analysis (random trisomies) FISH detected the presence of a clone in 
interphase cells indicating that these `random' abnormalities were in fact clonal. The 
use of unique-sequence probes to detect clonality has been demonstrated in a report by 
Van Rhee et al (Van Rhee, Kasprzyk, 1995). A patient with ALL was found to have 
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only chromosomally normal metaphases on a routine cytogenetic examination. 
However, when probes containing fragments of BCR and ABL genes were used the 
juxtaposition of the two genes on the apparently normal chromosome 22 was 
demonstrated. 
Thus, FISH can be successfully used for the detection of numerical as well as 
structural chromosome abnormalities. The main disadvantage of FISH is the fact that 
it is incapable of a comprehensive description of all chromosomal abnormalities 
occurring in the malignant clone. It is instead guided by cytogenetic analysis. 
In summary, conventional cytogenetics of haematological malignancy has proved to 
be a valuable tool in haematological practice. It has however important limitations. 
FISH which is at present time incapable of replacing cytogenetics in its diagnostic 
task has several advantages. The sensitivity of FISH and the fact that it does not need 
dividing cells makes it an ideal candidate to investigate cases where cytogenetics was 
ambiguous or unavailable. 
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1.2 CLONALITY AND LINEAGE INVOLVEMENT IN 
HAEMATOLOGICAL MALIGNANCY 
1.2.1 Normal haemopoiesis 
1.2.1.1 Stem Cell Model 
The modem concept of haematopoiesis is based on the stem cell model which assumes 
that all blood cells are derived from a pool of primitive progenitor cells called 
pluripotent stem cells. Pluripotent stem cells are capable of proliferation, 
differentiation, self-renewal and give rise to a series of committed progenitor cells for 
all blood cell lineages. Committed progenitor cells, which are capable of extensive 
proliferation without self-renewal, give rise after a number of cell divisions and 
differentiation steps to mature cells (McCulloch, 1983). 
The existence of myeloid and lymphoid progenitors has been demonstrated in mice 
(Curry et al., 1967; Abramson et al., 1977) and in humans (Messner et al., 1981) by in 
vitro culture techniques. Stem cells have also been demonstrated using glucose-6- 
phosphatase (G6PD) isoenzymes analysis in humans (Fialkow et al., 1977; Martin et 
al., 1980). 
Early myeloid committed progenitor cells are identifiable by in vitro assays (Johnson, 
Metcalf, 1977; Fauser, Messner, 1979; Messner et al., 1981; Gordon, 1993). These 
comprise mixed myeloid progenitor cells capable of giving rise to all myeloid lineages 
(CFU-GEMM), granulocyte-monocyte progenitors (CFU-GM), erythrocyte 
progenitors (CFU-E), megakaryocyte progenitors (CFU-Mk), basophil progenitors 
(CFU-B) and eosinophil progenitors (CFU-Eo). Late myeloid committed progenitor 
cells are identifiable by staining techniques and consist of myeloblasts, 
megakaryoblasts and erythroblasts. Mature myeloid cells are also identifiable by 
staining techniques both in bone marrow and peripheral blood and consist of basophils, 
eosinophils, neutrophils, erythrocyte, megakaryocytes and monocytes. 
The evidence for subsequent stages in lymphopoiesis, which result in the formation of 
B and T lymphocytes, has come from immunophenotype and molecular analysis of 
lymphoid malignancies. The concept of lymphopoiesis is based on the hypothesis that 
the leukaemic cells are the neoplastic counterparts of normal lymphoid progenitors 
'frozen' at various stages of their development. 
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The in vitro conditions to for the myeloid precursor (CFU-GEMM) are well 
established. In contrast, the existence of its lymphoid counterpart capable of giving rise 
to both B and T lymphocytes has not been proven as yet. There is however indirect 
evidence that such a lymphoid precursor may really exist. The evidence came from 
immunoglobulin gene (IGH) rearrangement studies. These have shown the presence of 
rearranged IGH genes in both T and B lymphocytes in mice (Kemp et al., 1980; 
Kurosawa et al., 1981) and in human lymphoid tumors (Pelicci et al., 1985) 
The subsequent stages of B cell development consist of the following stages: a proB, 
pre-B and mature B-cell. The pro-B stage is characterized by the DR and CD34 
expression. Both, heavy and light chain immunoglobulin genes are in the germline 
configuration. The pre-B stage is characterized by the expression of CD 10, CD 19 and 
CD34 which is later on replaced by CD22, CD20 and surface IgM. Heavy-chain 
immunoglobulin genes are rearranged at this stage. During the B-cell stage both heavy 
and light immunoglobulin genes are rearranged and the cell expresses CD 19, CD20, 
CD21, CD22. The mature B-cell stage is characterized by the expression of surface 
immunoglobulins (first IgM, then IgM plus IgD, then other isotypes) (Foon, Todd, 
1986; Pui et al., 1993). 
The sequence of events in T-cell development, originally proposed by Reinharz 
(Reinherz et al., 1980) and based on immunological data was later modified and 
enriched with data from T-cell receptor gene rearrangement studies. T-cell ontogeny 
divide into four stages: stage I-'double negatives' (CD4 -ve and CD8 -ve) with 
expression of CD3, CD2, CD7, TdT and beta chain T-cell receptor genes in germline 
position; stage II-'double positives' with CD4 and CD8 expression and beta chain genes 
rearranged; stage III with the retention of CD4 and CD8 but without TdT and stage IV 
with the expression of either CD4 or CD8 and fully assembled alpha/beta T-cell 
receptor complexes (Foon, Todd, 1986; Pui et al., 1993). 
1.2.1.2 Control of haematopoiesis 
Haematopoiesis maintains the number of cells of all lineages at a constant level during 
steady state but it is also capable of responding to an environmental stimulus (bacterial 
infection, hypoxia) by elevating the production of cells of a specific lineage. It follows 
that tight control over cell production (proliferation), specialization (differentiation, 
commitment) and programmed cell death (apoptosis) is necessary. The important role 
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in the control of haematopoiesis is played by haematopoietic growth factors (HGF) and 
haematopoietic microenviroment (HM) 
Haematopoietic growth factors 
Haematopoietic growth factors (HGFs) are the glycoprotein hormones that regulate the 
proliferation and differentiation of committed progenitors and the function of mature 
blood cells. The HGFs identified in in vitro colony assays are called colony stimulating 
factors (CFSs) and those derived from lymphocytes are termed interleukins (ILs). The 
main functions of HGFs are stimulation of cell survival (prevention of apoptosis), 
proliferation and differentiation. More mature cells may also respond to HGFs by 
increased functional activity and or production of other growth factors (Metcalf, 1989; 
Nicola, 1989; Cross, Dexter, 1991). Dependent on the cell stimulated, the growth 
factors are classified as multilineage and lineage restricted HGFs. Multilineage HGFs 
comprise stem cell factor (SCF), granulocyte, monocyte colony stimulating factor 
(GM-CSF) and interleukin 3 (IL-3). Lineage restricted HGFs comprise IL-5 (acting on 
eosinophilic lineage), IL-6 (restricted to megakaryocytic haemopoiesis), granulocyte 
colony stimulating factor (G-CFS) (stimulating granulopoiesis), erythropoietin (Eo) 
(stimulating erythropoiesis) and monocyte CSF (acting on monocyte precursors). 
All HGFs act via a common signalling pathway that consists of cell surface receptors, 
and intercellular signalling devices. Two types of HGF's receptor have been described. 
The first type (M-GCF receptor) has an extracellular, ligand-binding domain and an 
intracellular, tyrosine kinase domain responsible for transducing the signal (Ullrich, 
Schlessinger, 1990). The second type of receptor, common for 11-3, GM-CSF, IL-5 
contains several subunits but does not contain protein tyrosine kinase (PTK) (Miyajima 
et al., 1993). 
Haematopoietic microenviroment 
The haematopoietic microenvironment is the place of haematopoietic cell 
development. The haematopoietic microenvironment consists of macrophages, 
endothelial cells, fibroblasts and adipocytes (Du, Williams, 1994). The potential 
functions of the haematopoietic microenvironment are: the stabilization of growth 
factors by binding to extracellular matrix molecules or membrane proteins, the 
production of both positive and negative regulators of haematopoiesis and 
colocalizations of haematopoietic cells and growth factors allowing receptor 
modulation by small quantities of cytokines (Williams, 1993). 
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1.2.2. Malignant haematopoiesis 
1.2.2.1 Stem cell model and malignant haematopoiesis 
Although the outcome of neoplastic haematopoiesis is different from its normal 
counterpart the stem cell model is still applicable for the description of this kind of 
haematopoiesis. Experiments with clonogenic AML cells in vitro have revealed a small 
proportion of actively dividing cells that correspond to the haematopoietic cell 
progenitors (Griffin, Lowenberg, 1986; Lowenberg, Touw, 1993). Experiments with 
B-precursor leukaemia have also shown that subpopulations of cells at an early stage of 
differentiation show a clonogenic advantage, which is typical of progenitor cells 
(Estrov et al., 1993; Ashley et al., 1994; White et al., 1995). Also, experiments with C- 
ALL, revealed subpopulations with a less mature phenotype (Ryan et al., 1986) and 
showed that these had greater clonogenic activity (Ashley et al., 1994). 
1.2.2.2 Clonality 
In contrast to normal haemopoiesis which is multiclonal and contain members of 10 to 
25 clones as demonstrated by Fialkow (Fialkow, 1973), leukaemopoiesis is 
monoclonal. Haematological malignancy results from proliferation of the progeny of a 
single cell. The first indication of that was the observation in multiple myeloma that the 
secreted immunoglobulin was electrophoretically homogenous. The concept of 
monoclonality has finally become established after the work of Fialkow using specific 
markers of clonality such as glucose-6-phosphatase (G6PD). By analysis of G6PD 
isoenzymes a clonal origin has been demonstrated for the tumour cells in several 
haematological diseases. 
Techniques used for the detection of clonality 
In addition to G6PD isoenzymes analysis, evidence for the monoclonal origin of 
neoplasia has also come from the application of many other techniques. Techniques 
which have demonstrated the monoclonal nature of neoplasia include: X-linked 
restriction fragment length polymorphism (RFLP), light chain restriction, 
immunoglobulin and T-cell receptor rearrangements, cytogenetics, a combined 
morphology, antibody, chromosome (MAC) technique and fluorescence in situ 
hybridization (FISH). 
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Glucose-6-phosphatase (G6PD) isoenzymes analysis 
This technique has been widely used in order to establish the monoclonal origin of 
many haematological malignancies. The G6PD enzyme gene is located on the X 
chromosome. The enzyme occur in two forms A and B. Heterozygous females have 
both enzymes. According to the Lyon hypothesis, one of the two X chromosomes 
becomes inactivated. Some somatic cells will express G6PD A and some G6PD B. The 
G6PD isoenzymes analysis of a given tissue is accomplished by determining the ratio 
of two G6PD isoenzymes A and B. Polyclonal tissue will show both isoenzymes, 
while monoclonal only one either A or B. 
X-linked restriction fragment length polymorphism (RFLP) 
Restriction fragment length polymorphism (RFLP) indicates the variation in the size of 
a DNA fragment, detectable with a given probe, after digestion with a restriction 
enzyme. The combination of various RFLPs along one chromosome is called the 
haplotype. This technique is used to establish monoclonal or polyclonal origin of a 
given tissue in women having different RFLP haplotypes ('informative' women). 
Similar to the G6PD analysis, X-linked RFLP analysis of monoclonality is based on 
the Lyon hypothesis. Polyclonal tissue will show two different RFLP haplotypes, 
monoclonal only one haplotype. 
Immunoglobulin and T-cell receptor rearrangements 
This technique is applicable to lymphoid tissue only. The mono or polyclonal origin of 
tissue can be determined by examining immunoglobulin (IG) or T cell receptor (TCR) 
gene rearrangement patterns. In a polyclonal tissue a diversity of rearrangements will 
be present while monoclonal populations will have only one rearrangement. 
Light chain restriction 
This technique is applicable to B-lymphoid tissue only. A mature B lymphocyte 
expresses a surface immunoglobulin which contains either Kor ? light chain In a 
polyclonal population of B lymphocytes both K and 2 immunoglobulin light chain will 
be detected, in a monoclonal only one, either x or k. 
Cytogenetics 
This technique is now routinely used for the determination of clonality in 
haematological malignancy. The clonal status of a given tissue is established when two 
cells with the same structural change or chromosomal gain, or three cells sharing the 
same chromosomal loss are found. 
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Morphology, Antibody, Chromosome (MAC) 
Morphology, Antibody, Chromosome (MAC) technique can be used to identify 
chromosomal abnormalities in cells which had been previously morphologically or 
immunologically stained (Teerenhovi et al., 1984; Teerenhovi et al., 1986; Knuutila, 
Teerenhovi, 1989). The method differs from conventional cytogenetics in that after 
hypotonic treatment, the cells are cytocentrifu ged onto glass slides. In mitotic cells, 
this procedure results in an adequate spread of the chromosomes within the intact cell 
membrane. The cytoplasmic structure also remains intact, so that cytogenetic 
preparations are of good quality. Morphologic and immunologic identification of 
mitotic cells can be done using routine haematological stains, such as Giemsa or Sudan 
black B. and various antisera using immunofluorescence or alkaline phosphatase anti- 
alkaline phospahatase (APAAP) technique. The chromosomes can be simultaneously 
analyzed on slides stained with Q or G-banding. Such an approach enables the 
detection of chromosomal abnormalities in particular cell lineages. 
Fluorescence in situ hybridization (FISH) 
Certain chromosome abnormalities can be detected in interphase cells using DNA 
probes with fluorescent in situ hybridization (FISH). When interphase FISH is 
combined with morphology or immunophenotyping it is possible to establish in which 
cell lineages the chromosomal abnormalities occur. FISH can be carried out on 
peripheral blood or bone marrow smears which have been previously stained and 
morphologically classified. Selected cells must be photographed and then relocated 
after hybridization (van Lom et al., 1993; Nguyen et al., 1994). For the simultaneous 
detection of immunophenotype and chromosome abnormalities the APAAP technique 
for immunophenotyping has the advantage that it is visible with light as well as with 
fluorescent microscopy (Price et al., 1992). 
1.2.2.3 Leukaemic progenitor cell 
G6PD isoenzymes analysis, X-linked RFLP, MAC and FISH have all been used to 
determine the extent of clonality in different types of haematological malignancy. 
The detection of clonality in a particular cell lineage provides circumstantial 
evidence for the type of haematopoietic progenitor cell in which the malignant 
transformation has taken place. Thus, the greater the number of cell lineages 
involved the more pluripotent is the leukaemic progenitor cell. 
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The origin of myeloproliferative disorders 
All myeloproliferative disorders (MPDs) are thought to arise in a pluripotent stem cell. 
The presence of a single G6PD isoenzyme has been detected in the blood cells of 
women with CML who are heterozygotes for isoenzymes A and B (Fialkow et al., 
1967; Fialkow et al., 1977; Koeffler et al., 1980). The cells include red cells, 
neutrophils, eosinophils, basophils, monocytes and platelets. Fibroblasts and other 
somatic cells showed the presence of both isoenzymes. In some cases the involvement 
of B lymphocytes has also been shown (Martin et al., 1982). When the analysis of 
G6PD isoenzymes was applied to patients with polycythemia vera (PV) a single 
isoenzyme type was detected in granulocytes and platelets (Adamson et al., 1976). 
Using similar methods Raskind et al have also demonstrated the involvement of B- 
cells (Raskind et al., 1985). 
The origin of myelodysplastic syndrome 
The origin of MDS is still debatable. A variety of techniques such as chromosome 
analysis, X-linked RFLP and PCR amplification of point mutations in the ras gene 
have shown that MDS is a clonal disease which has arisen in a multipotent stem cell. 
The abnormal clone has been shown to give rise to granulocytes, monocytes and B and 
T- lymphoid cells (Janssen et al., 1989). In contrast, FISH of interphase peripheral 
blood cells with probes for chromosomes 7 or 8 in patients with monosomy 7 or 
trisomy 8 respectively has shown that chromosome abnormalities were not present in 
lymphoid cells (Gerritsen et al., 1992; Anastasi et al., 1993). 
The origin of acute myeloid leukaemia 
Studies of female patients with AML who are heterozygous at the G6PD locus indicate 
that virtually all cases of AML at clinical presentation are monoclonal (Fialkow et al., 
1979; Fialkow et al., 1981). It is now assumed that AML arises in a committed 
myeloid progenitor cell. The exact level of transformation, however, is disputable. A 
G6PD analysis of cells derived from different haematopoietic lineages in individual 
AML patients indicated that, in some cases, the disease was restricted to 
granulocyte/monocyte progenitors. Other cases suggested a multipotent myeloid 
progenitor giving rise to cells of the granulocyte, erythroid and megakaryocytic 
lineages (Fialkow et al., 1979; Fialkow et al., 1981). These studies reflect heterogeneity 
in the cell of origin in different cases of AML. In some patients the disease appears to 
be restricted to cells of the granulocyte/monocyte lineages wE ci would indicate that 
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transformation has occurred at CFU-GM level. In other cases the disease involves, in 
addition, erythroid and megakaryocytic lineages suggesting that the transformation has 
occurred at CFU-GEMM level. None of the studies, however, indicated the 
involvement of the lymphoid lineage which would have suggested that the target cell 
was a multipotent stem cell. Myeloid restriction of AML was also reported in the 
studies where certain chromosomal abnormalities were used as markers of clonality 
(Keinanen et al., 1988; Starnberg et al., 1988; Baurmann et al., 1993; van Lom et al., 
1993; Kwong, Chan, 1994). 
The origin of acute lymphoblastic leukaemia 
ALL is regarded as the result of a somatic mutation in a committed lymphoid 
progenitor cell. Dow et al (Dow et al., 1985) investigated isotypes of the glucose-6- 
phosphate dehydrogenase (G6PD) isoenzymes in 19 females heterozygous for this X 
chromosome-linked enzyme. The lymphoid blast cells from all cases displayed a 
single, (either A or B G6PD) isoenzyme type while in other cell lineages both A and B 
G6PD types were observed. The lack of myeloid involvement was also confirmed in 
the studies where certain chromosomal abnormalities were used as markers (Knuutila 
et al., 1993; Martin-Henan et al., 1994). 
The origin of the acute leukaemias may be heterogeneous. 
The assumption that acute leukaemia arises in a cell committed to lymphoid (ALL) or 
myeloid (AML) development cannot be however regarded as firmly established. It has 
been shown that in a proportion of Ph+ ALL the abnormality was detected not only in 
lymphoid but also in cells of myeloid origin (Tachibana et al., 1987; Kalousek et al., 
1988; Dow et al., 1989; Raimondi et al., 1990; Jackson et al., 1992). Similarly, the 
existence of so called `hybrid' or `mixed' leukaemias, showing features of both 
myeloid and lymphoid lineages, seems to contradict the above presumptions. Mixed 
lineage (biphenotypic) leukaemia refers to cases in which both lymphoid and myeloid- 
associated surface antigens are expressed on the same cells. The incidence of mixed 
lineage leukaemia has been estimated to be as high 15% to 20% in some studies but 
generally ranges from I% to 10% of ALL (Mirro et al., 1985; Hoelzer, Gale, 1987) and 
16.8% of AML cases (Pui et al., 1991). Mixed leukaemia has been strongly associated 
with the 11 q23 abnormalities and the Philadelphia translocation (Drexler et al., 1991; 
Hudson et al., 1991; Cuneo et al., 1992; Cuneo et al., 1993). There are two hypotheses 
aiming to explain the origin of `mixed' leukaemias. The basic concept of the so called 
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`lineage infidelity' theory is that the leukaemic cell has an aberrant combination of 
markers as a consequence of its leukaemic developmental programme. This model was 
originally suggested by McCulloch following the demonstration of erythroid and 
myeloid markers in several leukaemic cell lines (Marie et al., 1981). These 
observations were later extended to AML blasts that had cytoplasmic immunoglobulin 
and surface myeloid antigen (Smith et al., 1983). An alternative explanation was 
proposed by Greaves (Greaves et al., 1986). According to his `lineage promiscuity' 
theory, commitment to different lineages may be an inefficient process and certain cells 
may retain features which are normally lost during commitment to a lineage. 
Alternatively certain cells may actually develop features of a separate lineage from that 
to which they are committed. It is suggested that the leukaemic process will 
`immortalise' an otherwise non-viable marrow precursor in a pre-commitment phase of 
haematopoiesis. Coexpression of different lineage markers may, as a consequence, be 
associated with leukaemic blasts. 
1.2.3 Leukaemic stem cell and chemocurability 
Modem treatment regiments have produced striking differences in therapeutic success 
between different leukaemias. Thus, 70% of children with ALL are now expected to 
achieve long remission and probably cure (Chessells, 1992). In contrast, long term 
remission in adults with ALL is expected in no more than 30% of patients (Secker- 
Walker et al., 1997). Similar figures (16%-28%) are quoted for patients with AML 
(Ben-Bassat et al., 1993). The reason why these differences occur is a subject of a 
much speculation. Pinkel suggests that it is the genotype of the leukaemia that 
determines its response to therapy, but not the cell type (Pinkel, 1987). He argues that 
the genetic alterations underlying leukaemic cell transformation disrupt the 
characteristics of the cell to an extent that a clear relationship to a normal cell cannot be 
ascertained. He argues that chemotherapy of a given leukaemia should be dictated by 
the chromosomal or/and genetic make-up, rather by the presumed cell type. To support 
his hypothesis he quotes the well known fact that leukaemia can be stratified into 
different prognostic groups according to chromosomal abnormalities e. g. hyperdiploidy 
or Ph+ ALL. A different view is held by two authors. Jasmin at al (Jasmin, 1988) 
suggests that the low success rate in CML, MDS and adult acute leukaemia is the result 
of the stem cell origin of the tumour. He argues that haematological malignancies of 
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stem cell origin are chemo-incurable and can only be cured by bone marrow 
transplantation. A proportion of the acute leukaemias, occurring predominantly in 
children and which are chemo-curable, are derived from the compartment of 
haemopoietic progenitors already irreversibly committed to a single lineage. A similar 
view is held by Greaves. In his report Greaves hypothesises that most childhood acute 
lymphoblastic leukaemias and some other paediatric cancers are chemo-curable 
because they arise in cell populations which are functionally transient, chemosensitive 
and programmed for apoptosis. Greaves argues that most adult acute leukaemias are 
chemo-incurable, at least in part because they originate in relatively drug resistant 
pluripotent stem cells with extensive self renewal capacity. The latter property, in turn, 
increases the probability of clones evolving with multi-drug resistance (Greaves, 
1993). 
However, the association between stem cell leukaemia and prognosis seems to be more 
complicated. Secker-Walker et al. reviewed the prognostic implications of the lineage 
heterogeneity in Ph+ ALL (Secker-Walker, Craig, 1993). Patients with myeloid as 
well as lymphoid involvement of clonal cells had significantly longer survival than 
patients with lymphoid involvement only. This was later confirmed by Anastasi et al. 
(Anastasi et al., 1996). Paradoxically, this finding is contrary to the theoretically 
predicted features of stem cell leukaemia (Jasmin, 1988; Greaves, 1993). Further 
studies on the issue are required. Meanwhile, the therapeutic implications of the level 
of commitment of the leukaemic target cell has emerged as an important question. 
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1.3 THE DETECTION OF MINIMAL RESIDUAL DISEASE IN 
ACUTE LYMPHOBLASTIC LEUKAEMIA 
The current treatment of patients with ALL results in a high remission rate, especially 
in childhood. However, many of those who achieve complete remission will eventually 
relapse. It has been shown that most relapses originate in neoplastic cells that are a part 
of the clone seen at diagnosis (Borella et al., 1979; Dow et al., 1985; Pui et al., 1986; 
Raghavachar et al., 1987; Steward et al., 1994). It follows that leukaemopoiesis 
continues during remission. 
Complete remission (CR) is clinically defined as not more than 5% of blasts in a 
patient's bone marrow. The leukaemic cells which persist in the bone marrow of a 
patient in remission are termed minimal residual disease (MRD). It has been shown 
that the presence of 5% blasts in the bone marrow may represent a leukaemic burden of 
MRD as high as 1010 blasts (Van Bekkum, 1984). 
The importance of MRD detection in patients in complete remission lies in the 
possibility that it may be possible to establish a relationship between the size of the 
clone and risk of relapse. The ability to detect and quantitate MRD in ALL and to 
relate this to the risk of relapse would provide the means of monitoring the 
effectiveness of treatment and adjusting therapy when necessary. Although the exact 
link between the number of leukaemic cells and patient's prognosis has not yet been 
established, some evidence exists that the detection of low levels of leukaemic cells 
may precede the full re-emergence of the clone and subsequent relapse (Campana et 
al., 1990; Anastasi et al., 1991a; Potter, 1992; Cole-Sinclair et al., 1993; Nizet et al., 
1993; Cave et al., 1994; Nylund et al., 1994; Kitchingman, 1995). 
1.3.1 Methods for MRD detection 
Leukaemic cells can be distinguished from normal haematopoietic progenitors on the 
basis of morphologic and cytochemical properties, karyotypic or genetic abnormalities, 
antigen-receptor gene rearrangements, cell growth requirements in vitro and 
immunophenotype. Combinations of these characteristics have been exploited to detect 
small numbers of neoplastic blasts among normal cells. 
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1.3.1.1 Morphology 
The morphological approach for the detection of MRD involves microscopical 
evaluation of the bone marrow or extra-medullar sites such as the central nervous 
system and testis. In the bone marrow, the presence of normal blasts limits the 
sensitivity of this approach to 5%. A common problem which is encountered with 
morphological scanning for MRD in childhood ALL, is caused by the presence of a 
rebound lymphocytosis at the end of chemotherapy. This may lead to a false 
conclusion about impending relapse (Borella et al., 1972). Attempts to monitor disease 
by serial examinations of the bone marrow throughout chemotherapy have been 
disappointing (Komp et al., 1983; Rogers et al., 1984). One such study yielded 75% of 
false negative results (Komp et al., 1983). Problems have also been encountered when 
examining extramedullary sites. In the examination of cerebro-spinal fluid, false 
positives may occur due to contamination with peripheral blood, or cell morphology 
may be altered by centrifugation, viral infection or chemotherapy (Odom et al., 1990). 
The detection of MRD in testis has been complicated by high false negative rates 
resulting from sampling errors and the difficulty in distinguishing between testicular 
stromal cells, lymphocytes and lymphoblasts (Hudson et al., 1985; Pui et al., 1985). 
1.3.1.3 Cytogenetics 
Cytogenetics plays an important role in the diagnosis and prognosis of ALL. Improved 
cytogenetic methods allow detection of a chromosomally abnormal clonal population 
at diagnosis in up to 90% of cases (Pui et al., 1990; Secker-Walker, 1990; Dastugue et 
al., 1992; Van der Plas et al., 1992b; GFCH, 1993). However, the tracking of MRD 
with this technique suffers from serious limitations. The cytogenetic approach is 
restricted by time constraints to analysis of no more than 20 cells. This puts a serious 
limit on the sensitivity of the technique. It has been shown that analysis of 20 
metaphases will exclude the presence of an >I I% clone with 90% confidence (Hook, 
1977). This is much higher than the 5% limit of the definition of clinical remission and 
only clones with a high mitotic rate are likely to be detected. 
The main advantage of the cytogenetic approach is its flexibility. Cytogenetics unlike 
many other methods does not have to rely solely on the abnormalities detected at 
diagnosis. Providing clonal evolution has not involved loss of all the chromosomal 
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abnormalities, leukaemic cells can be still identified, even though their chromosomal 
4 make up' may have changed. 
1.3.1.4 Immunology 
Immunological methods represent a rapid option for investigation of MRD in a 
significant proportion of patients with ALL. This technique relies upon detection of 
leukaemia-associated immunophenotypes which were detected at diagnosis on 
leukaemic blasts. These can be then used to detect MRD at various levels of 
sensitivity. The potential sensitivity of detection of residual disease expressing any 
combination of antigens is determined by the background level of normal cells that 
express the same markers. Single antigens are not suitable for distinguishing neoplastic 
from normal lymphohaematopoietic cells, because the same antigens found on 
malignant cells are also present on their normal counterparts (Janossy et al., 1979; 
Greaves et al., 1980). To overcome this problem double and triple staining techniques 
have been developed. The detection of MRD in T-ALL using double staining has 
proved to be particularly effective. The combination of antigens which are found on T- 
ALL blasts, CD3/TdT, occur in 90% of T-ALL and are very rare in normal marrows 
(Campana, Pui, 1995). These combinations of antigens allow the detection of MRD 
with a sensitivity of < 0.01% (Campana et al., 1990). In B-lineage ALL, TdT is 
expressed in association with Cµ, CD21, CD33, Cdw65, CD13 or CD2 (Campana et 
al., 1990; Campana et al., 1991). The detection of MRD in B-lineage ALL using 
double staining is not as sensitive as its T-lineage counterpart. Thus, CD13/TdT or 
CD33/TdT positive cells constitute 5%-10% of the normal bone marrow population, 
while marker combinations of cp. /TdT or CDw65/TdT occur in up to 20% of the TdT 
population (Campana et al., 1990). The combination of TdT/ Cµ, which occurs most 
frequently in childhood ALL is present on cells found in the marrows of healthy 
infants and on marrows which are regenerating, and the sensitivity of detection using 
this marker combination is only 10-3 (Campana et al., 1990; Campana et al., 1991). 
The use of triple staining techniques can markedly improve the sensitivity of MRD 
detection in B-lineage ALL. There are at least 11 triple antigens combinations which 
are now being used as MRD targets and are sufficiently sensitive to detect between 
0.0 1% and 0.03%± 0.02% malignant cells (Campana, Pui, 1995). 
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1.3.1.5 Polymerse Chain Reaction (PCR) 
The introduction of PCR has set new standards for the analysis of MRD in patients 
with leukaemia by allowing the identification of as few as one malignant cell in a 
background of 105 or 106 normal cells (Fey et al., 1991; Sklar, 1991; Malinge et al., 
1992; Potter, 1992; Thompson et al., 1992; Cross et al., 1993). There are two marker 
categories which are used for MRD investigation: (i) disease-specific chimeric genes, 
created by the fusion of two genes at the breakpoints of chromosomal translocation and 
(ii) clone-specific junctional regions generated physiologically through 
immunoglobulin (Ig) or T-cell receptor (TCR) gene rearrangements. 
Disease-specific gene fusion in chromosomal translocations. 
Tumour-specific chromosomal translocations provide ideal disease markers that can be 
detected by molecular means in subgroups of ALL. At least 11 disease-specific fusion 
regions have now been cloned and become the targets for MRD investigation using 
PCR. These include BCR-ABL created in t(9; 22)(g34; ql1), E2A-PBXI created by 
t(1; 19)(g23; p 13), MLL-AF4 found in t(4; 11)(g21; q23), IL3-IGH found in t(5; 14), 
MLL-AF9 found in t(9; 11), E2A-HLF found in t(17; 19) and MYC-IgH found in t(8; 14). 
The molecular targets in T-ALL include RHOM2-TCR7 found in t(11; 14), TALI -TCRa 
found in t(l ; 14) and HOXJ J -TCRa found in t(10; 14) (Campana, Pui, 1995). 
Immunoglobulin or T-cell receptor rearrangements 
In addition to leukaemia specific chromosomal translocations, leukaemia-non-specific 
clonality markers such as the junctional region of the rearranged IG and TCR genes can 
be investigated by PCR. This is based on the fact that the junctional regions vary 
considerably due to the joining of different variable (V), diversity (D), and joining (J) 
gene segments as well as the random insertion and deletion of nucleotides at the 
joining sites. Such rearrangements are clonal. Demonstration of immunoglobulin and 
T-cell receptor (TCR) gene configurations at diagnosis provides a means of tracking 
the malignant clones throughout the disease. The main advantage of this approach is 
that it is wide applicable. Nearly all cases of ALL are characterized by a unique, clonal 
rearrangements of the immunoglobulin heavy chain (IGH) or the T-cell receptor (TCR) 
genes. The limitation of this approach is that the target loci may be deleted, and 
additional rearrangements may become dominant (clonal evolution) during the course 
of the disease (Maclntyre et al., 1989; Kiyoi et al., 1992; Tycko et al., 1992; Steward et 
al., 1994). 
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1.3.1.6 Fluorescence in situ hybridization (FISH) 
Fluorescence in situ hybridization techniques rely on chromosome-specific and gene- 
specific DNA probes to identify numerical and structural chromosome abnormalities. 
The main advantage of this approach is that it enables the detection of chromosomal 
abnormalities in interphase cells, greatly increasing the sensitivity over that of the 
chromosomal method. It is however markedly less sensitive than RT-PCR for the 
detection of aberrant fusion products. 
The sensitivity of the interphase FISH assay is limited by false positives. The 
frequency of false positives varies according to the particular chromosomal 
abnormality and the probe or set of probes used for their detection. The presence of a 
clone is only inferred if the number of positive cells in the sample being investigated is 
greater than the mean + twice the standard deviation of those in the control samples. 
This sets the limit of the sensitivity of the technique. The sensitivity for the detection of 
monosomy has been shown to be quite low allowing the detection of the clone which is 
at least 5% up to 18% of the sample (Kibbelaar et al., 1993; Brizard et al., 1994). The 
sensitivity for the detection of BCR-ABL translocation has been shown to be 0.5% - 
10% (Arnoldus et al., 1990; Tkachuk et al., 1990; Chen et al., 1993a; Dewald et al., 
1993; Amiel et al., 1995). The sensitivity for the deletion of the retinoblastoma gene 
has been reported to be 12% (Stilgenbauer et al., 1993). The range of 0.5%-4% has 
been reported for the detection of the single trisomies (Rivera et al., 1991; Anastasi et 
al., 1992; Jenkins et al., 1992; Chen et al., 1993b; Escudier et al., 1993; Kibbelaar et 
al., 1993; Brizard et al., 1994). 
FISH has been used with various types of probes to investigate the presence of MRD. 
Using FISH with an X chromosome-specific probe the detection of 1.6% of interphase 
cells bearing trisomy X has been reported in the remission bone marrow sample of a 
patient with ALL (Anastasi et al., 1991 a). The same group followed two children with 
ALL and trisomy 17 (Anastasi et al., 1991b). The investigation of remission bone 
marrow from these patients with alpha centromeric chromosome 17 specific probe 
made it possible to distinguish between leukaemic (triploid) and non-leukaemic 
(diploid) cells. Nylund et al used FISH to investigate MRD in interphase as well as 
metaphase cells of patients with various haematological malignancies (Nylund et al., 
1994). The author detected MRD in 3/7 patients with ALL. The persistence of MRD 
in ALL with high hyperdiploidy was reported in two studies. Hereema et al. examined 
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bone marrow samples from eight patients at early clinical remission. One month after 
diagnosis, significant numbers of cells with chromosome gains were detected in 2/7 
cases tested. (Heerema et al., 1993). Two months after diagnosis trisomic and 
tetrasomic cells were within control values. White et al. conducted 161 analyses of 
remission bone marrow aspirates in 13 children with hyperdiploid ALL (White et at., 
1995). MRD was detected in 5/13 cases of ALL investigated while on chemotherapy. 
One out of five newly diagnosed cases and all three relapse cases of ALL had 
significantly raised levels of hyperdiploid cells in the day-28 bone marrow aspirates. 
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1.4 AIMS OF THE STUDY 
The size of the malignant clone in haematological malignancies at diagnosis and the 
level of commitment of the target cell for malignant change both determine the 
extent and severity of the disease and may play an important role in the patient's 
response to treatment. Persistence of the clone in remission indicates the presence of 
minimal residual disease (MRD) which may require therapeutic intervention. The 
size of the clone can be judged from chromosome analysis of a bone marrow sample 
but this estimate may differ widely from the size of the clone in the bone marrow as 
a whole. Cytogenetic analysis provides information only about the small fraction of 
cells undergoing cell division. Furthermore cytogenetics gives no information about 
the types of cell in which the clone is to be found. The principle aim of this thesis 
was to gain insight into the size and location of the malignant clone in non-dividing 
cells from patients with a haematological malignancy. The findings are compared 
with our knowledge of the extent and `dynamics' of abnormal clones as indicated by 
cytogenetic studies. The investigations of leukaemic bone marrow comprise three 
topics. 
Investigation of the presence of a clone in chromosomally failed or 
normal samples and of the clonal status of a single abnormal cell in a 
population of normal cells. 
Cytogenetics, in a proportion of cases, fails (due to the lack of a clone in insufficient 
dividing cells) or results in the detection of only chromosomally normal cells. In 
other cases cytogenetic analysis results in the detection of one or more abnormal 
cells which do not constitute a clone. Such results are of no diagnostic value. The 
aim of the first study was to test the hypothesis that chromosomally abnormal clones 
occur in some of these cases, that the clones are present only in the resting cells and 
that FISH can be successfully used to detect clones in non-dividing cells. 
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Investigation of the cell types which belong to the clone in acute 
leukaemia. 
The level of commitment of the target cell for chromosomal change can be judged by 
the different cell lineages belonging to the clone. The aim of this project was to 
examine the extent of lineage involvement in malignant clones with specific 
chromosome abnormalities in patients with acute lymphoblastic leukaemia (ALL) or 
acute myeloid leukaemia (AML) and hence infer whether the target cell was a 
pluripotent stem cell or a lineage committed progenitor cell. 
The detection of minimal residual disease in patients with ALL and a 
high hyperdiploid clone. 
A high hyperdiploid clone (with gain of 4 or more chromosomes) is detected at 
diagnosis in 30% of children and up to 10% of adults with ALL. For several years a 
sensitive method of MRD detection (RT-PCR) able to detect 10-4 to 10-6 cells has 
been available only for patients with one of the translocations which have been 
cloned and sequenced. The aim of this study was to develop and apply an equally 
sensitive FISH method for MRD detection of hyperdiploid clones in patients with 
ALL. 
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Chapter 2 
MATERIALS AND METHODS 
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2.1 MATERIALS 
2.1.2 Patients material 
Samples of bone marrow which had been taken for clinical reasons at diagnosis or on 
follow up were investigated in this study. Two types of such samples were used in 
the study. (i) Samples remaining from cytogenetic investigation which had been 
prepared for chromosome analysis at diagnosis or during the course of leukaemia and 
were surplus to requirements. These archived samples had been stored in fixative at 4 
°C for periods ranging from 1 to 84 months. (ii) Freshly aspirated bone marrows 
which had been taken for clinical assessment. Bone marrow aspirates were collected 
into sterile tubes containing heparin as a anticoagulant or full culture medium as 
follows: RPMI medium, 50 IU/ml penicillin, 50µg streptomycin (GIBCO, UK) and 
10 U/ml heparin. 
2.1.2 YAC culture media materials 
Yeast N2 base, casein hydrolysate came from DIFCO, ammonium sulfate from BDH, 
adenine sulfate, sorbitol and sarkosyl from SIGMA. 
2.1.3 FISH materials 
2.1.3.1 Probes 
The probes and their source are listed in table 2.1 
2.1.3.3 FISH reagents 
Sodium chloride and sodium citrate came from BDH. FITC-avidin, FITC- 
avidin/rhodamine-labeled anti digoxigeneine, anti-avidin antibody and propidium 
iodide came from Oncor. 
2.1.4 Morphology/immunology materials 
2.1.4.1 May-Grunwald-Giemsa (MGG) staining 
May-Grunwald-Giemsa came from Sigma 
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2.1.4.2 Alkaline-phosphatase anti-alkaline-phospatase (APAAP) 
technique 
Antibodies 
The following monoclonal antibodies were purchased from DAKO: T-lymphoid 
(CD3), B-lymphoid (CD19), myeloid (CD13) and erythroid (Glycophorin A). The 
Rabbit anti-mouse antibodies came also from DAKO. 
APAAP reagents 
APAAP complex was purchased from DAKO, alkaline-phosphatase substrate from 
SIGMA. 
Table 2.1 
Probes used in the study 
Name Reporter 
molecule 
Locus Source 
D4Z1 biotin chromosome 4 centromere Oncor 
D4Z1 digoxigenin chromosome 4 centromere Oncor 
D6Z1 biotin chromosome 6 centromere Oncor 
D6Z1 digoxigenin chromosome 6 centromere Oncor 
D8Z1 biotin chromosome 8 centromere Oncor 
D1OZ1 biotin chromosome 10 centromere Oncor 
D1OZ1 digoxigenin chromosome 10 centromere Oncor 
D13Z1/D21Z1 biotin chromosome 13 and 
chromosome 21 centromere 
Oncor 
D14Z1/D22Z1 biotin chromosome 14 and 
chromosome 22 centromere 
Oncor 
D17Z1 biotin chromosome 17 centromere Oncor 
Dl 7Z1 digoxigenin chromosome 17 centromere Oncor 
D18Z1 biotin chromosome 18 centromere Oncor 
Dl 8Z1 digoxigenin chromosome 18 centromere Oncor 
DXZ1 biotin chromosome X centromere Oncor 
DXZ1 digoxigenin chromosome X centromere Oncor 
Chromosome 4 wcp* biotin chromosome 4 Cambio 
Chromosome 8 wcp* biotin chromosome 4 Cambio 
m-BCRIABL 
translocation probe 
biotin 
/digoxigenin 
m-BCR 22g11 ABL 9q34 Oncor 
M- BCRIABL 
translocation probe 
biotin 
/digoxigenin 
M-BCR 22g11 ABL 9q34 Oncor 
YAC 13HH4 biotin MLL 11 g23 B. D. Young 
*wcp = whole chromosome probe 
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2.2 METHODS 
2.2.1 Sample preparation 
Two types of samples were used in the study, samples remaining from cytogenetic 
investigation and samples separated on Ficoll by gradient centrifugation to obtain 
mononuclear cells (MNC) or high density fraction (HD). In all cases bone marrow 
had been taken for clinical assessment. 
2.2.1.1 Samples remaining from cytogenetic investigation 
Interphase and metaphase cells were obtained from cell pellets which had been 
prepared for chromosome analysis and stored in Carnoy's fixative (3: 1 methanol/acetic 
acid) at -20°C for up to seven years. Cell pellets were resuspended in fresh fixative and 
slides were made. The slides were left to air dry overnight and subsequently used for 
FISH experiments. The additional slides were wrapped in aluminium foil and stored at 
-20°C. In some experiments previously G-banded slides which had been stored for up 
to three years in room temperature were used. 
2.2.1.2 Samples prepared by gradient centrifugation 
Bone marrow or peripheral blood samples were collected using heparin as a 
anticoagulant. The white blood cell count was performed on all samples in order to 
determine the approximate number of cells which would be recovered after 
separation. 
2.2.1.2.1 Mononuclear (MNC) and high density (HD) cell isolation 
Samples were diluted 50: 50 with phosphate-buffered saline (PBS), if the WBC was 
low (i. e. <2.0x109/1) less diluent was added, more if it was high (>500x109/l). 
Approximately 10 mis of lymphoprep (Nycomed) was placed in a labeled universal 
and 10 mis of diluted bone marrow/peripheral blood was poured gently on top. 
Subsequently the sample was centrifuged at 800g (3000 rpm) for 20 minutes. Once 
the centrifugation was complete the mononuclear cell (MNC) layer was carefully 
removed using a glass pipette. The MNC layer was transferred to a second universal. 
Supernatant was removed from the first universal leaving the pellet containing the 
HD fraction. Approximately 15 mls of red cell lysis buffer (RCLB) was added to 
both universals. The pellet was resuspended and both universals left at room 
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temperature for 5 minutes. After lysis was completed, both universals were spun at 
400g (1500 rpm) for 5 minutes. The supernatant was removed and the cells were 
washed in 20 mis of phosphate-buffered saline (PBS) by centrifugation at 400g 
(1500 rpm) for 5 minutes. The supernatant was discarded and cells were either 
transferred to cryovials and stored in liquid nitrogen or resuspended in PBS to a 
concentration of 1x 109/1 prior to the preparation of the cytospins. 
2.2.1.2.2 Liquid nitrogen storage 
Freezing down 
The cell pellet was put on ice. 0.5 mis of fetal calf serum (GIBCO, BRL) and 0.5 mis 
of 20% DMSO (SIGMA)/RPMI (GIBCO, BRL) was added to each cryovial. The 
cell pellet was left at -70°C overnight. The next day the cryovials were submerged in 
liquid nitrogen. 
Thawing 
When required, the cryovials were taken out of the liquid nitrogen container and 
warmed up to 37°C by agitating gently in a waterbath. The cell pellets were diluted 
with 5 mis of RPMI and spun down at 1000 rpm for 3 minutes. Cells were 
resuspended in fresh RPMI. 
2.2.1.2.3 Preparation of cytospins 
100 µl aliquots of cell suspension were spun at 400 rpm in a Cytocentrifuge (Shandon, 
UK) for 2 minutes. The cell distribution of the cells on a slide was checked using x40 
objective lenses. If the cells were too crowded or too scanty, the cell concentration was 
adjusted. The slides were left to air dry overnight, wrapped in aluminium foil and 
stored at -20°C. 
2.2.2 Identification of cell lineages 
In order to investigate the clonal involvement of different cell lineages, bone marrow 
cells belonging to a particular cell lineage were first identified on cytospins by 
morphology using May-Grunwald-Giemsa (MGG) stain or by their immunophenotype 
using the alkaline-phosphatase anti-alkaline-phospatase (APAAP) technique. 
Subsequently, chromosomal abnormalities were investigated in the same preparations 
using the FISH technique (see below). 
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2.2.2.1 May Grunwald Giemsa (MGG) staining 
Slides were stained with May Grunwald Giemsa (SIGMA) for 2 mins. Subsequently 
they were rinsed with distilled water and allowed to dry. After mounting in Apathys 
they were examined under the light microscope. 
2.2.2.2 Alkaline-phosphatase anti-alkaline-phospatase (APAAP) 
technique 
Slides stored in -20C in aluminium foil were allowed to defrost at room temperature 
for 20 minutes and then unwrapped and fixed in acetone for 10 minutes. They were 
washed in Tris buffered saline (TBS) for 3 minutes and transferred to a humidified box 
where diluted antibodies were applied. Slides were incubated for 30 minutes at 37 °C, 
washed in TBS for 2 minutes, followed by incubation with 20u1 rabbit-anti-mouse 
(RAM) antibody (DAKO) diluted in 1/50 in TBS at 37 °C, washed again in TBS for 2 
minutes, incubated with APAAP complexes (DAKO) for another 30 minutes at 37 °C 
and finally washed again in TBS for 2 minutes. For the amplification the same steps of 
incubation and washes were repeated but incubation time was decreased to 10 minutes. 
Alkaline phosphatase substrate (SIGMA) was made just prior to use and was filtered 
directly onto slides which were then left for 20 minutes in a humidified chamber. 
Subsequently slides were washed in TBS for 3 minutes, in tap water for 5 minutes and 
counterstained in haematoxylin (SIGMA) for 5 minutes. When the slides became dry 
they were mounted in Apathys. Slides were examined under the light microscope. 
2.2.3 Fluorescence in situ hybridization (FISH) 
2.2.3.1 Probe preparation 
For most FISH experiments ready labeled probes were obtained from Oncor or 
Cambio. The investigation of lineage involvement of cases with 11 q23 abnormalities 
was conducted using a YAC 13HH4 containing the MLL gene. 
2.2.3.1.1 YAC culture 
2% glucose/AHC cultures (50µg/ml of ampicillin (Sigma) and 7.5 ug/ml of 
tetracycline (Sigma)) were inoculated with yeast cells containing YAC 13HH4. 
Following incubation at 37°C for 2 days, three of the four 5 ml cultures were 
inoculated into a 400m1 AHC culture as above and incubated for a further 24 hours. 
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The remaining 5 ml culture was used to make 15% glycerol stocks which were stored 
at -70°C. 
2.2.3.1.2 Preparation of DNA 
Following incubation, cells were centrifuged at 2500rpm for 15 minutes. The 
supernatant was removed and the pellet resuspended in 40m1 of sterile distilled 
water. The resuspended pellet was transferred to a 50m1 Falcon tube and centrifuged 
as above. The pellet was resuspended in 3.5m1 of SCE and 85µ12M DTT with 20 mg 
of yeast lytic enzyme (Sigma). The suspension was incubated at 37°C for 90 minutes. 
The cell suspension was lysed by adding 7 ml of lysis buffer containing 100µg/ml 
proteinase K (Sigma). The lysate was heated to 65°C for 15 minutes and cooled in 
water. A sucrose gradient was prepared using 11 ml 20% sucrose followed by 11 ml 
15% sucrose and underlayed with 3 ml of 50% sucrose. The lysate was added 
carefully to the top of the gradient and then spun at 26,000rpm in a Beckmann 
centrifuge for three hours at 20°C. The upper 30m1 of the sucrose gradient was 
aspirated. The DNA layer was removed with al Oml wide-bore pipette and placed in 
a universal. A dialysis bag was washed through with distilled water, clamped at one 
end and the DNA poured into the other end and clamped. The DNA was dialysed 
overnight against 2 liters pH 7.5 TE (10 mM Tris/0.1 Mm EDTA) at 4°C. 
The DNA was transferred from the dialysis bag into a falcon tube and equal volumes 
of butanol added. Following mixing and quickly centrifuging at 12,000g in a 
microfuge for 20 seconds the upper phase was discarded and the process repeated 
until less than 5ml of DNA suspension was left. The DNA was transferred to an 
eppendorf containing 100% ethanol and sodium acetate (10% v/v). Following 
centrifugation for 5 minutes in a microfuge and removal of the ethanol, the 
precipitated DNA was vacuum dried for 10-15 minutes and the pellet resuspended in 
50 µl of TE. 
2.2.3.1.3 Gel electrophoresis 
The DNA concentration was estimated by gel electrophoresis. For this a 0.8% 
agarose gel was prepared containing 0.5µg/ml of ethidium bromide as below: 0.56g 
of powdered agarose (Sigma) was mixed with 70ml of 0.5 x TBE buffer (0.045M 
Tris-borate, 0.001MEDTA) and heated until the agarose dissolved. The solution was 
cooled to 60°C prior to the addition of ethidium bromide. The agarose/ethidium 
bromide solution was poured onto a prepared gel. The gel was left to dry at room 
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temperature. Five microlitres of each DNA sample were mixed with 2µJ of gel- 
loading buffer (bromophenol blue) and loaded into each well in the gel. A series of 
standard DNA solutions were prepared by mixing known concentrations of uncut 
lambda DNA (20,50,100,200,400ng/µl )(Boehringer) with 2µJ of gel loading 
buffer. The gel was run at 5V/cm. The gel was photographed using short wavelength 
ultraviolet irradiation and the quantity of DNA in the sample estimated by comparing 
the sample DNA with the standards. 
2.2.3.1.4 Probe labeling 
To a 1.5m1 eppendorf tube containing 1µg of probe DNA 5µl l Ox nick translation 
buffer (0.5M Tris-HC1,50mM MgC12,0.5mg/ml BSA, 5 t1 dithiothreitol (DTT) 
(O. 1M), 4µl of nucleotide mix (0.5mM, dATP, dGTP, dCTP, 0.1mM dTTP) 
(Boehringer), 1µl of biotin, 2p1 of DNA polymerase I (IOU/L) (Boehringer) and 5p1 
DNase I (Sigma) (1: 1000 of 1 mg/ml solution) was added. The contents were mixed 
gently and incubated in a waterbath at 15°C for two hours. Five microlitres of 0.5M 
EDTA (pH 8) was added to stop the reaction. 
2.2.3.1.5 Fragment size 
Five microlitres of probe DNA were mixed with 2 µl of bromophenol blue and 5 µl 
of ddH2O and loaded onto the gel. The DNA of ýX 174 was loaded as a reference 
ladder. The gel was run at 5V/cm for approximately 90 minutes. 
2.2.3.1.6 Probe preparation and precipitation 
To 1µg of labeled probe, 50µg of Human-Cot-1 DNA (Gibco) and 100µg of salmon 
sperm DNA (Sigma) was added. This was followed by 1/10th the volume of 3M 
sodium acetate, pH 5.2 and 2.5 times 100% ethanol. The suspension was mixed, 
vortexed in a microfuge and incubated at -70°C for 30 minutes. Following 
centrifugation in a microcentrifuge for 15 minutes the supernatant was discarded and 
the pellets washed in 70% ethanol and centrifuged for 5 minutes. The supernatant 
was discarded and the pellet lyophilized for 10 minutes. The dried pellet was 
resuspended in hybridization buffer (50% deionized formamide (Cambridge 
BioScience), 2x SSC, 10% dextran sulfate (Sigma) and stored at -20°C until 
required. 
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2.2.3.2 Slide pretreatment 
Coverslips from G-banded slides were removed by soaking in Camoy's fixative. 
Removal of DPX mounting medium and Giemsa stain was achieved by washing in 
three changes of fresh Carnoy's fixative. Unbanded slides containing the cytogenetic 
preparation and cytospin slides which had been stored in -20°C were taken out of the 
freezer and left at room temperature to defrost. After 20 minutes the aluminum foil 
was removed. Slides containing the cytogenetic preparations were incubated at 37°C 
in 2x SSC for 30 minutes. Cytospin slides were fixed in 100% methanol prior to 
investigation by FISH. All slides were put through an ethanol gradient (70%, 90%, 
100%). 
2.2.3.3 Denaturation 
DNA on the slides was denatured by incubation in 70% deionized formamide/2 x 
SSC on a hotplate at 72°C for 2 minutes. After denaturation the slides were 
dehydrated through an ethanol gradient (70%, 90%, 100%). Prior to denaturation, 
alpha satellite centromeric probes were diluted with hybrisol VI (Oncor, Gaithesburg 
MD) to a concentration of 1 ug/ 1 ul. Alpha-satellite chromosome-specific probes, whole 
chromosome probes (WCPs) and the YAC probe were denatured by heating at 72°C 
for 5 minutes. WCPs were pre-annealed at 37°C for 30 minutes prior to 
hybridization. The m-BCR-ABL and M-BCR-ABL translocation probes did not 
require denaturation. 
2.2.3.4 Hybridization 
The probe was placed on the slide and covered with a glass coverslip and incubated 
overnight in a humidified chamber at 37°C. Approximately 100ng of WCP, 50ng of 
centromeric probe and 500ng of YAC were applied per hybridization. 
2.2.3.5 Post hybridization washes 
The YAC probe, WCPs and the m-BCR-ABL and M-BCR-ABL translocation probes 
were washed 0.5xSSC at 70°C. The alpha-satellite, chromosome-specific probes were 
washed in 0.5xSSC at 72°C. 
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2.2.3.6 Detection 
After washes were completed FITC-avidin (or FITC-avidin and rhodamine-labelled 
anti-digoxigeneine mixture in double/triple colour experiments) (Oncor, Gaithesburg 
MD) was applied, slides were covered with plastic coverslips and incubated for 20 
minutes at 37°C. Washes were done in 0.05% tween 20/ 4xSSC three times (2 minutes 
each). After washing anti-avidin antibodies (Oncor, Gaithesburg MD) were applied and 
slides were incubated at 37 °C for 20 minutes. Washes and the final layer of FITC- 
avidin (or FITC-avidin and rhodamine-labelled anti-digoxigeneine mixture in 
double/triple colour experiments) (Oncor, Gaithesburg MD) were done as previously 
described. After the final wash, propidium iodide (detection with FITC) or DAPI 
(detection with rhodamine) (Vector Laboratories, Burlingame, CA) at a concentration 
of 80ng/ml counterstain was applied. 
2.2.3.7 Triple colour FISH 
Some FISH experiments required that three chromosomal gains be detected 
simultaneously. For these, four probes were used to obtain three colours as follows. 
Probes labelled with digoxigenin (dig) were detected with rhodamine labeled anti- 
digoxigenin antibodies (red). Biotin (bio) labelled probes were detected with 
fluorescein labelled avidin (FITC) (green). To obtain a third colour (yellow) dig and 
bio labelled probes were mixed in a 1: 1 ratio. 
2.2.3.8 Scoring 
Control Samples 
Three 'chromosomally normal' bone marrow or peripheral blood samples per probe 
were used as controls. For each control 1000 (unless stated otherwise) nuclei were 
scored with each probe. The mean (M) and standard deviation 
(SD) for control cells 
with a given pattern of hybridization signals (e. g. one additional signal or 
BCR-ABL 
fusion signal) were calculated for each probe. 
Patient Samples 
For each case at least 300 nuclei were scored per probe unless stated otherwise. 
Cells 
which were overlapping or had poor or ambiguous signals were excluded. 
The number 
of cells having a given pattern of 
hybridization signals (e. g. one additional signal or 
BCR-ABL fusion signal) was recorded. If the number of cells with this pattern was 
64 
greater than the mean control value + twice the standard deviation (M+2SD) a clone 
was presumed to be present. 
2.2.4 Microscopy 
Slides were examined with a Zeiss-Axioskop. Images were taken with the laser 
confocal microscope (Olympus BH2) (early experiments) or with Zeiss Axioskop 
coupled with a CCD camera and with software from Digital Scientific, Cambridge, 
UK. 
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Chapter 3 
HYPERDIPLOIDY IN NORMAL AND FAILED ALLs 
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3.1 Summary 
High hyperdiploid (>50 chromosomes) and low hyperdiploid (47-50 chromosomes) 
clones in the leukaemic cells at diagnosis of acute lymphoblastic leukaemia (ALL) 
identify patients with a good and relatively good prognosis respectively. In the 
cytogenetic laboratory at the Royal Free Hospital, cytogenetic analysis in ALL fails (no 
clone detected in a yield of <20 metaphases) in 26% of cases and yields only normal 
metaphases in 12% of the successful cases. In this chapter patterns of chromosomal 
gains in hyperdiploid clones have been used to look for hyperdiploidy in patients with 
ALL, where cytogenetics had failed (35 cases, 13 adults, 22 children), or yielded only 
normal metaphases (30 cases, 13 adults, 17 children). Fluorescence in situ 
hybridization (FISH) with alpha-satellite, chromosome-specific probes was applied to 
interphase nuclei, at diagnosis, targetting chromosomes X, 6,16,18,20 and 21. FISH 
analysis revealed 5 cases with high hyperdiploidy, two cases with low hyperdiploidy 
and two cases with unspecified high or low hyperdiploidy. 
A high hyperdiploid clone was detected by FISH in 3/22 (9.1%) children with failed 
cytogenetics which was lower than the 31 % detected by cytogenetics in this age group. 
No case with a high hyperdiploid clone was found amongst children classified as 
normal. In adults, high hyperdiploidy was detected by FISH in 1/13 (7.7%) failed 
cases and in 2/13 (15.4%) normal cases. These figures compare with 12% detected by 
cytogenetics. The sizes of clones indicated by interphase FISH in cases classified as 
normal (seen in adults only) were lower (range 10%-42%) than in failed cases (range 
68%-82%) (seen in children and adults). The present study suggests that failure to 
detect a high hyperdiploid clone by metaphase cytogenetics may be more frequent in 
adults than in children. Clones smaller than 50% have been shown to occur in adult 
ALL and these appear to evade detection even when 20 cells have been analysed 
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3.2 Introduction 
The stratification of patients with acute lymphoblastic leukaemia (ALL) according to 
prognosis is important in therapy planning. The important prognostic implications of 
chromosome ploidy at diagnosis, initially reported by Secker-Walker at al. (Secker- 
Walker et al., 1978), are now well established (IWCL3,1981 a; Swansbury et al., 1981; 
Kaneko et al., 1982; Secker-Walker et al., 1982b; Williams et al., 1982; Bloomfield et 
al., 1986; Pui et al., 1987; Michael et al., 1988; Pui et al., 1988; Van der Plas et al., 
1992b; GFCH, 1993; Raimondi, 1993; Kobayashi et al., 1994). Hyperdiploidy (clones 
with chromosomal gain) is important because it is mostly associated with a good 
prognosis. There are three hyperdiploid groups, low hyperdiploidy (47-50 
chromosomes), high hyperdiploidy (50-65 chromosomes) and triploidy or near 
tetraploidy (>68 chromosomes). 
A significant proportion (23%-33%) of ALL patients escape classification by yielding 
insufficient dividing cells in bone marrow samples for chromosome analysis (Jackson 
et al., 1990; Secker-Walker, 1990; Harris et al., 1992). Furthermore, up to 39% of 
successfully analysed cases have only chromosomally normal metaphases or have only 
a single (random) cell with chromosomal gain or structural change or fewer than three 
cells with the same chromosomal loss, which are insufficient for the abnormality to be 
classified as clonal (Walters et al., 1990). Since standard cytogenetic analysis of 20 
metaphases is unlikely to detect clones present in less than 11 % of dividing cells 
(Hook, 1977), patients classified as `normal' may have minor or inert clones. 
Fluorescence in situ hybridization (FISH) can be used to detect chromosomal gains in 
the bone marrow of patients with haematological malignancy (Jenkins et al., 1992; 
Romana et al., 1993). In contrast to cytogenetics, FISH allows for the investigation of 
non-dividing as well as dividing cells. 
Moorman et al. (Moorman et al., 1996) observed patterns of chromosomal gain in 
patients with hyperdiploid ALL. Gains of certain chromosomes or certain 
combinations of chromosomes were often seen in one hyperdiploid group (e. g. high 
hyperdiploid) but rarely, if at all in another (e. g. low hyperdiploid). He proposed a 
strategy for the use of FISH in interphase cells whereby, using ten chromosome 
specific probes in a maximum of three steps, cases could be successfully recognised as 
being hyperdiploid and assigned to one of three ploidy groups: low hyperdiploid, high 
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hyperdiploid and triploid/tetraploid. In this chapter the possibility that high 
hyperdiploid clones may be found in the diagnostic bone marrow samples from 
patients with ALL whose cytogenetics was normal or failed is examined. 
3.3 Materials and methods 
3.3.1 Patients 
In the cytogenetics laboratory at the Royal Free Hospital, between 1990 and 1996,414 
patients were diagnosed with acute lymphoblastic leukaemia of which 263 were 
classified as abnormal, 36 as normal and 107 as failed. Bone marrow samples were 
available from 65 patients in whom the diagnostic cytogenetics was either normal or 
had failed. Bone marrows from three healthy, chromosomally normal individuals were 
used as controls. 
3.3.2 Strategy 
The strategy used to identify hyperdiploid cases and assign them to a particular ploidy 
group was proposed by Moorman et al. (Moorman et al., 1996) and is illustrated in 
figure 3.1. The strategy was based on the observation that certain chromosomes or 
combinations of chromosomes are often gained together in one ploidy group but rarely, 
if at all, in another. It was proposed that FISH employing a total of ten chromosome- 
specific probes in a step wise fashion would identify hyperdiploid cases and assign 
them as low hyperdiploid, high hyperdiploid or triploid/tetraploid. The purpose of this 
study was primarily to identify high hyperdiploid cases, so that only a part of the 
above strategy was adopted (see fig 3.1 for the part of the strategy used in the study). 
The strategy requires that cases be initially screened with probes to chromosomes X 
and 18 (see fig 3.1). Depending on the result of the initial screening, cases are then 
investigated as follows: cases positive for both X and 18 are investigated with probes 
to chromosomes 16 and 20, cases positive for either X or 18 are investigated with 
probes to chromosomes 6 and 21 (see fig 3.1). Cases negative for both probes to 
chromosomes X and 18 are presumed not to contain a high hyperdiploid clone and 
need not be investigated further. The results are then interpreted as follows: cases 
positive for X, 18,16 and 20 are assigned as triploid/tetraploid, cases positive for X, 18 
and either 16 or 20 are assigned as high hyperdiploid, cases positive for either X or 18 
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and both 6 and 21 are assigned as high hyperdiploid, cases positive for either X or 18 
and negative for both 6 and 21 are assigned as low hyperdiploid (see fig 3.1). Cases 
positive for X and negative for 18 and positive for either 6 or 21 are investigated with 
the probe to chromosome 14. Cases positive for 14 are then assigned as high 
hyperdiploid, those negative for 14 are assigned as low hyperdiploid (see fig 3.1). 
Cases positive for 18 but negative for X and positive for either 6 or 21 are considered 
to be hyperdiploid but cannot be specified (unspecified) whether high, low or 
triploid/tetraploid (see fig 3.1). 
3.3.3 Fluorescence in situ hybridization 
Probes 
Chromosome-specific alpha-satellite probes (Oncor, Gaithesburg) for chromosomes X, 
6,16 and 18 were available for this study. Also used were probes to chromosomes 14 
and 21 that cross hybridize with chromosome 22 and 13 respectively. 
Probe hybridization. detection and scoring 
are described elsewhere (section 2.2.3) 
Control values 
Control values for trisomic cells were calculated as described (section 2.2.3). 
3.4 Results 
3.4.1 Cytogenetic Results at Diagnosis at the RFH 
Laboratory records of diagnostic cytogenetics in ALL showed that no abnormal clone 
was found in approximately a third of cases. This was either due to cytogenetic failure 
(26%) or to a classification of normal (9%) (fig 3.2). Among successfully analysed 
cases approximately 34% had a hyperdiploid clone with low hyperdiploid 9%, high 
hyperdiploid 20% and triploid/tetraploid 5% (fig 3.3). If children (<15 years) and 
adults (> 15 years) were considered separately the incidence of all hyperdiploid groups 
in children was greater (42%) than that in adults (28%). This was mostly due to a 
greatly increased incidence of high hyperdiploidy in childhood (31 %) compared with 
that (12%) in adults (fig 3.4-3.5). 
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Fig 3.1 
The strategy for the use of chromosome specific probes with interphase FISH to identify hyperdiploid cases and assign them to low, high and triploid/tetraploid subgroups as proposed by Moorman et al (Moorman et al., 1996). 
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Key 
The probes used are shown in broken boxes, the final classification in solid 
boxes. He hyperdiploid (unspecified), HeL low hyperdiploid, HeH high 
hyperdiploid, TT triploid/tetraploid. The part of the strategy which was used in 
this study is indicated by the small frame. 
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Fig 3.2 
The distribution of patients between chromosomal categories normal, 
abnormal and failed cytogenetics. 414 patients with ALL investigated at 
diagnosis at the RFH over a6 year period (1990-1996) 
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Fig 3.3 
The distribution of patients between chromosomal categories high 
hyperdiploidy (HEH), low hyperdiploid (HEL), triploid/tetraploid (TT), normal 
and other abnormal. 299 patients with ALL and successful cytogenetics 
investigated at diagnosis at the RFH over 6 year period (1990-1996) 
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Fig 3.4 
The incidence of different chromosomal subgroups amongst 125 children 
with ALL, successfully karyotyped at diagnosis, investigated at the RFH 
between 1990-1996 
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Fig 3.5 
The incidence of different chromosomal subgroups amongst 174 adults with 
ALL, successfully karyotyped at diagnosis, investigated at the RFH between 
1990-1996 
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3.4.2 Investigation of hyperdiploidy by FISH 
Patients 
Clinical features, immunological data and cytogenetics of 65 patients investigated by 
FISH is shown in tables 3.1 and 3.2. In 35 patients cytogenetics had failed (cases 1-35) 
(table 3.1) and in 29 (cases 36-65) had been normal (table 3.2). In 11 cases one or more 
single (nonclonal) abnormal cells had been found (see table 3.3). 
Controls 
Control values (M+2SD) of cells showing an additional signal for the probes used in 
the study are shown in table 3.4. The lowest value was seen for probe 18 (1.4%) and 
was highest for the probe which hybridizes to chromosomes 13 and 21 (3.5%). 
Interphase FISH investigation 
All 65 cases were hybridized with the chromosome X probe. Nine cases (cases 1,17, 
18,27,34,35,53,56 and 57) were positive for +X (see table 3.5) and were assigned as 
hyperdiploid (see strategy, section 3.3.2). Cases I and 35 lacked material for further 
analysis. The remaining 63 cases were then hybridized with the chromosome 18 probe. 
Four (cases 17,18,27 and 56) were positive for +18 (see table 3.5). Further probing 
with probes 6 and 21 (see section 3.3.2 and fig 3.1) in the 3 cases positive for X but not 
18 (cases 34,53 and 57) revealed 1 case (case 53) with significant numbers of positive 
cells with both probe 6 and probe 13/21 identifying therefore this case as high 
hyperdiploid (see table 3.5). In the remaining two cases (case 34 and 57) both probings 
proved to be negative identifying therefore those cases as low hyperdiploid. 
Cases positive with both probes X and 18 (cases 17,18,27 and 56) (see table 3.5) were 
subsequently probed with probes 16 and 20 to distinguish high hyperdiploidy from 
tetraploidy (see section 3.3.2 and fig 3.1). Cases 27 and 56 were positive for 16, cases 
17 and 18 were positive for 20. None of those cases were positive for both probes so 
that those cases were assigned as high hyperdiploid. 
Fifty six cases were negative with the probes to chromosome X and chromosome 18 
probe and were presumed not to contain high hyperdiploid clones (see strategy, section 
3.3.2). 
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Table 3.1 
Clinical data on patients with acute lymphoblastic leukaemia and `failed' cytogenetic analysis 
case no age (yrs)/ sex immunophenotype WBC 
x109/1 
cytogenetics 
N [Ab] 
1 2/M c-ALL 31.9 4 
2 2/M c-ALL 8.8 1 
3 2/M c-ALL 8.5 0 
4 3/F c-ALL 15.2 3 
5 3/F Nk 6 0 
6 3/F Nk 5.7 16 
7 3/F Nk Nk 8 
8 4/F Nk 10 10 
9 4/M Nk 43 1 
10 4/M T-cell 50.3 0 
11 4/M c-ALL 33.5 0 
12 5/M pre-B 27 17 
13 5/M Nk 254 1 
14 6/F Nk 488 12 
15 6/M Nk 5.3 12 
16 7/M T-cell 189.6 6[1 ]* 
17 8/M c-ALL 2.3 0 
18 9/M c-ALL 13.5 0 
19 10/M c-ALL 3.8 5 
20 10/M Null 21.7 17[1 ]* 
21 13/M Nk 71.3 6 
22 14/F c-ALL 157 18 
23 15/F c-ALL Nk 3 
24 15/M c-ALL 5 1[11* 
25 16/M T-cell 171 4 
26 19/M T-cell 37 6[1 ]* 
27 21 /F pre-B Nk 1 [1 ]* 
28 21 /M c-ALL 55.4 0 
29 25/F c-ALL 3.8 12 
30 30/F T-cell 2.4 1 
31 31/M Nk 23 4[3 ]* 
32 32/F Null Nk 1 
33 37/F Nk Nk 0 
34 41 /M pre-B 59.3 0 
35 64/F c-ALL 4 0 
* see table 3.3, @= non clonal, N= number of normal cells, [Ab] = number of 
abnormal cells 
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Table 3.2 
Clinical data on patients with acute lymphoblastic leukaemia and `normal' 
cytogenetic analysis 
case no age (yrs)/ sex immunophenotype WBC 
x109/1 
cytogenetics 
N [Ab] 
36 1/F c-ALL 6.9 20 
37 1/M Nk Nk 20 
38 2/F c-ALL 46 20 
39 2/F c-ALL 13.5 20[1 ]* 
40 2/M Nk Nk 20[1 ]* 
41 3/F c-ALL 12.9 20 
42 4/F c-ALL/pre-B 10.3 22 
43 4/F Nk 7.1 20 
44 4/F Nk 7.1 20 
45 5/M Nk Nk 20 
46 5/M c-ALL 3.4 20 
47 6/F Nk 21 20 
48 6/M c-ALL Nk 21 
49 7/F Nk Nk 20 
50 12/M c-ALL 1.2 20 
51 13/F c-ALL 64.3 20 
52 14/M T-cell Nk 20 
53 16/F c-ALL 0.6 29[1 ]* 
54 16/M Nk 74 20 
55 17/F Nk Nk 20 
56 17/M pre-B Nk 20[1 ]* 
57 22/M T-cell Nk * 1[11 
58 23/F T-cell 43 30 
59 24/M c-ALL 1.7 29 
60 27/M Nk Nk 20 
61 31 /F Nk 3 20 
62 34/F c-ALL 8.1 20 
63 43/M T-cell 60 31 
64 44/M T-cell 4.8 20 
65 65/M B-cell 22.5 20 
* see table 3.3, @= non clonal, N= number of normal cells, [Ab] = number of 
abnormal cells 
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Table 3.3 
Karyotypes of cases with single (random) abnormal cells. 
case no karyotype 
16 46, XY[16] / 47, XY, +10[1 ] 
20 46, XY[l 0] / 46, XY, del(5)(p15)[1 ] 
24 46, XY[1 ]/ 47, XY +mar[1 ] 
26 46, XY[5] / 46, XY-9-14 + 2mars[1 ] 
27 58 [inc] [1] 
31 46, XY[l 1] / 48, XY, +22, +mar[1 ]/ 45, XY, add(8)(p), -11 /12[l ]/ 
46, XY, t(5; 9)(g31; q34)[1 ] 
39 46, XX[19] / 46, XX,? del(9)(p22)[1 ] 
40 46, XY[20] / 89, XXYY [1] 
53 46, XX [20] / 52, XX, +X, +4, +6, +8, +17, +22 [11 
56 46, XY [20] / 57, XY, +A, +B, +C, +D, +G [1] 
57 46, XY[20] / 50, XY, -1, -3, -4, +6, +6, +7, +8, -11, +12, +13, +17, - 
18, +20, +22[1 ] 
Table 3.4 
Control values based on the mean and standard deviation of the number of 
cells showing an additional signal for each probe used in the study 
chromosome specific probe Mean (%) SD (%) control values (M+2xSD) (%) 
X males 1.2 0.4 2 
X females 1.1 0.4 1.9 
6 0.9 0.3 1.5 
21 * 2.5 0.5 3.5 
16 1.3 0.3 1.9 
18 1 0.2 1.4 
20 1.4 0.2 1.8 
Key 
* cross hybridizes with chromosome 13 
SD = standard deviation 
M= mean 
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Table 3.5 
Patients classified as hyperdiploid by FISH. 
The percentage of cells with an additional signal to the probes tested 
case no probes 
X 18 6 21 16 20 
clone detected 
1 68.2* NMA NMA NMA NMA NMA HE 
17 85.7* 81.0* NI NI 1.8 76.9* HEH 
18 72.4* 78.0* NI NI 1.7 75.8* HEH 
27 75.6* 60.9* NI NI 73.9* 1.5 HEH 
34 78.7* 1.2 1.4 2.9 NI NI HEL 
35 82.3* NMA NMA NMA NMA NMA HE 
53 47.1 * 1.1 38.1 * 39.5* NI NI HEH 
56 9.7* 7.9* NI NI 11.0* 1.7 HEH 
57 41.1* 1.3 1.3 3.2 NI NI HEL 
KEY 
significantly above control values 
HE hyperdiploid >46 chromosomes 
HEH high hyperdiploid 50+ chromosomes 
HEL low hyperdiploid 47-49 chromosomes 
NI not investigated 
NMA no material available 
In summary, FISH analysis revealed 5 cases with high hyperdiploidy (cases 17,18,27, 
53 and 56), two cases with low hyperdiploidy (cases 34 and 57) and two cases with 
unspecified subgroup of hyperdiploidy (cases 1 and 35). High hyperdiploidy was found 
in 2/22 children (cases 17 and 18) and in 1/17 adults (case 27) with failed cytogenetics 
(see table 3.1) and in 2/13 adults (cases 53 and 56) with normal cytogenetics (see table 
3.2). 
The incidence of high hyperdiploidy detected by FISH in cytogenetically failed and 
normal cases is compared in fig 3.6. The incidence of high hyperdiploidy in children 
with failed cytogenetics detected by FISH was 9.1%. FISH failed to detect any cases 
with high hyperdiploidy among children with normal cytogenetics. Among adults, 
FISH detected 7.7% with high hyperdiploidy among failed and 15.4% among normal 
cases. This was considerably less than that detected cytogenetically in children 
in our 
laboratory (31%). The incidence of high hyperdiploidy detected by FISH compared 
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with that detected by cytogenetics (12%) in adults was lower among failed cases 
(7.7%) and greater among normal cases (15.4%). 
The size of the clone indicated by interphase FISH in cases originally classified as 
normal (cases 53,56,57) was lower (range 10% to 42%) than that in cases classified as 
failed (cases 1,17,18,27,34,35) (range 68% to 82%) (see fig 3.7). 
The three adults (cases 27,53 and 56) found to be high hyperdiploid by FISH, had each 
shown a single high hyperdiploid metaphase on cytogenetic investigation (see table 
3.3). Full analysis had been obtained for one of these cells. In case 53 the cytogenetic 
result showed, +X, +4, +6, +8, +17, +22. FISH confirmed +X, +6 but also showed +21 
suggesting either that the clone included more trisomies than seen in the single cell or 
that analysis of the single cell was incorrect. 
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Fig 3.6 
The incidence of high hyperdiploidy detected by FISH in 30 cases with 
normal and 35 cases with failed cytogenetics compared with that detected 
cytogenetically in 299 successfully analyzed patients. 
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3.5 Discussion and conclusions 
Sixty five patients with ALL for whom cytogenetic analysis had failed or yielded only 
normal cells have been investigated for the possible presence of a high hyperdiploid 
clone. Nine patients were found to have a hyperdiploid clone. Five out of nine were 
then found to be high hyperdiploid, two low hyperdiploid and the remaining two could 
not be further classified due to lack of cells. A high hyperdiploid clone was detected in 
2 of 39 children and 3 of 26 adults to whom the full strategy could be applied. 
Cases without abnormal clones i. e. cases with failed or normal cytogenetics constitute 
a remarkably big proportion of all ALL cases investigated cytogenetically at diagnosis. 
In our laboratory over a third (35%) of cases investigated over a period of 6 years have 
been classified as failed or normals. The incidence of failed cases in the cytogenetics 
laboratory at the Royal Free Hospital (26%) is within the range of 23%-33% reported 
by others (Jackson et al., 1990; Seeker-Walker, 1990; Harris et al., 1992). The 
incidence of chromosomally normal cases among all successfully investigated cases in 
our laboratory (12%) is at the lower end of the range of 9% to 39% reported by others 
(Fletcher et al., 1989; Walters et al., 1990; Van der Plas et al., 1992b; GFCH, 1993; 
Harbott et al., 1993; Raimondi, 1993; Kobayashi et al., 1994). 
There are two possible ways in which a high hyperdiploid clone may escape detection 
in cases with successful cytogenetics. (i) The size of the malignant clone may be too 
small for cytogenetic detection. Standard cytogenetic analysis is restricted by time 
constraints to 20 metaphases. This will exclude the presence of a 11% clone with 95% 
confidence (Hook, 1977). It follows that any clone of a similar size or smaller is likely 
to be missed. This was illustrated by one of our cases with normal cytogenetics. It was 
found by FISH to have a high hyperdiploid clone of 10%. A high hyperdiploid clone of 
similar size has been reported in a chromosomally normal ALL relapse. In one report 
interphase FISH detected case with 13.5% of high hyperdiploid cells (Heerema et al., 
1993). (ii) The malignant clone may become inert in culture and in spite of being 
relatively abundant, the chromosomally abnormal cells may be under represented 
among the dividing cells. This was illustrated by the two remaining cases with normal 
cytogenetics which were found to have 34% and 42% of hyperdiploid cells. 
This 
finding suggests that, in a proportion of high hyperdiploid cases, malignant cells divide 
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in culture less efficiently than their normal counterparts leading to apparently small or 
inert clones. This finding is supported by the report by Manabe et al. (Manabe et al., 
1992). He described a serum -free assay to compare survival requirements of 
leukaemic B-cell progenitors. In this assay the only two cases not giving rise to viable 
cells in culture were patients with high hyperdiploid clones. 
The incidence of high hyperdiploidy among children by FISH was 9.1 % in failed and 
0% in normals. This was much lower than the 31 % of cases with high hyperdiploidy 
detected in children with successful cytogenetics in our laboratory and reported by 
others (range 19.6% to 33%) (Fletcher et al., 1989; Van der Plas et al., 1992b; GFCH, 
1993; Harbott et al., 1993; Raimondi, 1993; Kobayashi et al., 1994). These findings 
may suggest that high hyperdiploid cases of childhood ALL are less likely to fail in 
culture. The incidence of high hyperdiploidy detected by FISH among adults was 7.7% 
in failed and 15.4% in normals. These figures are closer to the 12% of high 
hyperdiploidy among adult cases with ALL detected by cytogenetics in our laboratory 
and to the numbers reported by others 7.0% (Groupe Francais de Cytogenetique 
Hematologique, 1996) and 10% (Walters et al., 1990; Secker-Walker et al., 1997). This 
finding suggests that cytogenetic analysis is neither more nor less likely to fail in adult 
ALL with high hyperdiploidy than in any other group. 
Interestingly, while the relative proportion of children and adults with high 
hyperdiploidy detected by FISH among failed cases mirrored that detected by 
cytogenetics (more children than adults were high hyperdiploid), the proportion of 
childhood and adult cases in normals was reversed. This finding suggests that high 
hyperdiploid clones in adults are more likely to become inert than those in children. 
In three out of five cases found to be high hyperdiploid by FISH, the initial cytogenetic 
investigation had revealed a single high hyperdiploid metaphase. This shows that 
finding of a single high hyperdiploid cell in the diagnostic bone marrow of patients 
with ALL may be suggestive of the presence of a high hyperdiploid clone. 
In summary, the data presented here, suggest that failure to detect a high hyperdiploid 
clone by metaphase cytogenetics may be more frequent in adults than in children. This 
study demonstrates that clones smaller than 50% may evade detection even when 20 
cells have been analysed. In conclusion interphase FISH provides a useful adjunct to 
cytogenetics for the detection of 
high hyperdiploid clones in ALL. 
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Chapter 4 
SINGLE-CELL TRISOMY 
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4.1 Summary 
Finding a chromosomally abnormal clone in the bone marrow of a patient with a 
haematological disorder is important to confirm the neoplastic nature of the disease. 
The presence of a particular chromosomal abnormality may be indicative of prognosis. 
The presence of a clone can only be confirmed when two or more cells with the same 
structural change or chromosomal gain are detected. A bone marrow sample which 
yields 20 metaphases of which no two are clonal is classified as normal. Since 
cytogenetic analysis detects only actively dividing clones, the presence of a single 
(random) abnormal cell among 20 cells analysed raises doubts about its clonal nature. 
Fluorescence in situ hybridization (FISH) enables rapid detection of certain 
chromosomal abnormalities in both metaphase and interphase cells thus enabling the 
detection of minor or inactive clones. Seven samples each from a patient with 
haematological malignancy at diagnosis or in remission and each having one or more 
random abnormal cells were investigated, thus: The six diagnostic samples were from 
patients with AML (3 cases) and a cell with +4 (1 case) +7 (1 case) or two cells with 
+9, +22 /+10, +17, +17 (1 case); from patients with MDS (three cases) and a cell with +8 
(2 cases) or +9 (one case). The seventh sample was from a patient with ALL in 
remission and had one cell with +4. One of the patients, a male aged 66 years, with 
MDS (refractory anaemia with ringed sideroblasts) was found to have a minor clone 
with trisomy 8 in his diagnostic marrow. A follow-up marrow 42 months later showed 
no trisomy 8 cell among 62 metaphases analyzed, and the percentage of trisomic cells 
using FISH on interphase cells was within the control range. This patient has survived 
for more than 42 months requiring no treatment. The single cell abnormalities in six 
cases proved to be random events. Thus it appears that single cell abnormalities may 
not be clonal or may indicate the presence of a minor clone well below the level of 
cytogenetic detection. The prognostic significance of such minor clones is at present 
unclear. 
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4.2 Introduction 
Cases in which a clone is not detected in the bone marrow are described as 
chromosomally normal. These cases are of two kinds: those in which no abnormal cell 
is detected and those with random changes i. e. having a single cell showing structural 
change or chromosomal gain, or no more than two cells with the same chromosomal 
loss. Among many possible reasons why, in some cases, clones are not found may be 
the limitations of the cytogenetic technique itself which is restricted to dividing cells, 
and limited by time constraints to analysis of no more than 20 cells. Cases which are 
prone to misclassification are those where the size of a clone is small and where 
neoplastic cells are not dividing. 
Whole chromosome gain resulting in trisomy of one chromosome is a feature of clonal 
change in all haematological malignancies at diagnosis (United Kingdom Cancer 
Cytogenetics Group, 1992). Established subgroups in AML include those with 
trisomies 4,8,9,11,13,21 or 22 (Walker et al., 1994); in MDS those with trisomies 7, 
8,9 (Noel et al., 1993). In ALL trisomies 8,10,16,21 or X account for rare subgroups 
(Secker-Walker, 1990; Secker-Walker, 1994). Remission in the acute leukaemias is 
associated with loss of the cytogenetically abnormal clone. However, single abnormal 
cells are occasionally found in remission marrows (Heerema et al., 1993). 
Fluorescence in situ hybridization (FISH) using whole-chromosome or alpha-satellite 
centromeric probes is a technique which can be used to detect the presence of trisomies 
in both mitotically active and resting cells. It also makes it possible to include large 
numbers of cells in the analysis, making for more sensitive clone detection. 
In this chapter, samples of bone marrow, each having a single abnormal cell, were 
investigated by FISH using chromosome paints on metaphase cells and alpha satellite 
centromeric probes on interphase cells to confirm the trisomy and to discover whether 
the single cell trisomies were truly random events or whether they represented minor or 
inactive clones. 
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4.3 Materials and methods 
4.3.1 Patients 
The patients investigated by FISH each had one or two non-clonal cells with 
chromosomal gain (or gains) and a haematological malignancy as follows: acute 
myeloid leukaemia (AML) (3 patients at diagnosis), myelodysplastic syndrome (MDS) 
(3 patients at diagnosis) and acute lymphoblastic leukaemia (ALL) (1 patient in 
haematological remission). Bone marrows from 
individuals were used as controls. 
4.3.2 Fluorescence in situ hybridization 
Samples investigated 
three haematologically healthy 
Metaphase spreads were investigated on slides which had been prepared for 
chromosome analysis (case 2 and 3). They had been G-banded and stored at room 
temperature for 1 and 3 years. 
Interphase cells were obtained from cell pellets which had been prepared for 
chromosome analysis and stored in Carnoy's fixative (3: 1 methanol : acetic acid) at - 
20°C for up to three years (cases 1-7). Cell pellets were resuspended in fresh fixative 
and slides were made immediately prior to FISH. 
Probes 
Hybridization to metaphase spreads was carried out using a whole chromosome probe 
(wcp). Biotin labelled whole chromosome probes for chromosomes 4 and 8 (Cambio, 
Cambridge) were used. 
For interphase FISH, biotin labelled alpha satellite centromeric probes, specific for the 
centromeres of chromosomes 4,7,8,9,10,17 (Oncor, Gaithesburg MD) were used. 
Hybridization, detection and interphase scoring 
For the details of hybridization, detection and interphase scoring refer to section 2.2.3. 
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4.4 Results 
4.4.1 Cytogenetic results of diagnostic and remission samples at RFH between 
1985 and 1994. 
Table 4.1 shows the total number of samples investigated from patients with AML or 
MDS at diagnosis and patients with ALL in remission in the cytogenetic laboratory, 
The Royal Free Hospital School of Medicine, between April 1985 and March 1994 as 
follows: those with an abnormal clone, those with a clone of 47 chromosomes due to a 
single trisomy, and those with one or two (random) abnormal cell(s) in cases lacking a 
clone. 
Table 4.1 
The incidence of clonal trisomy and of single trisomic cells in cytogenetically 
normal bone marrow in patients with AML and MDS at diagnosis and ALL in 
remission among samples karyotyped over a9 year period in the cytogenetic 
laboratory at the RFHSM 
diag stage total 
no 
chromosomally 
abnormal cases 
chromosomally normal cases 
total 
no 
with a clonal 
trisomy 
total 
no 
with a single trisomic cell 
+4 +8 +9 +3 +4 +8 +9 +17 +22 
AML Diag 260 156 2 8 1 104 1 1 0 0 1 0 
MDS Diag 134 57 0 4 0 77 0 1 3 1 0 1 
ALL* Rem 296 5 0 1 0 291 0 1 0 0 0 1 
* Ph+ cases excluded 
4.4.2 FISH investigation of patients with single abnormal cell 
Patients 
The clinical and cytogenetic data of each of the 7 patients investigated by FISH are 
given in Table 4.2. Three patients had AML (cases 1-3), three had MDS (cases 4-6) 
and one had ALL. The random abnormal cell or cells had been seen at diagnosis (cases 
1-6) or in remission (case 7). Case 1 had two different abnormal cells, with a 
combination of trisomy 9 and 22 and a combination of trisomy 10 with tetrasomy 17. 
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In cases 2 and 4 although the trisomy was identified, the quality of banding was less 
than optimal. For these cases the G-banded slide was destained and hybridized with 
whole chromosome probes (wcp) to chromosome 4 (case 2) or wcp to chromosome 8 
(case 4). In each case the suspected trisomy was confirmed (Fig 4.1 & 4.2). In two 
cases the trisomies were found in metaphases with chromosome loss (cases 3& 4). 
Case 6 had tetrasomy 8 in a high hyperdiploid cell with 58 chromosomes. Follow-up 
samples were obtained for cytogenetic analysis from case 1, four and five months later 
and from case 5, fifteen and twenty nine months from diagnosis. No similar trisomic 
cell had been found in either case in 10 or 20 cells analysed. Case 7 (investigated in 
remission) had a high hyperdiploid karyotype at diagnosis which did not include 
trisomy 4. Previous and subsequent remission samples of case 7 had been 
chromosomally normal on 35-50 cells analysed. 
Table 4.2 
Diagnosis, Age, sex, survival and cytogenetics of patients with single cell 
abnormalities at diagnosis 
case diagnosis age(yrs) event-free cytogenetics 
no /sex survival 
months 
1 AML M4 9/M 7 46, XY [18]/48, XY, +9, +22 [1]/ 
49, XY, +10, +17, +17 [1] 
2 AML MO 26/M 18 46, XY, 22p+c [18]/47, idem, +4 [1] 
3 AML 65/M NA 46, XY [15]/45, XY, +7, -10, -18 [1] 
4 MDS RARS 65/M 48+ 46, XY[29]/40, X-Y, -6, +8, -11, -15, -17, -17, -20 
[1] 
5 MDS 74/F 42 46, XX [19]/47, XX, +9 [1] 
6 MDS RARS 90/F 76+ 46, XX[15]/58, XX+X, +8, +8, +9, +12, +12, +13, 
+13, +14, +16, +18, +21 [1 ] 
7 ALL' I 8/M 40+ 46, XY [40]/47, XY, +4 [1 ] 
= Died following bone marrow transplantation in first complete remission. 
2= In remission 7 weeks from diagnosis. 
3= Clonal karyotype at diagnosis 51, XY, +X, +6, +14, +21, +21 [19] /46, XY [1] 
AML = Acute myeloid leukaemia, 
MDS = Myelodysplastic syndrome, 
ALL = Acute lymphoblastic leukaemia 
RARS = Refractory anaemia with ringed sideroblasts, NA = not available 
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Fig 4.1 
FISH investigation in case 2. 
A 
Metaphase spread stained 
(arrowed). 
with G-banding. Note three chromosomes 4 
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The same metaphase spread hybridized with whole chromosome probe (wcp) 
to chromosome 4. 
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Fig 4.2 
FISH investigation in case 4. 
A 
Metaphase spread stained with G-banding 
(arrowed). 
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The same metaphase spread hybridized with whole chromosome probe (wcp) 
to chromosome 8. 
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Interphase Fluorescence in situ hybridization 
The percentages of cells with 0-4 signals is given for bone samples of patients 1-7 in 
table 4.3. They are compared with control values (M+2SD) for cells with three signals 
obtained for each probe. 
Out of seven patients examined only case 4 showed a significant number of trisomic 
cells at diagnosis, with 1.5% trisomy 8 cells which was just greater than the control 
value for the probe (1.06%). Examination of a follow up sample 42 months later 
showed the percentage of trisomic cells by FISH within the control range. No trisomic 
cell was found cytogenetically among 62 metaphases examined. 
Table 4.3 
Investigation of 1000 cells by FISH analysis of bone marrow samples from 
cases 1-7 with a single cell trisomy identified cytogenetically 
case probe percentage of cells with 0-4 signals Control values 
(M+2xSD) for 
cells with 3A 
signals 
0 1 2 3 4 
1 10 0.7 2.3 95.2 1.8 0.0 2.0+0.3 
1 17 0.6 7.7 90.4 1.2 0.2 0.2+0.2 
1 9 0.5 4.7 94.0 0.6 0.2 0.8+0.6 
2 4 0.9 2.9 94.8 1.3 0.1 1.6+0.4 
3 7 3.9 3.7 90.0 2.2 0.2 1.9+0.4 
4 8 0.5 3.2 94.5 1.5 0.3 0.9+0.2 
4* 8 0.6 2.9 95.6 0.8 0.1 0.9+0.2 
5 9 0.4 4.2 95.0 0.4 0.0 0.8+0.6 
6 8 1.4 2.4 95.1 0.9 0.2 0.2+0.3 
7 4 1.0 1.8 95.6 1.5 0.1 1.6+0.4 
A4 signals in cases 1 (chromosome 17-specific probe) and case 6 
* 42 months from diagnosis 
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4.5 Discussion and conclusions 
Seven patients with a haematological malignancy and one or two cells with apparently 
random trisomies at diagnosis or in remission have been investigated for possible 
clonality. All single cell trisomies examined in our study had been unequivocally 
verified either by banding on well spread metaphases or, in two cases, supplemented by 
chromosome painting. Clonality was demonstrated in only one case, a patient with 
MDS was found to have a small clone with trisomy 8. 
Trisomy 8 is the most frequent trisomy in human neoplasia and has been shown to 
account for 194/349 of all cases with a single chromosomal gain as the only change 
(Heim, Mitelman, 1986). Trisomy 8 is the most frequent numerical change in MDS 
and is found in 19% of all cases (Mufti, 1992). In the cytogenetic database at the 
RFHSM MDS cases showed trisomy 8 as the sole change in 4/57 or 7% of 
chromosomally abnormal cases. These 4 cases each had a major clone involving >60% 
of the cells analysed. In addition a single cell with trisomy 8 was found in 3/77 or 4% 
of chromosomally normal cases. The present study demonstrated that one of the two 
cases available for study had a small clone. 
The FISH technique employed in this study is not only capable of verifying clonality 
but also determines whether the cytogenetic absence of a clone was due to its small 
size or to the lack of division of the clonal cells. The clone detected in this study 
turned out to be very small, and was only 0.44% above control values. Although the 
clone size was very small it is worth remembering that it represents between 1010-10" 
of total cell mass (Van Bekkum, 1984). This size of clone is similar to that detected by 
FISH in other studies with single cell trisomy 8 in at least 20 metaphases analysed. 
Clonality has been demonstrated in 14/23 such cases investigated, predominantly in 
cases of MDS (Jenkins et al., 1992; Chen et al., 1993b; Kibbelaar et al., 1993) (see 
table 4.4). In four cases the size of the clone was equal to control values (mean +2SD) 
(Kibbelaar et al., 1993), other cases showed clones of between 0.4% and 8% (median 
1.6%) above control values (Jenkins et al., 1992; Chen et al., 1993b; Kibbelaar et al., 
1993) (see table 4.4). The picture emerges that when a single cell with trisomy 8 is 
found in MDS it is the size of the clone rather than the inability of the clone to undergo 
cell division that is responsible for the apparent lack of a clone on cytogenetic analysis. 
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Table 4.4 
Reported cases with single trisomy 8 cell detected by cytogenetics and 
analyzed by FISH. 
case 
no 
no of cells 
analyzed 
on GTG 
banding 
percentage of 
interphase 
cells with 3 
signals (FISH) 
controls 
Mean +2xSD 
(FISH) 
reference 
1 36 3.0 3.0 Kibbelaar et al, 1993 
2 30 3.0 3.0 Kibbelaar et al, 1993 
3 20 4.0 3.0 Kibbelaar et al, 1993 
4 30 3.0 3.0 Kibbelaar et al, 1993 
5 20 3.0 3.0 Kibbelaar et al, 1993 
6 21 2.4 1.0 Chen et al, 1993 
7 20 2.4 1.0 Chen et al, 1993 
8 20 7.0 1.0 Chen et al, 1993 
9 20 2.2 1.0 Chen et al, 1993 
10 30 3.0 2.0 Jenkins et al, 1993 
In MDS, patients with a clonal cytogenetic abnormality have a worse prognosis than 
those without and trisomy 8 has been shown to be associated with a particularly poor 
prognosis (Nowell, Besa, 1989). The significance and clinical importance of small 
clones in the bone marrow of patients with MDS is difficult to evaluate at present. The 
patient with a minor clone at diagnosis described in this study has responded in a 
manner more reminiscent of patients without clonal involvement. He remained well 
for 42 months, is currently off all treatment and requires only occasional blood 
transfusions. In addition the lack of trisomic cells detected by FISH 42 months later 
indicates that such minor clones may be transitory. 
It cannot be ruled out that the clone is falsely represented in the bone marrow due to 
sampling in cases where the leukaemic population is not evenly distributed. However if 
the clone is indeed present in a small minority of cells it may indicate that 
chromosomal change is a late event which occurs after clonal expansion. Alternatively 
it may represent an early stage of the disease when the clone is maintained but has not 
yet suffered a second hit required to confer a true proliferative advantage over normal 
cells. 
Other trisomies of chromosome 4,7,8,9 & 17 were shown to be random events or, if 
clonal, to be below the level of detection of this technique. This contrasts with a report 
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by Chen et al (Chen et al., 1993b) who used interphase FISH to investigate the 
clonality of single trisomic cells in six cases of MDS, two of AML and one each of 
myeloproliferative disorder and chronic lymphocytic leukaemia. In each case the 
presence of a clone was confirmed. 
One patient with AML had a single cell with trisomy 4. This was the only AML with 
a random trisomy 4 cell found in the cytogenetic laboratory at the RFHSM (see table 
4.1). In the cytogenetic laboratory at the RFHSM single trisomic cells in 
chromosomally normal cases of AML have been rare with only three examples in 104 
(3%) normal cases analysed (see table 4.1). Trisomy 4 is well established as a clonal 
change, particularly in AML M2 and M4 (Prieto et al., 1987; Sandberg et al., 1987; 
Suenaga et al., 1993). It is however a rare subgroup in AML, accounting for 1.3% of 
all abnormal cases ( see table 4.1). 
Another patient had a single cell with trisomy 7. No case of AML with clonal trisomy 
7 has been found in the cytogenetic laboratory at the RFHSM but trisomy 7 has been 
reported in at least 13 cases, in two cases as the only change (Mitelman, 1991). 
Trisomy 9 in MDS has also been reported (Mitelman, 1991). The demonstration that 
neither of the two cells with 48 and 49 chromosomes in AML case 1 were clonal was 
of interest since trisomy 9,22,10 and 17 have all been reported in AML although the 
particular combination of trisomies seen in these cells has not been reported as clonal. 
High hyperdiploid clone investigated in case 6 was shown not to be clonal. High 
hyperdiploid clones are rare in MDS but have been reported (Mitelman, 1991). 
Trisomy 4, found in a single cell in a remission marrow from a patient with ALL was 
also found to be a random event. In the cytogenetic database at the RFHSM among 
291 remission samples from patients with ALL , with a normal 
karyotype, this sample 
was one of two with a single trisomic cell. In contrast 22 samples have had a single 
cell with structural change. The trisomy in remission in case 4 was not one of the 
trisomies found in the hyperdiploid clone at diagnosis and was not found in an earlier 
or subsequent remission marrow from the same patient, who remains in remission. 
Similar events have been described by Heerema et al and appear to be unimportant to 
prognosis (Heerema et al., 1993). 
The total number of cells analysed cytogenetically in our cases was between 15 and 40. 
The detection of an abnormal cell in these samples suggested the presence of a clone of 
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between 15% and 6% (Hook, 1977). This supposition was not supported by interphase 
FISH in this investigation. 
It can be concluded that single trisomies are most frequently due to random non- 
disjunctional events, while a minority may represent extremely minor clones in the 
leukaemic tissue sampled. The clinical significance of such cells is at present unclear. 
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Chapter 5 
CLONAL INVOLVEMENT OF DIFFERENT CELL LINEAGES 
IN ACUTE LEUKAEMIA 
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5.1 Summary 
The identification of the leukaemic progenitor cell may have important therapeutic 
implications. In this chapter FISH combined with morphology and/or immunology has 
been used to examine the clonal involvement of different cell lineages in acute 
leukaemia. Twelve patients with ALL and five with AML have been investigated. Four 
kinds of chromosomal abnormality were investigated, high hyperdiploidy in ALL (9 
cases), the Philadelphia chromosome in ALL (3 cases), trisomy 8 in AML (3 cases) 
and translocations involving 11 q23 in AML (2 cases). The presence of the cytogenetic 
abnormality in both myeloid and lymphoid lineages was demonstrated in two cases of 
Philadelphia chromosome positive (Ph+) ALL. In both cases the breakpoint occurred 
within the major breakpoint cluster region of the BCR gene (M-BCR). In the remaining 
case of Ph+ ALL with the minor breakpoint cluster region of the BCR gene (m-BCR) 
and in all cases of high hyperdiploid ALL, the abnormalities investigated were found to 
be restricted to the lymphoid lineage. In the 3 cases with AML and trisomy 8 and in 
two cases with AML and with the involvement of the MLL gene, the abnormalities 
investigated were found in myeloid lineage only. 
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5.2 Introduction 
Acute lymphoblastic leukaemia (ALL) and acute myeloblastic leukaemia (AML) are 
haematological malignancies characterised by proliferation and accumulation of 
genetically altered, immature haematopoietic cells and their progenitors. ALL is an 
accumulation of primitive lymphoid cells and is presumed to arise in a cell committed 
to lymphoid development. In contrast AML is an accumulation of primitive myeloid 
cells and it is presumed to arise in a cell committed to the myeloid development. 
However, there also exist so called `hybrid' or `mixed' leukaemias showing features of 
both myeloid and lymphoid lineages which indicates that some acute leukaemias may 
arise in a pluripotent stem cell (Bradstock et al., 1981; Smith et al., 1983; Pui et al., 
1984; European Group for the Immunological Characterization of Leukemias (EGIL) 
et al., 1995). 
Only a proportion of acute leukaemias are chemocurable. It has been suggested that 
the chemosensitivity of different leukaemias is related to the proliferative properties of 
the cell in which neoplastic transformation has occurred (Jasmin, 1988; Greaves, 
1993). Leukaemias originating in a pluripotent stem cell would be chemoresistant, 
while those originating from a committed progenitor cell would be relatively 
chemosensitive. The identification of the leukaemic progenitor cell can therefore, have 
important therapeutic implications. 
Chromosomal abnormalities are frequently found in the malignant clone in 
haematological neoplasms. The Philadelphia chromosome results from the 
translocation t(9; 22)(q34; ql 1). This abnormality accounts for 92% of chronic myeloid 
leukaemia (CML) cases. In ALL, the Philadelphia chromosome is detected in 3% -5% 
of childhood cases and 15% to 25% of adult cases and is associated with a bad 
prognosis (Secker-Walker et al., 1976; Bloomfield et al., 1977; Priest et al., 1980; 
IWCL3,1981b; IWCL3,1981a; Ribeiro et al., 1987; Secker-Walker, 1990). At a 
molecular level the Philadelphia chromosome is the product of the fusion of the part of 
the ABL gene located on chromosome 9 and the BCR gene located on chromosome 22. 
There are two different breakpoint cluster regions within the BCR gene: the 5.8 
kb 
major breakpoint cluster (M-BCR) region and 35 kb minor cluster region 
(m-BCR). 
Hyperdiploidy with more than 50 chromosomes identifies an important subgroup of 
patients with ALL. It is found in approximately 25% of childhood and 
in between 5% 
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to 11% of adult cases (Seeker-Walker, 1994; Groupe Francais de Cytogenetique 
Hematologique, 1996; Seeker-Walker et al., 1997). These patients have a better 
prognosis than that for any other ploidy group (Pui, Crist, 1992). The most common 
gains include chromosomes: X, 4,6,10,17,18 and 21. 
Whole chromosome gain resulting in trisomy of one or more chromosomes occurs as 
clonal change at diagnosis in varying proportions of patients in all haematological 
malignancies (United Kingdom Cancer Cytogenetics Group, 1992). Established 
subgroups in AML include the following trisomies as the only change 4,8,9,11,13, 
21 or 22 (Walker et al., 1994). 
Abnormalities involving 11 q23 are often observed in acute leukaemia. The 
t(6; 11)(g27; q23) translocation has been chiefly found in AML M4 and AML M5 
(Mitelman F, 1994). The gene involved in the fusion product is MLL while its partner 
gene is AF6 located at the band 6q27 (Prasad et al., 1993). The t(11; 17)(g23; 21) is 
mostly found in AML M4 and AML M5 (Harrison et al., 1998). 
Chromosome abnormalities can be detected using fluorescence in situ hybridization 
(FISH) in individual cells. FISH combined with morphology or immunophenotyping 
makes possible to detect chromosomal abnormalities in particular cell lineages 
(Kibbelaar et al., 1992; Price et al., 1992; van Lom et al., 1993; Nguyen et al., 1994). In 
this section FISH combined with morphology and immunphenotyping has been 
applied to investigate clonal involvement of different cell lineages in order to discover 
the probable level of commitment of the high hyperdiploid cases in ALL, in 
Philadelphia positive patients with ALL, in patients with trisomy 8 and AML and in 
patients with 11 q23 abnormalities and AML. 
5.3 Materials and methods 
5.3.1 Patients 
Patients diagnosed with ALL and high hyperdiploidy (9 cases), ALL and the 
Philadelphia chromosome (3 cases), AML with trisomy 8 (3 cases) and AML with 
11 q23 abnormalities (2 cases) were identified from laboratory records. Peripheral 
blood samples from three healthy individuals were used as controls. 
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5.3.2 Samples 
Cells remaining from the cytogenetic investigation stored in Carnoy's fixative at -20°C 
were used for the metaphase FISH investigations. Investigations of lineage 
involvement were performed on cytospins which had been prepared from the 
mononuclear layer or high density fraction of cells from the patients' bone marrow. For 
the details of cell isolation, density gradient centrifugation, cell storage and cytospin 
preparation see section 2.2.1. 
5.3.3 Investigation of the clonal involvement of different cell lineages. 
In order to investigate the clonal involvement of different cell lineages, cells belonging 
to particular bone marrow cell lineages were first identified on cytospins by 
visualising either their morphology using May-Grunwald-Giemsa (MGG) stain or their 
immunophenotype using the alkaline-phosphatase anti-alkaline-phospatase (APAAP) 
technique. Subsequently, the same preparations were used for FISH investigation. 
MGG stainin 
In order to visualise cell morphology, cytospins prepared from bone marrow aspirates 
were stained with MGG. For the details of the staining method see section 2.2.2. 
Following the MGG staining, cytospins were scanned and the localisation of cells of 
interest was recorded using low (x20) magnification. Their morphology was recorded 
using high (x 100) magnification. The recording was achieved using a CCD camera 
coupled with a Zeiss microscope and an Apple Mac Computer equipped with the 
Smart Capture Software. When recording was complete, slides were destained in 100% 
methanol for 1 minute, air dried and prepared for FISH. 
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APAAP technique 
Antibodies 
To determine cell immunophenotype, monoclonal antibodies from DAKO were used 
as follows: T-lymphoid (CD3), B-lymphoid (CD19), myeloid (CD13) and erythroid 
(Glycophorin A). 
Detection 
For the details of the detection method see section 2.2.2. Following APAAP staining, 
the coverslips were removed by soaking in deionised water, air dried and prepared for 
FISH. 
Fluorescence in Situ Hybridization (FISH) 
Probes 
Chromosome-specific alpha-satellite probes (Oncor, Gaithesburg) were obtained for 
chromosomes X, 6,7 and 8. Chromosome X was targetted in cases 1-4 and 6-9 (see 
table 5.1), chromosome 6 in case 5 (see table 5.1), chromosome 7 in case 11 (see table 
5.2) and chromosome 8 in cases 13-15 (see table 5.3). 
Translocation probes (t(9; 22)) identifying fusion of ABL with the minor (m) or the 
major (M) BCR were available from Oncor (Oncor, Gaithesburg). The probes were 
used in cases 10-12 (see table 5.2). 
The YAC 13HH4 (Das et al., 1992; Kearney et al., 1992) containing MLL gene was 
used for the investigation of patients with 11 q23 abnormalities (cases 16 and 17, table 
5.4). Yeast cultures, a preparation of DNA and the labelling of the probe is described 
in section 2.2.3. 
Hybridization and detection 
Hybridization, detection are described elsewhere (section 2.2.3) 
Control values 
Control values for trisomic cells were calculated as described (section 2.2.3). 
Scoring 
At least 50 cells were scored in each lineage investigation. If less than 50 cells were 
available for the analysis of a given cell lineage, the analysis was regarded as a 
failure. 
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5.4 Results 
5.4.1 Patients 
Clinical data and karyotypes of patients with ALL and AML are shown in table 5.1- 
5.4. Karyotypes of patients investigated included, in ALL, high hyperdiploidy (9 cases) 
(table 5.1) and t(9; 22) (3 cases) (table 5.2), in AML, trisomy 8 (3 cases) (table 5.3) and 
translocations involving 11 q23 (2 cases) (table 5.4). 
Table 5.1 
Clinical data and karyotypes of patients with ALL and high hyperdiploidy 
investigated for lineage involvement. 
case age(yrs) immuno WBC karyotype stage probe 
no /sex phenotype x109/1 
1 3/F Nk 12.3 53 XX, +X, +4, +6, del(6), +17, +21, +22 inc diag X 
2 4/M Nk Nk 53, XY, +X, +14, +18, +21, +21, +marl, +mar2 diag X 
3 4/M Pre-B 7.8 63-66, XY, +X, der(1), +2, +4, +5, +6, +7, +8, rel X 
+10, +11, +12, +16, +17, +18, +19. +20, +21, +22 
4 4/M common 2.4 65, XY, +X, +1, +4, +5, +6, +6, +8, +9, +10, +10, +11, rel X 
+12, +14, +add(17)(p), +18, +21, +21, +21, +22 
5 4/M Nk Nk 54, XY, +Y, +4, +6, +10, +14, +17, +21, +21 diag 6 
6 5/F Nk 7.9 52, XX, +X, +4, +18, +21 inc diag X 
7 11/F common Nk 65-72, XX, +X, +X, +1, +1, +2, +5, +6, +6, +8, diag X 
+9, del(9), +10, +11, +12, +16, - 
17, +18, +19, +20, +20, +21, +21, +22, +2mar 
8 19/M Nk 0.71 54-55, XY, +X, +4, +11, +21 inc diag X 
9 23/M Nk Nk 79-87, XX, YY, -4, -8, -8, -11, -11, -12, -15, - diag X 
15, +22, +mar, +mar inc 
Table 5.2 
Clinical data and karyotypes of patients with ALL and t(9; 22) investigated for 
lineage involvement. 
case age(yrs) immuno WBC karyotype stage probe 
no /sex phenotype x109/1 
10 18/M common 285 46, XY, t(9; 22) refract M-BCR-ABL 
ory 
11 38/F common Nk 44, XX, -7, t(9; 22), -22 diag 7 
11 54, XX, +X, t(1; 7), +5, +8, +8, follow- m-BCR-ABL 
t(9; 22), t(9; 22), +11 del(12p), up 
+12+17+19 
12 61/M common Nk 46, XY, t(9; 22) diag M-BCR-ABL 
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Table 5.3 
Clinical data and karyotypes of patients with AML and trisomy 8 investigated for 
lineage involvement. 
case age(yrs) FAB karyotype stage probe 
no /sex 
13 34/M M5 47, XY, +8 diag 8 
14 49/F M4 47, XX, +8, inv(16) diag 8 
15 69/M M4 47, XY, +8, inv(16) diag 8 
Table 5.4 
Clinical data and karyotypes of patients with AML and translocations involving 11 q23 
investigated for lineage involvement. 
case 
no 
age(yrs) 
/sex 
FAB karyotype stage probe 
16 14/F M4 46, XX, t(6; 11)(g27; q23) rel YAC 13HH4 
17 19/F M4 46, XX, t(11; 17)(g23; q21) diag YAC 13HH4 
5.3.2 Controls 
The control values of cells with detected pattern of hybridization signals for the probes 
used in the study are shown in table 5.5 
Table 5.5 
Control values of cells with the detected pattern of hybridization signals obtained from 
control blood samples from three females and three males. 
probe The hybridization cells with the hybridization pattern 
pattern of signals in detected 
cells detected 
Mean Standard Control 
(M) Deviation values(M+2x 
(%) (SD) (%) SD) (%) 
alpha-satellite chromosome X 2 signals 1.2 0.4 2 
(male controls) 
alpha-satellite chromosome X 3 signals 1.1 0.4 1.9 
(female controls) 
alpha-satellite chromosome X 4 signals 0.8 0.4 1.6 
(female controls) 
alpha-satellite chromosome 6 3 signals 0.9 0.3 1.5 
alpha satellite chromosome 7 1 signal 3.2 0.3 3.8 
alpha-satellite chromosome 8 3 signals 0.7 0.1 
0.9 
M-BCR-ABL t(9; 22) translocation M-BCR-ABL fusion 5.1 0.4 5.9 
probe signal 
m-BCR-ABL t(9; 22) translocation m-BCR-ABL fusion 5.9 0.6 
7.1 
probe signal 
YAC 13HH4 YAC 13HH4 split 4.3 0.3 4.9 
signal 
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5.3.3 The results of APAAP/FISH and MGGJFISH investigation 
Cases with ALL and high hyperdiploidy 
Nine patients with high hyperdiploidy (cases 1-9) (table 5.1) were investigated with 
APAAP/FISH and MGG/FISH using an alpha-satellite chromosome specific probe to 
one of the chromosomes gained. The FISH investigation confirmed the presence of the 
relevant chromosomal gain on metaphase spreads in cases where such material was 
available (cases 3-4,9-12). In the remaining cases the presence of the chromosomal 
gains was confirmed on interphase nuclei on cytospins. 
The results of APAAP/FISH study are shown in fig 5.1. Significant values of cells with 
one additional signal to chromosome X (+X) (cases 1-4,6, and 8), two additional 
signals to chromosome X (+X+X) (case 7) or one extra signal to chromosome 6 (+6) 
(case 5) were observed in CD 19+ cells only. In CD3+, CD 13+ and Glycophorin A+ 
cells the numbers of cells with +X, +X+X or +6 were within control values. An 
example of APAAP/FISH investigation is shown in fig 5.2. Similar results were 
obtained with the MGG/FISH investigation (see fig 5.3). Significant values of cells 
with +X, +X+X, or +6 were observed in immature lymphoid cells only. In cells with 
myeloid or erythroid appearance, the numbers of cells with +X, +X+X or +6 were 
within control values. The example of MGG/FISH investigation is shown in fig 5.4. 
Cases with ALL and t(9; 22) 
Three patients with t(9; 22) (cases 10-12) (table 5.2) were investigated with MGG/FISH 
for the clonal involvement of cells with BCR-ABL fusion. The patients were first 
examined with the M-BCR and m-BCR t(9; 22) translocation probes on metaphase 
spreads to confirm the translocation at the molecular level and to determine the BCR 
breakpoint. Two patients were found to have M-BCR breakpoint (cases 10 and 12) and 
one (case 11) with two t(9; 22) and no normal 9 or 22 to have two copies of m- 
BCR/ABL fusion. 
Subsequently the appropriate BCR/ABL probes were used on cytospins stained with 
MGG to determine the lineage involvement of cells with BCR-ABL fusion. The results 
of this investigation are shown in fig 5.5. In two patients with 
M-BCR (cases 10 and 
12) elevated numbers of the cells with M-BCR-ABL fusion were observed 
in both 
lymphoid and myeloid cells (see fig 5.6). In the remaining patient with the m-BCR and 
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the two t(9; 22) translocations significant values of cells with the double m-BCR-ABL 
fusion were observed in lymphoid cells only (see fig 5.6 and 5.7). The karyotype of 
this patient at diagnosis was 44, XY, -7, t(9; 22) -22. The MGG/FISH analysis of this 
sample with alpha-satellite chromosome 7 specific probe revealed that -7 cells were 
present in cells of blast appearance only. No myeloid cells with monosomy 7 were 
found (see fig 5.8). 
Cases with AML and trisomy 8 
Three patients with trisomy 8 were examined with APAAP/FISH using alpha-satellite 
chromosome 8-specific probe for the clonal involvement of trisomic cells. The FISH 
investigation of metaphase spreads at diagnosis confirmed the presence of the gain of 
chromosome 8 in the great majority of metaphases in all cases. The results of the 
APAAP/FISH investigation are shown in fig 5.9. Significant values of cells with an 
additional signal to chromosome 8 (+8) were observed in CD 13+ cells only. In CD3+, 
CD 19+ and Glycophorin A+ cells the numbers of cells with +8 were within control 
values. The example of this investigation is shown in fig 5.10. 
Cases with AML and translocations involving 11 q23 
Two patients with translocations involving 11 q23, t(6,11)(q 13; g23) (case 16) and 
t(11; 17)(g23; q21) (case 17) were examined with MGG/FISH using YAC 13HH4 for 
the clonal involvement of the malignant cells. The location of the YAC 13HH4 was 
first determined by hybridization to peripheral blood from healthy controls. The YAC 
13HH4 signal was confirmed to be on chromosome 11, at the q23 region (fig 5.11). 
The control values for cells with split YAC signal (identifying cells with the 11 q23 
region involvement) were obtained from mononuclear cells from peripheral blood of 
healthy controls (see table 5.5). The investigation of mononuclear bone marrow cells 
from two patients with 11 q23 translocations revealed that significantly raised numbers 
of cells with the split YAC 13HH4 signal were observed in immature myeloid cells 
only (fig 5.12). The numbers of cells with a split signal in lymphoid cells were within 
control values. The example of this investigation is shown in 
fig 5.13 
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Fig 5.1 
APAAP/FISH investigation of 9 cases of high hyperdiploid ALL. In 9/9 cases 
with high hyperdiploidy, cells with an additional signal to the alpha-satellite 
chromosome X specific probe were only seen in CD19+ve (B-lineage) cells. 
In CD3+ (T-lineage), CD13+ (myeloid) and Glycophorin A+ (erythroid) cells 
the numbers of cells with an additional signal to the alpha-satellite 
chromosome X specific probe were within control values. 
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Fig 5.2 
The results of APAAP/FISH investigation in case 7. Double gain of 
chromosome X is present in CD 19+ cells only. Cells positive with a given 
antibody are stained red. Green dots represent hybridization signals with 
alpha-satellite chromosome X specific probe. Note four dots present in 
CD19+ cells but only two present in CD3+, CD13+ and Glycophorin A+ cells. 
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Fig 5.3 
MGG/FISH investigation in ALL with high hyperdiploidy. in 9/9 cases cells 
with an additional signal to the alpha-satellite chromosome X* specific probe 
were only seen in lymphoid blasts. Cells with an additional signal to the 
alpha-satellite chromosome X specific probe were within control values in 
cells of myeloid or erythroid appearance. 
* +6 (case 5), +X+X (case 7) 
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Fig 5.4 
The results of MGG/FISH investigation in case 1. Gain of chromosome X 
present in immature lymphoid cells but absent in differentiating myeloid cells. 
Red dots represent the hybridization signals with alpha-satellite chromosome 
X specific probe. 
4, - 
109 
Fig 5.5 
The MGG/FISH investigation of Ph+ ALL. Ph+ cases showed fusion of M- 
BCR-ABL in lymphoid as well as myeloid cells (cases 10 and 12) and fusion 
of m-BCR-ABL in lymphoid but not myeloid cells (case 11). 
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Fig 5.6 
The results of MGG/FISH investigation in case 12. Translocation t(9; 22) 
present in both in lymphoid and myeloid cells. Red dots represent 
hybridization signals with BCR and green with ABL probes respectively. 
Yellow signals represent BCR-ABL fusion. 
Fig 5.7 
The results of MGG/FISH investigation in case 11. Double t(9; 22) present in 
lymphoid blasts but absent in differentiating myeloid cells. Red dots 
represent hybridization signals with BCR and green with ABL probes 
respectively. Yellow signals represent BCR-ABL fusion. 
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Fig 5.8 
The results of the MGG/FISH investigation with alpha-satellite chromosome 
7 specific probe in case 11. Red dots represent hybridization signals with 
alpha-satellite chromosome 7 specific probe. Note monosomy 7 present in 
blast cells only. Cells with myeloid morphology show 2 signals 
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Fig 5.9 
The APAAP/FISH investigation of cases with AML and trisomy 8 with alpha- 
satellite chromosome 8 specific probe. Significant values of cells with 3 
signals were observed in CD13+ cells only. In CD3+, CD19+ and 
Glycophorin A+ cells, cells with 3 signals were within control values. 
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Fig 5.10 
The example of APAAP/FISH investigation in case 13. Green dots represent 
hybridization signals with alpha-satellite chromosome 8 specific probe. Note 
that 3 signals are present in CD13+ cell only. 
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Fig 5.11 
The localization of the YAC 13HH4 
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Fig 5.12 
The results of MGG/FISH investigation of cases with AML and translocations 
involving 11q23. In both cases the significant values of cells with the YAC 
13HH4 split signal was observed in cells of blastoid appearance. In 
lymphocytes, the numbers of cells with the split signal were within control 
values. 
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Fig 5.13 
The results of MGG/FISH investigation using YAC 13HH4 in case 16 
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5.5 Discussion and conclusions 
Twelve patients with ALL and five with AML have been investigated using FISH 
combined with immunphenotyping and/or FISH combined with morphology for the 
clonal involvement of different cell lineages. In all cases of AML the abnormality was 
restricted to the myeloid lineage. In[majority of cases with ALL the clonal abnormality 
was restricted to lymphoid lineage. The exceptions were found in Ph+ subgroup. In this 
group two cases showed involvement of both lymphoid and myeloid lineages. In both 
cases the breakpoint occurred within the major breakpoint cluster region of the BCR 
gene. The remaining Ph+ case with m-BCR was lymphoid only. 
CML is a stem cell disorder, in which the target cell is capable of differentiating into 
myeloid, erythroid and lymphoid lineages. Studies with glucose-6-phosphate 
dehydrogenase isoenzymes have demonstrated that CML is a disorder of a pluripotent 
stem cell which is capable of differentiating into granulocytes, erythrocytes and 
macrophages (Fialkow et al., 1977). The involvement of B-lymphocytes has also been 
shown (Martin et al., 1980). The morphological picture of CML in lymphoid blast 
crisis is indistinguishable on morphological grounds from Ph+ ALL. It has been 
suggested that Ph+ positive ALL may be, in fact, CML presenting in a blast crisis 
(Chan et al., 1987; Clark et al., 1989). 
In the present study myeloid and lymphoid lineage involvement was demonstrated by 
FISH/morphology in two cases of the Philadelphia chromosome positive ALL. In both 
cases the break had occurred within the major breakpoint cluster region of the BCR 
gene (M-BCR). Lymphoid restriction was shown in one case with the minor breakpoint 
cluster region of the BCR gene. 
The lineage involvement of the Ph+ ALL has been the subject of the much debate. 
Cytogenetic studies of haemopoietic colonies derived from patients with Ph+ ALL 
have shown that Ph+ clones can be lymphoid restricted as well as occur both in 
lymphoid and myeloid compartment. Thus, Kalousek et al. (Kalousek et al., 1988) 
reported 4 cases with myeloid involvement and 4 without. Similarly, Dow et al. (Dow 
et al., 1989) reported 2 cases with myeloid involvement and 4 without. Three cases 
with lymphoid involvement only were reported by Kitano et al. (Kitano et al., 1988). In 
contrast, Tachibana et al. (Tachibana et al., 1987) reported two cases of Ph positive 
ALL and both of them with myeloid involvement. The investigation of the lineage 
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involvement of Ph+ ALL using molecular approach makes possible to distinguish 
between M-BCR (CML-like) and m-BCR (ALL-like) variant of Ph+ ALL. Three such 
studies were undertaken. In the first two, the cell compartments of Ph+ ALL were 
isolated by density gradient centrifugation and the presence of M-BCR or m-BCR 
rearrangements were detected by Southern blotting. Thus, Craig et al (Craig et al., 
1990) reported two cases with M-BCR and m-BCR which were lymphoid restricted. 
Seeker-Walker et al (Seeker-Walker, Craig, 1993) reported two cases, one m-BCR and 
one M-BCR, both lymphoid restricted and two M-BCR cases with myeloid 
involvement. A different molecular approach was applied in the third study (Anastasi 
et al., 1996). The minor and major BCR were detected using FISH combined with 
morphology staining. The authors reported 4 cases of the M-BCR and 4 of the m-BCR 
Philadelphia positive ALL. In concordance with the study presented here, cases with 
m-BCR were lymphoid restricted and cases with M-BCR showed myeloid 
involvement. Secker-Walker et al. (Seeker-Walker, Craig, 1993) reviewed the 
prognostic implications of lineage heterogeneity and the BCR breakpoint in Ph+ ALL 
and showed that there was no correlation between the breakpoint and survival. 
However, patients with myeloid involvement of clonal cells had significantly longer 
survival. This was later confirmed by Anastasi et al. (Anastasi et al., 1996). 
Paradoxically, it contradicts the theoretically predicted features of stem cell leukaemia 
(Jasmin, 1988; Greaves, 1993). These authors associated a lack of chemosensitivity 
with the involvement of the stem cell and relative chemosensitivity with the 
involvement of a committed progenitor cell. 
Eight cases of hyperdiploid ALL investigated in this study were all shown to be 
lymphoid restricted. Lineage involvement of ALL has been the subject of three 
studies. Dow et al. (Dow et al., 1985) investigated types of glucose-6-phosphate 
dehydrogenase (G6PD) isoenzymes in 19 females heterozygous for this X 
chromosome-linked enzyme. Patients' karyotypes were hyperdiploid or pseudodiploid. 
The lymphoid blast cells from all cases displayed a single, (either A or B) G6PD 
isoenzyme type while in other cell lineages both A and B G6PD types were observed. 
Molto et al. (Martin-Henao et al., 1994) reported 2 hyperdiploid cases investigated with 
morphology/FISH technique using trisomy 7 and trisomy 8 as markers of clonality. 
The chromosomal abnormalities were found in lymphoid cells only. Knuutila et al 
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(Knuutila et al., 1993) investigated a male patient with ALL with t(5; 14) and disomy 
X using the MAC technique. That technique, like the one used it 
present 
study, makes 
it possible to study karyotypes in cells with an intact morphology. The chromosomal 
abnormalities were restricted to cells of lymphoid morphology only. Thus, the 
lymphoid restriction of clones in ALL other than Philadelphia-positive cases reported 
in this study is fully concordant with other studies published up to date. 
All three cases of AML with trisomy 8 and two cases each with a different 
translocation involving 11 q23 investigated in this study were found to be restricted to 
the myeloid lineage only. Lineage restriction in AML has been subjected to a number 
of studies, which differed in the techniques used. The MAC technique was used in 
three reports. Keinanen et al (Keinanen et al., 1988) investigated 12 cases with trisomy 
8 and monosomy 7; Suciu et al. (Suciu et al., 1993) investigated 11 cases with various 
chromosomal abnormalities and Starnberg at al. (Starnberg et al., 1988) reported one 
case of AML with trisomy 8. In all three reports chromosomal abnormalities were 
found in cells of myeloid but not lymphoid lineage. FISH combined with morphology 
was utilised in two studies. Van Lom et al. (van Lom et al., 1993) investigated three 
cases with trisomy 8, monosomy 7 and -Y. Kwong et al. (Kwong, Chan, 1994) 
reported one case of AML with monosomy 7. In both studies the chromosomal 
abnormalities were found in the myeloid compartment but not in lymphoid cells. 
Interphase FISH combined with immunostaining was used in one study. Baurmann et 
al. (Baurmann et al., 1993) reported one case of AML with monosomy 7 restricted to 
the myeloid lineage. Chromosome X-linked polymorphism was used in five reports. 
Fialkow at al. investigated types of glucose-6-phosphate dehydrogenase (G6PD) 
isoenzymes in subsequent reports (Fialkow et al., 1979; Fialkow et al., 1981; Fialkow 
et al., 1987) in 1,4,27 cases of AML respectively. All reports were fully concordant 
showing a single G6PD type in myeloid blasts only. In two other reports using a 
similar approach, Kere et al (Kere et al., 1987) reported one case of AML with 
monosomy 7 and Najfeld et al. (Najfeld et al., 1988) reported one case of AML M7. 
Both cases were found to be myeloid restricted. Thus, the results of all above reports 
are concordant with the study presented here showing lack lymphoid involvement 
in 
AML 
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The data presented here, shows that a number of clonal chromosomal abnormalities in 
acute leukaemia are found only in one type of cell. This suggests that in these cases the 
acute leukaemia originates in a committed progenitor cell. Another possibility that 
cannot be ruled out is that the abnormalities might arise in a pluripotent stem cell 
which is then directed towards either the myeloid (in AML) or the lymphoid (in ALL) 
lineage only. Philadelphia positive ALL appears to be an exception to this rule. This 
study showed 2/3 cases in which the Philadelphia chromosome was found in both 
lymphoid and myeloid lineages, indicative of a pluripotent target cell. 
In summary, lineage restriction appears to be the rule in the acute leukaemias but Ph+ 
ALL appears to be an exception. 
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Chapter 6 
MINIMAL RESIDUAL DISEASE IN ACUTE LYMPHOBLASTIC 
LEUKAEMIA WITH HYPERDIPLOIDY 
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6.1 Summary 
A theoretical analysis showed that false positive hybridization signals that limit the 
sensitivity of an interphase FISH assay represent probabilistically independent 
events. Therefore simultaneous targeting of two or more chromosome gains should 
result in increased sensitivity. The theoretical approach was tested by applying 
chromosome-specific probes singly, in pairs and as a triplet to three control samples. 
Control values (mean (M) + twice the standard deviation (SD) of positive cells in 
normal peripheral blood) were 1.6% to 2.0% in single probing (500 cells), 0.01% to 
0.02% in double probing (104 cells) and 0% in triple probing (104 cells). Serial 
dilutions of bone marrow from a patient with a clone of >50 chromosomes in >85% 
of cells with peripheral blood were prepared. Each dilution mixture was probed with 
single, dual or triple probes and the clone was detected at dilutions of 10-1 (single, 
double and triple probing), 10-3 (double and triple probing) and 10-4 (triple probing). 
Subsequently, inrphase FISH using double and triple probing was applied for 
MRD detection in patients with high hyperdiploidy. The chromosomes gained at 
diagnosis (13 cases) or in relapse (3 cases) were confirmed by FISH. Of 30 follow- 
up samples examined in remission 13 were positive for the hyperdiploid clone with 
between 0.01% and 0.06% of clonal cells. Positive samples in first remission were 
more frequent during the first 7 months of treatment (7/12) than thereafter (3/11). 
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6.2 Introduction 
In this chapter the results of MRD investigation in patients with ALL and high 
hyperdiploidy using an adapted interphase FISH approach which was specific for the 
hyperdiploid clone are presented. By targetting three chromosomal gains 
simultaneously a sensitivity of 10-4 was achieved. 
Acute lymphoblastic leukaemia (ALL) is a malignant disease of which 65% of children 
and 25% of adults achieve durable remissions and may ultimately be cured. (Chessells 
et al., 1995) Cytogenetic classification identifies a subgroup of patients with high 
hyperdiploid clones (>50 chromosomes) in which the malignant cells have at least 5 
supernumerary (or trisomic) chromosomes. (Secker-Walker, 1994) Providing neither 
the Philadelphia translocation nor t(4; 11)(g21; q23) is present these patients, whether 
children or adults, have a better prognosis than those with any other chromosomal 
finding. (Pui, Crist, 1992; Raimondi et al., 1996) An unusual feature of some high 
hyperdiploid clones is an apparent ability to remain dormant for many years. Relapse 
in this subgroup, which occurs in approximately 25% of children and 35% of adults, 
tends to be after the completion of treatment and even up to many years later (Dastugue 
et al., 1992). Also indicative of the relative inactivity of these clones is that second 
remissions, if they are achieved, tend to be longer than usual. (Seeker-Walker, 1984) It 
was originally believed that the presence of any translocation would compromise the 
good prognosis of high hyperdiploid patients but more recent studies have not 
confirmed this. (Williams et al., 1986; Seeker-Walker et al., 1989; Rubin et al., 1991) 
Therefore there is, at present, no way of identifying the patients in this subgroup who 
are destined to relapse. 
It has been shown that failure to achieve clinical remission, 21 days from diagnosis, is 
associated with a poor prognosis in childhood ALL. (Legrand et al., 1994) It might 
therefore be expected that persistence of minimal residual disease (MRD), below the 
level of morphological detection, would be a similarly adverse indicator. Sensitive 
methods of detection of cytogenetic clones for MRD in ALL are at present limited to a 
minority of translocations, such as t(9; 22)(g34; q 11) and t(1; 19)(g23; p 13), which have 
been cloned and sequenced. These can be investigated by the reverse transcription 
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polymerase chain reaction (RT-PCR) with a sensitivity of 104 to 10-6 (Devaraj et al., 
1995). 
Additional copies of whole chromosomes, as found in high hyperdiploid clones, can be 
detected in interphase cells by fluorescence in situ hybridization (FISH) using 
chromosome-specific alpha-satellite probes. However, the detection of single 
additional chromosomes by interphase FISH cannot compete in sensitivity with RT- 
PCR for aberrant fusion products because of relatively high control values, caused by 
the presence of false positives (Saunders, Mauer, 1969; Heerema et al., 1993; Amiel et 
al., 1995; Zhao et al., 1995). 
The aim of the study presented here was to develop a sensitive interphase FISH assay 
and to apply this technique for the detection of minimal residual disease in patients 
with ALL and hyperdiploidy. 
The study involved the following steps. (i) The theoretical analysis of the sensitivity of 
an interphase FISH assay. (ii) Testing the sensitivity of a new approach to interphase 
FISH. (iii) The application of the above technique for MRD detection in patients with 
ALL and hyperdiploidy. 
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6.3 Analysis of sensitivity of interphase FISH 
6.3.1 Background 
Trisomies of certain chromosomes present in high hyperdiploid clones can be detected 
by interphase FISH using alpha-satellite chromosome-specific probes. Application of 
this technique allow the investigator to distinguish between normal and hyperdiploid 
cells (Rivera et al., 1991; Anastasi et al., 1992; Jenkins et al., 1992; Chen et al., 1993b; 
Escudier et al., 1993; Kibbelaar et al., 1993; Brizard et al., 1994). The distinction is 
based on the number of hybridization signals to a specific probe. Three signals identify 
a trisomy (as in a hyperdiploid cell), two signals identify a normal, diploid 
chromosome complement. The application of interphase FISH to normal controls 
results in two hybridization signals in a great majority of cells. However, cells with 0, 
1,3 or 4 signals are also found. The presence of cells with 3 signals (`false positives') 
limits the sensitivity of interphase FISH used for the detection of MRD in patients with 
hyperdiploid clones. 
In this section an attempt to overcome the above limitation is presented. It is assumed 
that the acquisition of an extra hybridization signal (`false trisomy') by normal cells is 
a probabilistically independent event for each alpha-satellite chromosome specific 
probe applied. If two or more probes, targetting two or more chromosomes, are 
applied simultaneously, only cells showing trisomies of both chromosomes would be 
screened as `positive'. It follows from the definition of probabilistic independence (see 
below, sections 6.3.2.2 and 6.3.2.3) that the simultaneous use of two or more probes 
should result in a decrease in number of cells with false trisomies. To test this 
assumption a model of hybridization signal distribution based on the conditional 
probability of independent events was introduced. Using this model the predicted 
frequencies of cells with extra hybridization signals using two chromosome specific 
probes simultaneously was calculated. The predicted frequencies were then compared 
with the frequencies of such cells obtained from normal controls. 
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6.3.2 Materials and methods 
6.3.2.1 Frequencies of cells with one extra hybridization signal on normal controls 
The frequencies of cells with an extra hybridization signal with a single probe were 
obtained for the X. 6 and 18 chromosome from peripheral blood samples from 3 
healthy male controls from three peripheral blood samples (500 cells). Three blood 
samples were also used for the following probe pairs: X+6, X+18 and 6+18 (104 cells). 
6.3.2.2 Conditional probability of independent events 
Conditional probability of the simultaneous occurrence of two events if they are 
independent is defined as follows (Hayslett, 1997; Helms, 1997): 
Events E1 , 
E2 
9 ... E are 
independent if 
II P(Ei) cýý 
1=1 1=1 
where i, n EN, P((E; ) = is the probability of the joint occurrence of n events and 
P((u)E1) = P(E1nE2n... n E), 
P(Ei) is the probability of the occurrence of an event Ei, and 
II P(Ei) = P(E1 )x P(E2)x. .. x 
P(E ). 
Note that for n=2 formula 1 is expressed as: 
P(E1nE2) = P(E1)xP(E2) (2) 
where E, and E2 are events 1 and 2, P(E1nE2) is the probability of the joint occurrence 
of the events E1 and E2, P(E1) and P(E2) are the probabilities of each event occurring 
separately. 
6.3.2.3 Probabilistic model of the distribution of hybridization signals 
In order to apply conditional probability of independent events as described above for 
the description of the distribution of hybridization signals in an interphase FISH assay, 
the following definitions were introduced: 
(i) A probabilistic event, E;, is the gain of an extra hybridization signal by a given cell 
with a probe i. 
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(ii) The probability of a single event, P(E), is the frequency of cells with a gain of one 
extra hybridization signal in a single probing. 
(iii) The probability of a joint occurrence of two independent events, P(E1nE2), is the 
predicted frequency of cells with a gain of one extra hybridization signal with each 
probe in a double probing. 
Thus, the predicted frequency of cells with a gain of one extra hybridization signal with 
each probe in a double probing is expressed using formula 2 as follows: 
P(E 1 nE2) = P(E 1)xP(E2) 
where E1 and E2 are the gains of an extra hybridization signal by a given cell with 
probe 1 and 2, P(E1nE2) is the predicted frequency of cells with a gain of one extra 
hybridization signal with each probe in a double probing and P(EI) and P(E2) are the 
frequencies of cells with a gain of one extra hybridization signal in a single probing. 
6.3.3 Results 
The predicted (calculated using formula 2) and observed frequencies of cells with 
additional hybridization signals from each of the probe pairs are shown in table 6.1 
Table 6.1 
The observed and predicted frequencies of cells with one extra signal for the alpha- 
satellite chromosome-specific probe(s) (indicating trisomy for that chromosome) in 
three control samples 
probe(s) specific to 
chromosomes 
% of cells with one extra hybridization 
signal 
observed calculated* 
X 1.2 NA 
6 0.9 NA 
18 1.0 NA 
X+6 0.003 0.011 
X+18 0.007 0.012 
6+18 0 0.009 
NA not applicable 
The frequencies of cells with extra hybrdization signal were calculated 
using formula 2 as follows: 
For the probe pair X+6, P(E1) is the observed frequency of cells with 1 extra 
hybridization signal using probe X (1.2% see table 6.1), P(E2), the observed 
frequency of cells with 1 extra hybridization signals using probe 6 (0.9% see table 
6.1). P(E1nE2) is the predicted frequency of cells with two extra hybridization signals 
(one from probe X and one from probe 6) (see formula 2). The formula 2 is then 
applied as follows: 
P(E1nE2)= P(E1)xP(E2)=0.012x0.009= 0.00011=0.011 % 
The frequencies of cells with extra hybrdization signal for the other probe pairs i. e. 
X+18 and 6+18 were calculated in the same way. 
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The frequency of cells with an extra hybridization signal in a double probing was 
approximately 100 fold lower than the same frequency in a single probing for all the 
probe combinations tested (see table 6.1). 
The probabilistic model tested gave a good prediction of the frequency of cells with an 
extra hybridization signal in a double probing. The predicted frequencies (range 
0.009% -0.012%, mean 0.011%) were close to their observed counterparts (range 0% - 
0.007%, mean 0.003%). 
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6.4 Testing the sensitivity 
6.4.1 Materials and methods 
The new approach tested in this section involved applying two or three probes for the 
simultaneous detection of chromosomal gains, combined with a method for estimating 
the number of cells scanned. The accuracy of the estimation method and sensitivity of 
the assay were tested as described below. 
6.4.1.1 Cell number estimation 
The method involved being able to score large numbers of cells. In order to avoid 
having to make repeated counts of the cells, the number of cells on a slide was 
extrapolated from representative fields of view. Cytospins were chosen because these 
give an even distribution of cells and the area of the cytospin is defined. It was 
assumed that the density of cells within a cytospin was constant and the number of 
cells per cytospin was calculated from the formula N= n(D/d) 2 (3) where N= the 
number of cells in a cytospin; n= the average number of cells from 10 fields of view 
using a x100 objective; D= the diameter of the cytospin and d= the diameter of the 
field of view. Formula 3 was obtained as follows. Figure 6.1 illustrates the geometrical 
relations between x100 objective field of view and a field of the cytospin. VF-density 
of cells on a cytospin, Vt-density of cells in a x100 objective field of view, R-radius of 
a cytospin, r-radius of a x100 objective field of view, F-field of a cytospin, f-field of a 
x100 objective field of view. N= VFxF and n= Vfxf. Let VF=Vf =V= constant, then 
N=(F/f)xn. The cytospin and the x100 objective field of view are circles therefore 
F=IIxR2 and f=lIxr2. It follows that N=(IIxR2/IZxr2)xn and N=(R2/r2)xn. Since R=D/2 
and r=d/2 then N=[(D2/4)/(d2/4)]xn. Thus N= (D2/d2)xn, as was to be proved. 
The accuracy of the method was tested for 20 cytospins by counting the number of 
cells present and comparing the actual number of cells with that estimated. An average 
cytospin contained 4000 cells requiring 3 cytospins to achieve a yield of 104 cells. 
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Fig 6.1 
The method for approximating the number of cells scanned. Geometrical 
relations between x100 objective field of view and a field of the cytospin. (See 
section 6.4.1.1) 
d- diameter of a x100 objective field of view 
r- radius of a x100 objective field of view 
D- diameter of a cytospin 
R- radius of a cytospin 
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6.4.1.2 Sensitivity 
In order to determine the sensitivity of the assay with regard to the number of probes 
used for the detection of chromosomal gains, the following dilution experiment was 
performed. Leukaemic marrow with the clonal karyotype 55, XY, +X, +6, +18, +21, inc 
was hybridized with probes to chromosome X singly, to chromosomes X and 6 as a 
pair and to chromosomes X, 6 and 18 as a triplet. Each hybridization yielded more than 
85% cells with gains of one, two or three signals respectively. This marrow was mixed 
with peripheral blood mononuclear cells from one of the control samples to obtain the 
following dilutions (1: 10; 1: 100 1: 1000 1: 10,000). The following probes were 
hybridized and cells scored for each diluted sample: X singly (500 cells); X, 6 paired 
and X, 6,18 as a triplet (104 cells). 
6.4.2 Results 
6.4.2.1 Cell number estimation 
Fig 6.2 illustrates the correlation between the number of cells scored and the number 
of cells estimated on 20 randomly chosen cytospins. The numbers of cells scored 
ranged from 859 to 7165 and the number estimated ranged from 880 to 8142. The 
correlation was good (r = 0.9170, p<0.001) confirming the reliability of estimating the 
number of cells in a cytospin from 10 representative fields of view. 
6.4.2.2 Sensitivity 
The results of the serial dilution tests using probes X singly, X, 6 in pairs and X, 6,18 as 
a triplet are shown in fig 6.3. The number of cells with one extra hybridization signal to 
each probe used was significantly above control values down to a dilution of 10-1 using 
a single probe and down to 10-3 using a pair of probes. Using the triplet, cells with 
three additional signals were detected in samples down to a dilution of 104. Examples 
of FISH on metaphase chromosomes and on interphase cells from a patient with 
hyperdiploidy using probes singly, as a pair and as a triplet are shown in fig 6.4. 
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Fig 6.2 
Correlation between the number of cells scored and the number of cells 
estimated on 20 randomly chosen cytospins (r=0.9170, p<0.001). 
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Fig 6.3 
The results of FISH following serial dilutions of control cells with bone marrow 
with >85% hyperdiploid cells are shown for probes to chromosome X alone, 
X+6 together and X+6+18 as a triplet. The percentage of positive cells was 
significantly above control values using one, two and three probes at 10-1, 
using two and three probes at 10-3 and using three probes down to 10-4 cells. 
Control values (mean + standard deviation x2) for the percentage of cells with 
gain of X, 6 and 18 hybridized to mononuclear cells of normal peripheral blood 
singly, in pairs and as a triplet are also shown 
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Fig 6.4 
The results of FISH in case 6 (female) using chromosome specific centromeric 
probes at diagnosis on metaphase and interphase cells showing trisomy for 
chromosome 6 (red), 18(green), and X (yellow), A6 hybridized alone, B 6+18 
together, C X+6+18 together. D shows a normal female cell with two signals 
for each probe. 
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6.5 Application of the assay 
6.5.1 Materials and methods 
6.5.1.1 Patients 
Bone marrow from patients with ALL found by metaphase cytogenetics to have a high 
hyperdiploid (>50 chromosomes) clone at diagnosis (13 patients) or in relapse (3 
patients) were identified either in the cytogenetics laboratory at the RFHSM or by the 
Leukemia Research Fund, United Kingdom Cancer Cytogenetic Group (UKCCG) 
karyotype database in ALL. A total of 29 remission samples was obtained from these 
patients at periods ranging from 1 to 48 months after the initial sample. Control 
samples of peripheral blood were obtained from 3 healthy males and 3 healthy females 
6.5.1.2 Control Values 
Control values for the detection of trisomy X (or disomy X in males) with a single 
probe were obtained for the X chromosome from peripheral blood samples from 6 
healthy controls (3 males and 3 females). Control values for each of the following 
autosomes 4,6,10,17,18 were obtained using three peripheral blood samples (500 
cells scored from each sample). Three blood samples were also used for the following 
probe pairs: X, 18 and X, 6 and for each triplet: X, 4,6; X, 4,10; X, 4,17; X, 4,18; X, 6,17; 
X, 6,18; and X, 17,18 (104 cells). Cells with three signals (or two for males using the X 
probe) for each probe used were recorded and expressed as a percentage of cells 
scored. 
6.5.2 Results 
6.5.2.1 Control Values 
Control values for trisomic cells were calculated for each probe used, from the mean 
(M) and standard deviation (SD) of cells with one extra signal in three control samples. 
Control values were set at M+2SD. Using single probes, control values ranged from 
1.5% to 2.1% as shown in table 6.2. Cells with simultaneous gain of two hybridization 
signals with probe pairs: X, 6 and X, 18 gave control values of 0.01% and 
0.02% 
respectively. For each triplet (see section 6.5.1.2) no cell with all three additional 
signals was seen in 104 cells. 
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Table 6.2 
Control values based on the mean and standard deviation of the number of 
cells showing an additional signal for each probe(s) used in the study 
probe(s) specific to 
chromosomes 
Mean (M) 
(%) 
SD (%) M+2xSD 
X female 1.1 0.4 1.9 
X male 1.2 0.4 2.0 
4 1.6 0.2 2.0 
6 0.9 0.3 1.5 
10 1.1 0.3 1.7 
17 1.2 0.2 1.6 
18 1.0 0.2 1.4 
X+6 0.003 0.005 0.013 
X+18 0.007 0.005 0.017 
Key 
SD=standard deviation 
M=mean 
6.5.2.2 FISH in active disease. 
The bone marrow used for FISH was part of the sample taken for karyotyping at 
diagnosis (13 cases) or at relapse (3 cases). Clinical data at diagnosis and karyotypes of 
the 16 patients studied is shown in table 6.3. The patients were 14 children (aged 1 
year-10 years) and 2 adults (both aged 16 years), 11 were male and 5 were female. 
Immunophenotypes were common ALL (14 cases) or pre-B (2 cases). None of the 
patients had Down Syndrome. The chromosomal gains, detected cytogenetically and 
subsequently used for FISH in the MRD study, were confirmed using dual probes 
(cases 2 and 10) or triple probes (cases 1,3-9,11-16). The percentage of trisomic cells 
from diagnostic samples ranged from 75.4% to 91.4%, and from relapse samples from 
31.9%-80.6%. (see fig 6.5). In one case (case 8) full cytogenetic analysis had not been 
achieved but FISH revealed a gain of chromosome X, which 
had not been identified 
cytogenetically. 
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6.5.2.3 FISH for follow up bone marrows 
Part of the follow up bone marrow samples, taken for clinical assessment in remission, 
was received for FISH analysis. Thirty remission samples, one BM sample during CNS 
relapse and two in BM relapse were received. The results of FISH on follow-up 
samples are shown in fig 6.5. 
The results were considered to be significant when the percentage of positive cells 
exceeded M+2SD of control values i. e. > 0% for triple probing > 0.01% for the X, 6 
pair and > 0.02% for the X, 18 pair (see section 6.5.2.1). 
For most samples a sensitivity of 10-4was achieved following triplet probing (see 
section 6.4.2.2). Exceptions were samples from cases 2 and 10 to which only paired 
probes were applied (sensitivity of 10-3). During remission, at these levels of 
sensitivity, a small percentage of hyperdiploid cells was detected in at least one sample 
in 8 out of 16 patients tested. The percentage of trisomic cells detected ranged from 
0.01% to 0.06%. Positive samples in first remission were more frequent during the first 
7 months from diagnosis (7/12 positive) than later on (10-24 months from diagnosis 
3/11 positive). Only one of the five samples taken at the end of treatment or later 
showed cells with additional signals to the probes used. This patient, case 11, had 
0.06% clonal cells at the end of treatment. It was of interest that this patient relapsed 6 
months later. Serial samples (available in 8 cases) showed a tendency for the clone to 
diminish or disappear with time. Exceptions were case 11, who subsequently relapsed 
as described above and case 6, in whom 0.01% of clonal cells were detected 18 months 
from diagnosis following previous serial negative samples. This patient remained well 
30 months later. In 8 patients the clone was apparently eliminated by chemotherapy 
and in another by bone marrow transplantation. 
Examples of a field of interphase cells at diagnosis and in remission, probed with the 
triplet X, 17,18 are compared in fig 6.6. There was no difference in age, sex, or initial 
WBC's (> or < 10x109/1) between patients with positive and negative samples. 
6.5.2.4 FISH in subsequent relapse 
Three patients were investigated in relapse. Case 2 in CNS relapse, showed no 
abnormal cells in the bone marrow either by morphology or by FISH. Case 15, initially 
investigated in first relapse, had a second BM relapse 28 months later. This was 
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chromosomally normal but FISH showed it to have the trisomies identified previously 
in 10% of cells. Case 11, in BM relapse 30 months from diagnosis was found to have 
the gains described at diagnosis in 3/50 metaphases investigated by cytogenetics and 
FISH revealed 14% of clonal cells. Interestingly enough, this patient had a positive 
remission sample as the only one out of 3 patients investigated at the end of treatment. 
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Table 6.3 
Clinical data and karyotypes showing probes used for FISH. 
case age WBC immuno karyotype probes 
no (yrs) x109/1 specific 
/sex to 
chromo 
somes 
1 1/M 9.0 common 51-54, XY, +X, +4, +6, +14, +21, +22, +mar X, 4,6 
2 l /M 55.8 common 56-59, XY, +X, +4, +10, +12, +16, +18, +21, +21, X, 18 
+mars 
3 2/M 44.3 common 53, XY, +X+6, +10, +14, +17, +21, +21, +21 X, 6,17 
4 3/F 7.4 common 55, XX, +X, +6, +14, +17, +18, +21, +22, +marl X, 6,18 
5 3/M 3.6 common 54, XY, +X, +Y+6, +de1(10)(g22q26), +14, +17, X, 6,17 
+21, +21 
6 3/F 42.8 common 56, XX, +X, +4, +6, +8, +10, +14, +17, +18, +21, X, 6,18 
+21 
7 3/F 23.8 common 57, XX, dic dup(1)(g10q42), +4, +6, +8, +9, +10, 4,6,17 
+14, +17, +18, +20, +21, +21 
8 4/M 9.8 common 57-59, XY, +4, +5, de1(6)(g13q15), +8, +9, +14, X, 4,18 
+15, +17, +18, +21, +21 inc 
9 4/M 5.7 common 52, XY, +X, +6, +14, +17, del(17)(g25), +18, +21 X, 6,18 
10 8/M 6.7 common 51 XY, +X, +6, +14, +21, +21 X, 6 
11 10/M 9.5 common 54, XY, +X, +4, +6, +14, +17, +18, +19, +21 X, 17,18 
12 16/M 6.1 common 54, XY, +X, dup(1), +4, +10, del(13), +14, t(14; 16), + X, 4,17 
17, +18, +21, +21 
13 16/F 2.2 common 56-60, XX, +X, +4, +6, +10, +11, +14, +18, +21, X, 4,6 
+22, +mar 
14A 3/F 16.8 pre-B 55, XX, +X, +6, +10, +10, +14, +18, +21, +del(14) X, 6,18 
(g11, q22), +del(18)(g12) 
15^ 4/M 1.0 common 57-60, XY, +X, +2, +4, +6, +10, +11, +12, +14, +18, X, 4,10 
+18, +21, +21, +marl, mar2[cp] 
16^ 4/M 7.1 pre-B 63-66, XY, +X, der(1), der(1), +2, +4, +5, +6, +7, X, 6,18 
+8, +10, +11, +12, +16, +17, +18, +19, +20, 
+21, +22[cp] 
A First investigated in relapse 
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Fig 6.5 
Results of FISH on initial investigation (0) at diagnosis cases 1-13 or in 
relapse (R) (cases 14-16) and on follow up in remission or relapse (R). Figures 
in boxes show the percentage of positive cells. Sensitivity (dependent on the 
number of probes used and the number of cells scanned) was 10-4 except 
where indicated as 10-3 
case no / 
1 65.4 
2 9.2 
3 90.4 
4 88.3 
% +ve cells 
CNSR 
103 
alto-BMT 
29 
5 85.3 
30 
6 75.2 0.01 
D 
7 87.8 
8 76.9 
9 91.4 0.01 0.01 
44 48 48 
10 5.4 
103 103 
11 91.2 0.01 0.06 14.0 R 30 
1276.4 0.04 
13 85.9 0.02 0.01 0.01 
alto-BMT 
14 31.9 R 28 38 
15 59.7 
altoBMT 
16 0.6 0.03 . 
02 
0 135 79 11 13 15 17 19 21 23 
months from initial investigation 
Key 
alto BMT = allogeneic bone marrow transplant, R= bone marrow relapse CNS 
R= central nervous system relapse, figures above boxes = months from initial 
investigation 1> = alive and well. 
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Fig 6.6 
An example of interphase FISH on bone marrow using probes to 
chromosomes X (yellow), 17 (red), and 18 (green/blue) in a male patient with 
hyperdiploid ALL. A, at diagnosis, note the majority of nuclei with gains. B in 
remission, note only one nucleus with gains. These figures are compilations of 
cells captured separately in order to show all probes in all cells. 
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6.6 Discussion and conclusions 
The study of patients with ALL who had a high hyperdiploid clone at diagnosis or in 
relapse, in whom minimal residual disease was investigated using an interphase FISH 
assay is presented. Probes used were to chromosomes known to have been present as 
trisomies in active disease. 
The sensitivity of the interphase FISH assay depends on the level of false positives. 
The frequency of false positives depends on the particular chromosomal abnormality 
and the probe or set of probes used for their detection. Others have reported a range of 
5%-18% for the detection of monosomy (Kibbelaar et al., 1993; Brizard et al., 1994), 
0.5% - 10% for the detection of BCR-ABL translocation (Arnoldus et al., 1990; 
Tkachuk et al., 1990; Chen et al., 1993a; Dewald et al., 1993; Amiel et al., 1995) and 
12% for the deletion of the retinoblastoma gene (Stilgenbauer et al., 1993). A range of 
0.5%-4% has been reported for the detection of the single trisomies (Rivera et al., 
1991; Anastasi et al., 1992; Jenkins et al., 1992; Chen et al., 1993b; Escudier et al., 
1993; Kibbelaar et al., 1993; Brizard et al., 1994). 
This study has shown that by targetting more than one chromosomal abnormality the 
rate of false positive cells can be reduced. Using the probabilistic model for the 
distribution of hybridization signals it was shown that each false gain was an 
independent event. Targetting two or three chromosomal gains simultaneously has 
resulted in reducing control values by 100 and 1000 fold respectively. Furthermore the 
level of sensitivity of the technique has been established by means of a dilution 
experiment. This showed that the detection of a single gain was limited to one aberrant 
cell in 10, while dual or triple targetting would detect one cell in 1000 and 10000 
respectively. The control values for alpha centromeric probes applied singly in our 
study were between 1.5% and 2.1 % which is similar to that, reported by others (range 
2% - 4%) (Anastasi et al., 1992; Jenkins et al., 1992; Escudier et al., 
1993; Heerema et 
al., 1993; Kibbelaar et al., 1993; Brizard et al., 1994). Had control values been below 
1%, as reported by some investigators (Chen et al., 1993b; White et al., 1995), our 
sensitivity experiment using a single probe would have been expected to have enabled 
detection of one aberrant cell in 100. 
The application of the technique benefited from being able to estimate the number of 
cells in a cytospin from 10 random fields of view. This removed the need for doing a 
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full count of every cytospin. The availability of an automated scanning system would 
undoubtedly be of value. 
A notable feature of this study was the extremely low level of clonal cells detected in 
remission samples. These were well below the level of detection which, in this study, 
could be achieved with a single probe. In contrast, two other studies of MRD in ALL 
using single-probe FISH have reported persistence of hyperdiploid cells in first 
remission in 4/12 and 4/20 samples investigated (Heerema et al., 1993; White et al., 
1995). All these studies have been small, and follow-up has been short. Differences 
between studies may be due to chance. It is worth emphasising that while the 
interpretation of single probe studies is complicated by relatively high control values, 
this study shows that this is not a problem if a multiprobe approach is used. 
FISH for the detection of MRD in hyperdiploid ALL showed heterogeneity between 
patients in the speed with which the clone was eliminated. The finding that positive 
samples were most frequent in early remission and that the clone tended to decrease in 
size with time would be consistent with elimination of the clone with further courses of 
treatment. Similar results have been reported in studies where PCR has been used for 
the detection of aberrant fusion products, for immunoglobulin gene rearrangements 
(Yamada et al., 1990; Nizet et al., 1991; Potter et al., 1993) or T=cell receptor gene 
rearrangements (Biondi et al., 1992) in remission. 
Early elimination of leukaemic blasts from the bone marrow by day 7 (Gaynon et al., 
1994), by day 14 (Miller et al., 1994) and by day 28 (Legrand et al., 1994), has been 
shown to be associated with improved event-free survival. The demonstration of 
heterogeneity for the persistence of the clone in early remission, albeit at extremely low 
levels, is worthy of follow-up and raises the possibility that FISH in the early stages 
may provide important prognostic indicators. In addition regular monitoring of the 
clone by FISH may, as in one of our cases, enable early detection of a re-emerging 
clone. This would allow early therapeutic intervention ahead of a full blown relapse. 
The use of FISH may have other advantages to patient management in ALL. 
Examples of these in this study were confirmation of the return of the original clone in 
a chromosomally normal relapse, similar to that in one of the cases reported by 
Heerema et al (Heerema et al., 1993). This study demonstrated that the presence of 
clonal cells at the end of treatment may herald relapse and has shown that central 
nervous system relapse may be an isolated event. This study confirms two other studies 
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which using either immunoglobulin gene rearrangements (Yamada et al., 1990) or RT- 
PCR (Devaraj et al., 1995) have shown lack of bone marrow involvement in a CNS 
relapse. FISH at diagnosis can also be used to identify chromosomal gain which has 
been missed due to poor chromosomal morphology. 
Until now sensitive methods of MRD detection of chromosomal abnormalities have 
been limited to the use of RT-PCR for the detection of aberrant fusion products created 
by certain chromosomal translocations (Potter, 1992; Campana, 1993; Deane, 
Hoffbrand, 1994; Campana, Pui, 1995). Interphase FISH targetting three chromosomal 
gains together provides an equivalently sensitive, chromosomally based method of 
MRD detection for an important subgroup of ALL for which RT-PCR for aberrant 
fusion gene products is not applicable. This approach to MRD detection is technically 
simple, leukaemia specific, quantitative and sensitive to 10-4. It may be of advantage to 
extend its application to any case with a clone showing three concomitant genetic 
events for which suitable probes are available. 
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Chapter 7 
CONCLUSIONS 
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The studies carried out and reported in this thesis were designed to gain insight into 
the size and location of the malignant clone in non-dividing cells from patients with 
a haematological malignancy. The size of the malignant clone in haematological 
malignancies at diagnosis and the level of commitment of the target cell for 
malignant change both determine the extent and severity of the disease and may play 
an important role in the patient's response to treatment. Persistence of the clone in 
remission indicates the presence of minimal residual disease (MRD) which may 
require therapeutic intervention. 
The studies described in chapters 3 and 4 concerned samples from patients with 
haematological malignancies which had been classified cytogenetically as `failed' or 
'normal'. Thus, in these cases, a chromosomally abnormal clone had not been found 
in metaphase cells. The aim of these studies was to test the hypothesis that 
chromosomally abnormal clones with hyperdiploidy occur in some of these cases, 
that the clones are present only in the resting cells and that FISH can be successfully 
used to detect clones in non-dividing cells. The investigation of sixty five patients 
with ALL for whom cytogenetic analysis had failed or yielded only normal cells 
revealed the presence of a hyperdiploid clone in nine cases (chapter 3). The 
investigation of seven patients with a haematological malignancy and one or two cells 
with apparently random trisomies at diagnosis or in remission showed the presence of a 
malignant clone in one case (chapter 4). The presence of a malignant clone in a non- 
dividing population of cells in a proportion of cases with failed or normal cytogenetics 
as reported in the studies described above is not surprising. It is well known that clones 
which are present in less than 11 % of the metaphase population are likely to be missed 
on routine cytogenetic examination and such cases will be classified either as failed or, 
if at least 20 metaphases can be analysed as chromosomally normal (Hook, 1977). This 
situation would be expected to occur in cases where the malignant cells are dividing 
less efficiently in culture than their normal counterparts. As a result a malignant clone 
which is underrepresented within the dividing population may escape cytogenetic 
detection. The existence of malignant clones with low survival properties has been 
described (Manabe et al., 1992). From the study reported in chapter 3 it is clear that 
both high and low hyperdiploid clones may fail to reach metaphase in short term 
culture. 
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The aim of the study described in chapter 5 was to gain insight into the level of 
commitment of target cell for different cytogenetic abnormalities in the acute 
leukaemias. It is thought that the striking differences in therapeutic success between 
different leukaemias can be explained by the differences in the level of commitment of 
their leukaemic progenitor cells. Thus, most childhood acute lymphoblastic leukaemias 
and some other paediatric cancers are chemo-curable because they arise in cell 
populations which are functionally transient, chemosensitive and programmed for 
apoptosis. In contrast, most adult acute leukaemias are chemo-incurable, at least in part 
because they originate in relatively drug resistant pluripotent stem cells with extensive 
self renewal capacity (Jasmin, 1988; Greaves, 1993). The investigation of twelve 
patients with ALL and five with AML for the clonal involvement of different cell 
lineages which was carried out in chapter 5 showed that in all cases of AML the 
abnormality was restricted to the myeloid lineage. In the majority of cases with ALL 
the clonal abnormality was restricted to the lymphoid lineage. The exceptions were 
found in the Ph+ subgroup. In this group two cases showed involvement of both 
lymphoid and myeloid lineages. This study shows that a number of clonal 
chromosomal abnormalities in acute leukaemia are found only in one type of cell. This 
suggests that in these cases the acute leukaemia originates in a committed progenitor 
cell. Another possibility that cannot be ruled out is that the abnormalities might arise 
in a pluripotent stem cell which is then directed towards either the myeloid (in AML) 
or the lymphoid (in ALL) lineage only. Philadelphia positive ALL appears to be an 
exception to this rule. This study showed that in 2/3 cases the Philadelphia 
chromosome was found in both lymphoid and myeloid lineages, indicative of a 
pluripotent target cell. 
The aim of the study described in chapter 6 was to develop and apply a FISH method 
for MRD detection of hyperdiploid clones in patients with ALL. The purpose was to 
provide a method of MRD detection that was as sensitive as PCR in this group of 
patients. The theoretical analysis showed that false positive hybridization signals that 
limit the sensitivity of an interphase FISH assay represent probabilistically 
independent events. Simultaneous targeting of two or more chromosome gains 
lowered the number of false positive cells and thereby increased the sensitivity of the 
interphase FISH assay to 10-4. Using this approach a high hyperdiploid clone was 
successfully detected in remission 
in a proportion of patients who had a high 
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hyperdiploid clone at diagnosis. Until now sensitive methods of MRD detection of 
chromosomal abnormalities have been limited to the use of RT-PCR for the detection 
of aberrant fusion products created by certain chromosomal translocations (Potter, 
1992; Campana, 1993; Deane, Hoffbrand, 1994; Campana, Pui, 1995). The study 
presented here showed that interphase FISH targetting three chromosomal gains 
together provides an equally sensitive, chromosomally based method of MRD 
detection for an important subgroup of patients with ALL for which RT-PCR for 
aberrant fusion gene products is not applicable. 
This thesis demonstrates the value of supplementing metaphase cytogenetics with 
molecular cytogenetic techniques such as interphase FISH. FISH studies revealed 
aspects of clonal neoplasia that could not have been discovered by cytogenetic 
analysis. Furthermore it has been shown that FISH may be used for the detection of 
certain chromosomal abnormalities in studies of minimal residual disease and this 
may achieve a high degree of sensitivity. 
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